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0. Abstract 
Background 
The unfavourable therapeutic index of most treatment modalities has greatly impeded progress 
in the development of effective cancer therapy. Therefore a need exists for treatment modalities 
that are less taxing on a patient’s health status (i.e. maintain a patients reserve capacity and thus 
prolong survival) while additionally not invoking counter evolutionary strategies from tumour 
cells. Plant biologist have long distinguished between the host’s ability to accommodate 
pathogen burden, as oppose to its ability to antagonise pathogen load. Hence, the disease 
trajectory is not only dependent on the hosts’ ability to resist an infection, but also on the 
capacity to tolerate pathogen burden. This distinction have only recently been applied to 
animals. A number of observations suggest that this distinction may be of great immunological 
relevance, including the prevalence of asymptomatic carriers and natural variation in the 
population with regards to disease progression. Thus, the tolerance/resistance (T/R) paradigm 
represents a novel approach for understanding disease progression. We hypothesise that similar 
mechanisms might underlie host-tumour dynamics. 
Study aims and experimental design 
The current study aimed to evaluate the application of the T/R framework within an oncological 
context. A syngeneic mice model system was used to compare tolerance and resistance between 
two cancer cell lines. C57BL/6 mice were inoculated with either mammary carcinoma cells 
(EO771) or melanoma cells (B16). In a clinical setting, health status would not only be 
influenced by tumour load, but also by therapeutic interventions such as cytotoxic therapies, 
which must also be tolerated. Thus, a second study was performed using chemotherapeutic 
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regimes as a variable to explore the effect of high (5 mg/kg) and low (2 mg/kg) dose 
doxorubicin (DXR) treatment on tolerance and resistance in mice. In addition, attempts were 
made to identify mechanisms underlying differences between groups with regards to variation 
in tolerance and resistance. To this end, a combination of immunoblotting and proteomic 
analyses were performed. 
Methodology: quantifying tolerance and resistance 
Resistance was quantified as the slope of a regression line, with tumour volume as response 
variable, and time as independent variable. Tolerance was measured similarly, but with body 
weight as response variable and tumour load as independent variable. Differences in regression 
slopes was used to compare tolerance and resistance. To confirm tolerance, differences in 
gastrocnemius muscle cross-sectional area (MCA) were compared between groups. 
Results 
Mice inoculated with melanoma (B16) cells showed a significantly lower resistance compared 
to mice inoculated with breast cancer EO771 cells. With regards to tolerance, B16 cells also 
exhibited lower tolerance, though tests for homogeneity of regression slopes demonstrated that 
these differences did not reach significance (p = 0.0856). Similarly, B16 and EO771 groups 
did not exhibit any difference in MCA. Comparing the effect of high and low dose DXR on 
mice bearing EO771 revealed that DXR decreases resistance: both low dose and higher dose 
DXR increased tumour growth as demonstrated by significantly steeper slopes in DXR groups 
compared to the tumour control group. 
In order to explain the increase in EO771 tumour growth in mice receiving DXR, the activation 
of a panel of signalling proteins associated with cell growth and survival (cRaf, ERK, p38 
MAPK, JNK, PTEN, PI3Kp85, PDK1, Akt, mTOR, Bcl-2) as well as apoptotic markers 
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(Caspase 3, 8 and 9) in tumour samples were evaluated by western blot analyses. However, the 
only significant finding include elevated ERK activation in mice receiving DXR, suggesting 
that extracellular signalling molecules might drive tumour growth. 
Since the liver plays a critical role in energy homeostasis, as well as in the production and 
clearance of circulating factors, western blot analyses were performed on liver samples. 
Markers of autophagy (p62 and LC3B-II) as well as growth signalling proteins (Akt and 
mTOR) and apoptosis (Caspase 3) were evaluated by western blot analyses. Mice inoculated 
with B16 demonstrated a marked increase in both p62 and LC3B-II, signifying an increase in 
autophagosome pool size, most likely due to dysfunctional lysosomal fusion. Surprisingly, 
other makers in both EO771 and B16 did not significantly differ from control liver samples.  
Subsequently, liver proteomics were performed making use of a Gene Ontology approach in 
order to describe biological, functional, structural and other processes that are uniquely altered 
between groups. Interestingly, a comparison between livers of mice inoculated with B16 
melanoma cells and EO771 breast cancer cells also suggested that autophagic activity was not 
upregulated compared to the control group. DXR groups also did not exhibit differences in 
autophagic processes, though proteins involved in the proteasomal pathway were upregulated 
in mice receiving high doses of DXR. An increase expression of enzymes associated with 
retinoic acid metabolism was observed in the B16 group, which might explain decrease 
tolerance and resistance in this group. An increase in steroid metabolism was also observed in 
mice receiving DXR. Since cholesterol form a key component of cell membranes, it is possible 
that cholesterol synthesis might enable rapidly growing tumours of mice receiving DXR. 
Finally, concurrent up- and downregulation of certain proteins involved in radical scavenging 
in DXR mice might suggest a differential free radical scavenging response, thus explaining 
why anti-oxidant therapies have not proven successful in clinical settings in response to DXR. 
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Collectively, these observations highlight alteration in hepatic activities through which 
tolerance and resistance mechanism might manifest. 
In summary, this study have demonstrated the implementation of the T/R framework within an 
oncological setting. Evidence suggest that defects in hepatic autophagy might contribute to 
lower tolerance, and possibly also resistance. Autophagy was not significantly upregulated in 
response to DXR which was associated with lower tolerance. Similar, mice inoculated with 
B16 tumours exhibited lower tolerance as well as evidence for suppressed lysosomal fusion 
with autophagosome. These observations suggest that a compromised autophagic apparatus 
might contribute towards the lower tolerance. Proteomic results are also suggestive of a 
potential role played by altered liver metabolism, including retinoic acid and steroid 
metabolism. Future studies evaluating the role of this pathways might identify novel tolerance-
promoting pathways. 
Stellenbosch University  https://scholar.sun.ac.za
   
 
     vii 
0.  Opsomming 
Agtergrond 
Die ongunstige terapeutiese indeks van behandelingsopsies het die ontwikkeling van 
effektiewe kankerterapie grootliks vertraag. Dit is dus noodsaaklik dat behandelingsopsies 
gevind moet word wat minder stremmend op ‘n pasiënt se gesondheidstatus is (dws terapie wat 
‘n pasient se reserwekapasiteit en gevolglik oorlewing verleng); terwyl dit ook nie teen-
evolusionêre strategieë in kankerselle ontlok nie. Plantbioloë het lankal reeds onderskei tussen 
die gasheer se vermoë om patogene te akkomodeer teenoor sy vermoë om patogeenlading te 
onderdruk. Die siekteverloop is dus nie net afhanklik van die gasheer se vermoë om weerstand 
teen ‘n infeksie te bied nie, maar ook sy vermoë om die patogeen lading te tolereer. Hierdie 
onderskeiding is eers onlangs op diere toegepas. Uit heelwat navorsing blyk dit dat hierdie 
onderskeiding van groot immunologiese belang kan wees, insluitend die voorkoms van 
asimptomatiese draers en natuurlike variasie in die populasie ten opsigte van siekteverloop. 
Die toleransie/weerstand (T/R) paradigma verteenwoordig dus ‘n nuwe verstaan van 
siekteverloop. Ons hipotese is dus dat ‘n soortgelyke meganisme gasheer-tumor dinamika 
onderlê.  
Studie doelwitte en eksperimentele plan 
Die doel van hierdie studie is om die toepassing van die T/R raamwerk in ‘n onkologiese 
konteks toe te pas. ‘n Singeneïese muismodel is gebruik om toleransie en weerstand tussen 
twee kankersellyne te ondersoek. C57BL/6 muise is ingespuit met borskankerselle (EO771) of 
met melanoomselle (B16). In ‘n klinese opset word gesondheidstatus nie net beïnvloed deur 
tumorlading nie, maar ook deur intervensies soos sitotoksiese terapieë wat ook getolereer moet 
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word. ‘n Tweede studie is dus gedoen waar chemoterapie as veranderlike gebruik word om die 
effek van ‘n hoë (5 mg/kg) en ‘n lae (2 mg/kg) dosis doxorubicin (DXR) behandeling op 
toleransie en weerstand in muise te bepaal. Daar is verder ook gepoog om meganismes te 
identifiseer wat onderliggend is aan die verskille tusssen groepe ten opsigte van variasie in 
toleransie en weerstand. Vir hierdie doel is immunokladtegnieke asook proteoom analises 
gebruik. 
Metodologie: kwantifisering van toleransie en weerstand 
Weerstand is gekwantifiseer as die helling van ‘n regressielyn, met tumorvolume as 
responsveranderlike en tyd as onafhanklike veranderlike.  Toleransie is soorgelyk gemeet, maar 
met liggaamsgewig as responsveranderlike en tumorlading as onafhanklike veranderlike. 
Verskille in die regressie hellings is gebruik om toleransie en weerstand te vergelyk. Om 
toleransie te bevestig, is verskille in die gastrocnemius spier dwarssnit oppervlak (SDO) 
vergelyk tussen groepe. 
Resultate 
Muise wat ingespuit is met melanoom (B16) selle, het ‘n insiggewende laer weerstand getoon 
teenoor muise wat met EO771 borskankerselle ingespuit is. B16 selle het ook ‘n laer toleransie 
getoon, alhoewel homogenisiteit ten opsigte van regressie hellings getoon het dat 
insiggewendheid nie bereik is nie (p = 0.0856). Soortgelyk het B16 en EO771 groepe ook nie 
insiggewend verskil in die SDO nie. ‘n Vergelyking van die effek van ‘n hoë en ‘n lae dosis 
DXR in muise met EO771 tumore het getoon dat DXR weerstand laat afneem: beide lae en hoë 
dosisse DXR het ‘n toename in tumorgroei veroorsaak soos aangetoon is in die insiggewende 
steiler hellings van die DXR groepe in vergelyking met die tumor kontrole groep. 
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Om die toename in EO771 tumorgroei in muise wat DXR ontvang het, te verklaar, is die 
aktivering van ‘n paneel seinoordrag proteïene wat geassosieer word met selgroei en oorlewing 
(cRaf, ERK, p38 MAPK, JNK, PTEN, PI3Kp85, PDK1, Akt, mTOR, Bcl-2) sowel as 
apoptotiese merkers (Caspase 3, 8 and 9) in tumorweefsel geevalueer deur middel van 
westelike kladtegnieke. Die enigste insiggewende verandering wat waargeneem is, is ‘n 
verhoging in ERK aktivering in muise wat DXR ontvang het, wat dus voorstel dat 
ekstrasellulêre seinoordragmolekules tumorgroei in hierdie muise stimuleer het. 
Aangesien die lewer ‘n kritiese rol in energie homeostase speel, sowel as in die produksie en 
verwydering van sirkulerende faktore, is westelike kladanalises ook op lewerweefsel gedoen. 
Merkers van autofagie (p62 and LC3B-II) sowel as groei seinoordragproteïene (Akt en mTOR) 
en apoptose merkers (Caspase 3) is geevalueer deur middel van westelike kladtegnieke. Muise 
wat ingespuit is met B16 selle het ‘n merkbare toename in beide p62 en LC3B-II getoon, wat 
montlik ‘n aanduiding kan wees van ‘n toename in die aantal autofagosome, heel waarskynlik 
as gevolg van disfunksionele lisosomale samesmelting. Dit is interessant dat geen ander 
merkers in beide E0771 en B16 selle insiggewend verskil het van die lewer kontrole weefsel 
nie.  
Lewerproteoom analises is gevolglik uitgevoer waar daar gebruik gemaak is van ‘n Geen 
Ontologie benadering om biologiese, funksionele, strukturele en ander prosesse wat uniek 
verander is tussen groepe, te bepaal. Interessant, is dat ‘n vergelyking tussen lewers van muise 
wat met B16 melanoom selle en EO771 borskankerselle ingespuit is, aangedui het dat autofagie 
aktiwiteit nie opgereguleer is in vergelyking met die kontrolegoep nie. DXR groepe het ook 
geen verskille in autofagie prosesse getoon nie, alhoewel proteïene in die proteosomale paaie 
opgereguleer is in muise wat hoë dosisse DXR ontvang het. ‘n Toename in die uitdrukking van 
ensieme wat geassosieer word met retinoïese suur metabolisme is waargeneem in die B16 
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groep wat ‘n afname in toleransie en weerstand in hierdie groep kan verklaar. ‘n Toename in 
steroïedmetabolisme is ook waargeneem in muise wat DXR ontvang het. Aangesien cholesterol 
‘n sleutelkomponent van selmembrane is, kan verhoogde cholesterolsintese moontlik 
verantwoordelik wees vir die vinnige groei van tumorselle in die DXR groep. Gelyktydige op- 
en afregulering van sekere proteïene wat betrek kan word by vry radikaal opname, kan 
moontlik ook verklaar waarom antioksidant terapie onsuksesvol in ‘n kliniese konteks in 
reaksie op DXR is. Hierdie waarnemings plaas klem op veranderinge in hepatiese aktiwiteite 
waardeur toleransie en weerstand kan manifesteer.  
Om op te som, hierdie studie demonstreer die implementering van die T/R raamwerk in ‘n 
onkologiese konteks. Bewyse stel voor dat afwykings in hepatiese autofagie ‘n rol kan speel in 
laer toleransie, asook moontlik in weerstand. Autofagie is nie insiggewend opgereguleer in 
reaksie op DXR nie wat moontlik met laer toleransie geassosieer kan word. Soortgelyk, muise 
met B16 tumore het laer toleransie sowel as onderdrukte lisosomale versmelting met 
autofagosome getoon. Hierdie bewyse toon dat ‘n foutiewe autofagie apparaat aanleiding kan 
gee tot laer toleransie. Proteomiese resultate dui ook aan dat ‘n veranderde lewermetabolisme, 
insluitende retinoïese suur en steroïedmetabolisme, ‘n potensiële rol kan speel. Evaluering van 
die rol van hierdie paaie kan nuwe toleransie promoverende paaie identifiseer in toekomstige 
studies. 
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1.  Chapter 1 
This chapter describes the framework that guided the research activities. An outline of the 
dissertation content is also given. 
1.1 Introduction 
Despite intense global efforts, in most cases, metastatic cancer remains an incurable disease 
(Hanahan, 2014). The slow progress made in finding effective therapies is exemplified by the 
Nobel prizes awarded to scientist working within the field of oncology. The 1966 Nobel Prize 
in Physiology or Medicine was awarded to Peyton Rous for demonstrating the oncogenic effect 
of certain viruses (in particular, his work on Rous sarcoma virus) and to Charles Brenton 
Huggins for establishing the dependency of prostate cancer on trophic factors (i.e. the treatment 
of prostate cancer with hormones). The only other Nobel Prize awarded for cancer-related 
discoveries was in 2008 to Harald zur Hausen in recognition for his work in establishing the 
role of papilloma viruses in the development of cervical cancer. Undoubtedly, vaccines against 
viruses such as human papilloma virus have saved millions of lives (Malagon et al., 2015). 
Similarly, the androgen-deprivation therapy limited tumour growth in most cases. However, 
the effect of hormone-starving cancer is usually short lived and the vast majority of cancers do 
not arise from a viral infection. The marginal impact of these interventions are also reflected 
by the unfortunate fact that an estimated 15.5 million Americans are currently (2016) living 
with cancer (Siegel et al., 2016). 
This disappointing statistics also raise the question: “Why is it so difficult to find a cure for 
cancer?” This question is particular relevant when comparing the efficacy of antibiotics in 
curing a variety of otherwise lethal bacterial infections. In this regard, the problem posed by 
cancer could be reduced to two key factors. Firstly, cancer cells are directly derived from the 
host. Consequently, both the host and the cancer cells make use of the same molecular 
machinery and cellular physiology, thus explaining the unavoidable on-target toxicity of 
chemotherapeutic drugs. This is in contrast to bacteria which have diverged from eukaryotes 
billions of years ago. Secondly, cancer cells are constantly evolving: despite the fact that anti-
neoplastic therapies effectively decrease tumour volume during initial cycles of therapy, cancer 
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cells invariably evolve drug resistance. Thus, the fact that the host shares cancer cell 
vulnerabilities, while cancer cells remain able to evolve novel strategies for developing drug 
resistance, remain major clinical obstacles.    
As lifestyle intervention and better therapeutic options continue to decrease the mortality rate 
of cardiovascular diseases, cancer mortality is expected to increase: cancer already represent 
the leading cause of death in 21 states of the USA [(Siegel et al., 2016). However, progress has 
been made in managing cancer. Recent statistics indicate that, as a result of better cancer 
prevention (e.g. decrease in smoking and the development of vaccines against oncoviruses), 
early detection as well as better therapeutic interventions, cancer’s mortality rate has declined 
by almost a quarter (23%) since the 1991 (Siegel et al., 2016). 
However, another factor that contributes to the lower mortality rate in cancer is the fact that 
the life expectancy of patients with cancers has increased. That is, an increase incidence of 
cancer does not translate to an increase in mortality, as more advanced clinical support for 
cancer patients extend life expectancy (Miller et al., 2016). As an example, although the 
incidence of prostate cancer has increased in most countries, the mortality rates have not 
similarly increase (Center et al., 2012). These observations indicate that supportive care can 
increase life expectancies in cancers patients. In fact, some have raised the opinion that, instead 
of pursuing a ‘cure’ for cancer, neoplastic infections might be rendered a chronic, but 
manageable disease in the near future (Beck and Ng, 2014; Gatenby, 2009; Phillips and 
Currow, 2010). As example, preclinical evidence suggests that administering frequent, but low 
dose chemotherapy (referred to as ‘metronomic chemotherapy’) could decrease adverse effects 
of chemo-toxicity and avoid the evolution of chemo-resistance, while controlling tumour 
burden (Pasquier et al., 2010).  
There is also a feeling that the current approach in treating cancer is not effective, voicing the 
need of a paradigm shift (Goldstein et al., 2012). Indeed, a number of research centres are 
currently employing scientists form fields such as physics, mathematics, ecology and even 
economy and political science in an attempt to develop more effective strategies in the War on 
Cancer (Blagoev, 2016; Dolgin, 2014; Drake, 2011; Enriquez-Navas et al., 2015; Wu et al., 
2015). These attempts clearly demonstrate the unspoken consensus: the current approach to 
cancer therapy is unsatisfactory.  
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1.2 The role of a paradigm 
The concept of a paradigm and the fundamental role it plays in science may be introduced by 
reference to a celebrated ‘chicken-or-egg’ question within the philosophy of science: do 
observations precede a hypothesis, or follow it? Popper points out that, in science, there is no 
such thing as a ‘view from nowhere’ and in fact, that observations are made from the vantage 
point of the researcher’s experience (Popper, 2009): 
The problem 'Which comes first, the hypothesis (H) or the observation (O),' is 
soluble; as is the problem, 'Which comes first, the hen (H) or the egg (O)'. The 
reply to the latter is, 'An earlier kind of egg'; to the former, 'An earlier kind of 
hypothesis'. It is quite true that any particular hypothesis we choose will have 
been preceded by observations — the observations, for example, which it is 
designed to explain. But these observations, in their turn, presupposed the 
adoption of a frame of reference: a frame of expectations: a frame of theories. 
If they were significant, if they created a need for explanation and thus gave 
rise to the invention of a hypothesis, it was because they could not be explained 
within the old theoretical framework, the old horizon of expectations. 
Popper thus reasons that observations are ultimately theory-laden, as it is theory that would 
direct the researcher to perform experiments to test the validity of hypothesis (or as Popper 
would claim, to attempt to refute a conjecture). Consequently, the theory-dependent nature of 
an observation also explains why research is not a haphazard activity, but guided by insightful 
research questions. 
Thomas Kuhn, in his influential work The Structure of Scientific Revolutions forcefully 
articulates the role of a paradigm in not only directing research questions, but in fact dictating 
all research activities within a field. Similar to Popper, Kuhn also maintains that science is not 
‘algorithmic’ (i.e. science is not a purely logical activity whereby knowledge is gained by 
deducting universal theories from neutral observations). However, Kuhn expands the role of 
the paradigm in guiding research activities conducted by the scientific community. According 
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to Kuhn, and unlike Popper, such a ‘disciplinary matrix’ does far more than suggest the 
observations necessary for explaining a phenomenon.  
Instead of recounting the points of departure between Kuhn and Popper, it may be more 
instructive to view Kuhn’s reason for emphasising the formative role of a paradigm on 
scientific activates. Firstly, two paradigms may invoke contrasting axiomatic structures, with 
different assumptions about the same phenomena. Since proponents of different paradigms do 
not share each other’s assumptions, they are likely to formulate different conclusions on the 
same set of data. That is, in addition to the role of a paradigm in instructing the scientist on the 
kind of observations that would provide insight into a phenomenon, two rational scientists may 
agree on the outcome of an observation, but disagree on the interpretation of the observation, 
or its significance. Secondly, researchers may find appeal in different paradigms for various 
personal reasons (i.e. motivated by factors outside of science) (Kuhn, 1977). As an example, 
one paradigm may explain one phenomenon of interest with a higher degree of accuracy, 
whereas another paradigm may exhibit a superior descriptive explanation in a different context. 
Similarly, scientists may differ on the stock they place in a particular assumption, or simply 
feel that one set of assumptions is more reasonable than another. In short, rational researchers 
may agree on the facts, but derive different conclusions. To summarise in Kuhn’s own words: 
“Practicing in different worlds, the two groups of scientists see different things when they look 
from the same point in the same direction.” 
In summary: the way in which a researcher perceives the world depends on the paradigm 
followed. In turn, the conceptual commitment of the researcher dictates the interpretation of 
results, what experimental procedure or methodology is considered adequate, and also when 
an experimental outcome is deemed a result of empirical error or a legitimate refutation. 
Consequently, the paradigm from which a researcher approaches a topic is likely to play a key 
role in gaining true insight into a research field.  
1.3 Cancer paradigms 
There are numerous ways of viewing cancer. Cancer has been described as a “disease of the 
genome” (Sager, 1985), thus expressing the manifestation of cancer as a cell-autonomous 
event, resulting from the step-wise accumulation of aberrations within a single cell. 
Alternatively, cancer has been described as “wounds that never heal” (Dvorak, 1986), thereby 
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emphasising cancer as a biological process being misapplied, and implicating the role of 
stromal cells and the host in general. Similarly, the observation that tumours consist of a 
heterogeneous population of cells is explained by two different paradigms. The cancer stem 
cell (CSC) hypothesis describes the existence of a sub-population of cancer cells with the 
ability to divide asymmetrically (i.e. give rise to more differentiated cancer cell progeny) 
(Magee et al., 2012). The model does not only explain the origin of tumour heterogeneity (i.e. 
asymmetric cell division giving rise to different cells) but also explains drug resistance: 
chemotherapy induces cell death in the progeny of CSC, but leaves the CSC population mostly 
intact, allowing these cells to repopulate the tumour bed after antineoplastic interventions have 
ablated the differentiated progeny. In contrast, the clonal evolution model of cancer emphasises 
cancer as an evolutionary process (Nowell, 1976). Here, both drug resistance and tumour 
heterogeneity can be understood as arising from cancer cells being subjected to different 
selective pressures within their respective micro-environment.  
There are clearly many ways of viewing cancer, and in suit, numerous ways of expressing the 
challenges faced in finding a cure. At the very least then, each paradigm provides an 
opportunity to forward different research questions and arrange observations into arguments 
supporting diverse interpretations. However, different paradigms also moderate certain aspects 
of a phenomenon, for example by neglecting or obscuring certain complexities, while possibly 
over-emphasising other aspects. Consequently, not all paradigms provide the same level of 
insight into all aspects of a complex disease such as cancer.  
1.4 Project outline 
In this dissertation, the tolerance and resistance (T/R) framework is developed in two ways. 
Firstly, the T/R framework represents a paradigm – a conceptual framework from which to 
understand the manifestation of pathology and its relevance on the disease trajectory. 
Secondly, the T/R framework as an empirical tool to quantify the disease state is developed in 
this dissertation. Since a paradigm plays a formative role in research activities, developing 
novel ways of describing cancer may illuminate our understanding, and present new research 
questions. One promising approach consists in transferring principles and concepts developed 
in other fields of study to oncology. In this regard, much interest has been generated in applying 
more than a century of insight gained from studying ecological systems to oncological 
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problems as cancer recapitulates many of the same interactions seen in ecological systems 
(Aktipis and Nesse, 2013; Gatenby et al., 2009; Gatenby et al., 2011; Merlo et al., 2006; 
Nowell, 1976; Taylor et al., 2012). Similarly, the implementation of the T/R framework within 
an oncological setting might open up novel therapeutic avenues. 
In Chapter 2, the immunological concept of tolerance and resistance (T/R) is introduced. The 
adaptation of this immunological concept within an oncological setting is also described in this 
chapter. In Chapter 3 concepts developed in preceding chapters are applied and the 
manifestation of pathology is revisited. Differences in tumour growth (resistance) was 
investigated by immunoblotting of tumour samples in order to elucidate the cell signalling 
cascades which describe altered tumour growth (Chapter 4). Differences in host tolerance was 
investigated by western blot analyses of liver samples (Chapter 5) followed by a more 
comprehensive analyses of liver samples through proteomic analyses (Chapter 6). Finally, a 
brief overview of main findings and future recommendations are provided in Chapter 7. 
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2.   Chapter 2 
In this chapter, an introduction to the distinction between tolerance and resistance (T/R) is 
provided. We also discuss the application of this paradigm within an oncological context 
and point out the utility of distinguishing between pathology driven by tumour load, versus 
the noxious phenotype of cancer, and discuss potential application of the T/R framework. 
2.1 Introduction 
Humans play host to a vast array of pathogens ranging in complexity from single-celled 
prokaryotes to multicellular invertebrates. With the singular exception of viruses and certain 
neglected tropical diseases (Feasey et al., 2010), most classes of pathogens can be treated 
effectively with tolerable side effects. Yet, despite the political will driving a concerted global 
effort, marginal (though perceptible) progress has been made in the War on Cancer (Haber et 
al., 2011; Siegel et al., 2013). One aspect contributing to the comparatively poor progress in 
managing cancer relates to the severe collateral damage associated with current treatment 
modalities (Chen et al., 2007; Lord and Ashworth, 2012; Monsuez et al., 2010; Prasanna et al., 
2012). In turn, treatment toxicity reflects the phylogenetic relationship we share with cancer: 
since vertebrates and invertebrates diverged more than half a billion years ago (Smith et al., 
2013), the most related pathogen, being an invertebrate, would have shared a common ancestor 
no more recently than this demarcated timespan (i.e. 0.5 billion years ago). In contrast, cancer 
is host-derived, implying an immediate common ancestor. Although genetic drift and diverging 
selective pressure progressively diversify the molecular machinery of pathogens, cancer shares 
the vast majority of its vital apparatus with its host. Consequently, what might inflict harm on 
cancer cells will invariably also injure the host. 
An additional challenge posed by neoplastic infections takes form in the almost universal 
development of drug resistance (Gillet and Gottesman, 2012; Gillies et al., 2012; Knight et al., 
2010). This process is well exemplified by targeted therapy. In a handful of cases, cancer arises 
due to a mutated protein within the receptor tyrosine kinase-signalling pathways (Gschwind et 
al., 2004; Knight et al., 2010) which can be targeted with superb specificity. However, cancer 
cells often become resistant to therapeutic intervention by either mutating ligand targets of 
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therapeutics or via alternative activation of redundant signalling pathways (Wilson et al., 2012). 
Indeed, it has been pointed out that the “much acclaimed success in the development of targeted 
therapy often provides just a few months of survival advantage to patients with late-stage 
cancer” (Wan et al., 2013). In addition, many cancer cells simply do not possess the same (or 
easily drugable) targets (Garraway and Lander, 2013).  
Thus, the evolvability of cancer in conjunction with an unfavourable therapeutic index 
associated with most treatment modalities has greatly impeded progress in the development of 
effective cancer therapy. Indeed, some deem the current paradigm to be worn out and have 
expressed the need for a change in tactics if we are to circumvent the persistent difficulties 
faced in the clinical setting (Gatenby, 2009; Goldstein et al., 2012). One promising approach 
consists of transferring principles and concepts developed in other fields of study to oncology. 
For example, much interest has been generated in applying more than a century of insight 
gained from studying ecological systems to oncological problems as cancer recapitulates many 
of the same interactions seen in ecological systems (Aktipis and Nesse, 2013; Gatenby et al., 
2009; Gatenby et al., 2011; Merlo et al., 2006; Nowell, 1976; Taylor et al., 2012). 
Here, we develop a concept predominantly studied in ecology and implement it within an 
oncological context. During an infection, a host not only has to counteract the spread and 
dissemination of a pathogen, but also need to deal with the negative consequences associated 
with an infection which is referred to as tolerance. Resistance on the other hand, describes the 
host’s ability to antagonise the proliferation of pathogens. Similarly, the antagonistic 
relationship between host and tumour demonstrates comparable characteristics. In particular, 
disease is not only dependent on tumour load, but also on the host’s capacity to accommodate 
homeostatic challenges imposed by the tumour. A brief outline of tolerance and resistance is 
provided, focusing on parameters and methodological adaptation in an oncological context. It 
is also argued that this approach can be expanded. Indeed, it has been noted that, although 
tolerance and resistance express host performance in dealing with an infection, “there might be 
some kind of interaction between host genotype and parasite genotype” (Little et al., 2010; 
Råberg et al., 2009), thus indicating that tolerance and resistance should have a functional 
counterpart within the pathogen. Indeed, the terms tolerance and resistance both imply the 
existence of an exogenous factor which is being tolerated or resisted. We define these 
pathogen-derived factors as virulence and pathogenicity. Hence, the disease state manifests as 
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an interaction between these host and cancer factors: tolerance, resistance, pathogenicity and 
virulence. This approach have implications in marker identification (e.g. cancer cachexia) and 
the development of novel approaches to cancer therapies (e.g. tolerance-promoting or anti-
pathogenicity therapeutics).  
2.2 Tolerance and resistance: An immunological paradigm 
Resistance refers to the host’s ability to reduce or eliminate the infectious agent, whereas 
tolerance, on the other hand, denotes a host’s ability to accommodate a given pathogen load 
(i.e. to reduce the health penalty incurred ‘per unit pathogen’). More precisely, tolerance is 
defined as the slope of a regression line plotted with pathogen load as the independent variable 
and health (or some other performance parameter as a proxy) as the dependent variable. The 
distinction between a host’s ability to tolerate a pathogen versus resistance has long been 
realised by plant breeders and pathologists. This concept has, however only recently been 
explored in animal models, first by Råberg (Råberg et al., 2007) who demonstrated that 
different mice strains varied in their ability to tolerate and resist a panel of Plasmodium strains. 
The demarcation between tolerance and resistance as two parallel immunological strategies 
also impose interesting consequences. As an example, immunologists have long taken note of 
the fact that most infections result in vastly different disease states in members of the same 
population: it is estimated that, for every symptomatic cholera infection, between three and 100 
individuals experience asymptomatic infection (King et al., 2008). Similarly, certain 
individuals exhibit an extraordinary asymptomatic carrying capacity for malaria parasites 
(Boutlis et al., 2006). Indeed, an empirical relationship has been observed for some infections, 
which suggests that 80% (or occasionally more) of infections are caused by 20% (or less) of 
carriers (Lau et al., 2013; Woolhouse et al., 1997). The difference in disease progression may 
partially be explained by differences in the host’s immunological strategies in both tolerance 
and resistance.  
In essence, the T/R framework describes how a host manages an antagonistic relationship with 
a pathogen. As is argued here, this established framework (see (Ayres and Schneider, 2012; 
Medzhitov et al., 2012; Råberg et al., 2009; Schneider and Ayres, 2008) for cardinal reviews 
in the field) could also be applied to host-tumour systems which recapitulate similar 
antagonistic dynamics. 
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2.3 Resistance within an oncological context 
“[R]esistance is typically measured as the inverse of parasite burden” (Råberg et al., 2007). 
However, this approach may limit the kind of analysis conducted on the data captured. For 
instance, it has been pointed out that a trade-off between tolerance and resistance cannot be 
investigated with this quantification approach as “resistance and tolerance are not independent 
of one another, given that tolerance has parasite burden as the denominator” (Rohr et al., 2010). 
Thus, it may be advantageous to make use of other metrics. 
Tumour growth is often fitted to a logistic growth function (Figure 2.1). Biologically, this 
growth curve provides three parameters of interest. The carrying capacity (maximum tumour 
volume -K) represent the tumour burden at which tumour growth becomes stunted. An example 
of a factor that may impact on the carrying capacity include inter-cell competition: as the 
tumour reaches a certain size, cells start competing for resources (e.g. niche space close to 
capillaries). Secondly, a lag phase describes the latent period before exponential growth. This 
interval may represent the duration wherein cells undergo molecular ‘retooling’ as they adapt 
to in vivo conditions. Occasionally, this lag period can be extensive, possibly reflecting a period 
during which clonal selection may take place: even commercially available cell lines exhibit at 
least some genetic variation (e.g. differences in karyotypes (Chang and Delany, 2004) which 
may affect tumorigenicity in vivo (Masramon et al., 2006). Finally, the slope of the log-linear 
growth (LLG) phase represents the maximum growth rate of the tumour in vivo. Thus, two 
tumours with different LLG-slopes have different growth rates. This then also provides a means 
of comparing the ability of two therapeutic strategies to retard tumour growth. 
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Figure 2.1. Expression of virulence as the maximum growth rate (i.e. the slope of the log-linear 
growth phase) render it possible to compare differences between different host-tumours systems 
in a reproducible manner. 
Though a logistical growth curve is usually used to model tumour growth within a clinical 
setting, exponential growth closely approximate tumour growth if tumours are small (i.e. in the 
log-linear growth phase). This fact allows for a practical adaptation to simplify analysis: if the 
growth kinetics of the tumour is modelled by an exponential curve, the log of the function will 
provide a linearized data set. Simple linear regression can subsequently be performed on data 
from groups and slopes can be compared (Figure 2.2). Thus, resistance between hosts infected 
with a similar cancer can be rated by comparing the LLG-slope of each system, where shallow 
slopes would imply higher resistance.  This approach can be illustrated in a hypothetical 
example where two groups of tumour-bearing mice each receive two different 
chemotherapeutic regiments, “Chemo A” and “Chemo B” (Figure 2.2). The tumour volume of 
each mouse is measured, log-transformed and plotted against time. The groups with the lowest 
slope (in this case, the Chemo B group) represent the intervention that inhibit tumour growth 
the most.  
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Figure 2.2. Hypothetical effect of chemotherapy on tumour growth in two groups of mice receiving 
different chemotherapeutic agents. Note, tumour growth is measured during the linear growth 
phase. 
2.4 Tolerance within an oncological context 
Similar to resistance, tolerance is expressed by the slope of a regression line. However, 
tolerance represents ‘the unit health cost per unit tumour’. That is, tolerance is the slope of a 
regression line, with a metric of health as the response variable and tumour load as the predictor 
variable. As an example, the tolerance to an identical cancer in context of two different 
chemotherapeutic regimes (Chemo A and Chemo B) can be evaluated by comparing slopes of 
regressions lines (Figure 2.3). In the example, Chemo A exhibit a superior strategy for 
promoting health status in the face of tumour load.  
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Figure 2.3. Hypothetical effect of a chemotherapy protocol on tolerance. Tolerance is expressed as 
the slope of a regression line fitted to the log-log plot of body weight (used as metric of health) 
against tumour volume. Comparative effect of chemotherapeutic efficacy is measured by comparing 
the slopes of these two groups’ regression line. 
Therapeutic efficacy of a given intervention can be expressed as a ratio between the tolerance 
and resistance of a given therapeutic intervention. As an example, Chemo A appears to be less 
effective in antagonising tumour growth than Chemo B (Figure 2.2). However, the tolerance 
slope of Chemo B is less negative than that of Chemo A (Figure 2.3). Thus, a benefit-to-harm 
ratio may be obtained by comparing regression slopes of resistance (Figure 2.2) to tolerance 
slopes (Figure 2.3).  
Tolerance is a challenging parameter to quantify, as health is a complex trait. However, various 
markers of pathology can give an indication of health status.  In the interest of rendering results 
comparable, criteria often associated with cancer cachexia may represent desirable health 
metrics (Fearon et al., 2011) . As an example, a decrease in body weight, and in particular 
muscle wasting, are robust indicators of cancer cachexia (Fearon et al., 2011; Martin et al., 
2013). Serum markers generally used for prognostic function in cancer patients (Vigano et al., 
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2000) are also candidates for quantifying tolerance. Certain acute-phase proteins may also be 
used, though it should be noted that the half-life of certain molecules is short and thus only 
presents a snapshot of the disease state (Cray et al., 2009; Epstein et al., 1999; Pang et al., 
2010). 
Also, applying more than one metric for each parameter can aid in validating results. However, 
problems may arise when metrics only partially corroborate each other. As an example, in a 
recent study by Li and co-workers (Li et al., 2013), it was demonstrated that mice may exhibit 
molecular signs of metabolic deregulation without other overt signs of pathology (e.g. 
reduction in body weight). In particular, tumour bearing mice demonstrated a healthy body 
mass, while analysis of serum markers indicated elevated triglycerides and reduced 
albumin/globulin ratios, indicative of metabolic deregulation and liver dysfunction (Li et al., 
2013). Furthermore, elevated serum levels of  C-reactive protein and transforming growth 
factor beta also indicate liver damage (leading to hepatomegaly which possibly inflated body 
weight, giving the false impression of good health status) (Li et al., 2013). Clearly, metrics of 
health should be carefully chosen, bearing in mind how the pathology may manifest. As an 
example, these factors must be taken into account when measuring body weight in diseases 
associated with oedema or accumulation of fluid. 
In a clinical setting, it may be appropriate to measure a critical trait that is unique to each case. 
In a palliative context, the Edmonton Symptom Assessment System (ESAS) can be used to 
quantify “symptoms that have a larger subjective component” including depression, pain and 
general well-being (Richardson and Jones, 2009). However, since cancer cachexia manifests 
at a late stage of disease and also do not include the early onset pathology elating from 
chemotherapy, alternative metrics more suited to the initial phase of disease trajectory may be 
more appropriate. For example, the use of mTOR inhibitors to treat a number of cancers, is 
often associated with a number of haematological disorders (Xu and Tian, 2014; Zaytseva et 
al., 2012). In this regard, tolerance may be measured as the decline in blood counts. Similarly, 
liver function tests could be used as a metric of tolerance during radiation therapy of hepatic 
cancers. In fact, the T/R framework can also be applied in measuring therapeutic efficacy as 
the ratio between tumour inhibition versus adverse events or general therapeutic toxicities. 
Novel therapeutic strategies aimed at abrogating immune-inhibition often lead to various 
adverse events (Larkin et al., 2015). Here, reduction in tumour load (resistance) can be 
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compared to alternative metrics of tolerance such as the grade and frequency of adverse effects. 
Indeed, the T/R model could also be adapted to include well-being and psychological distress 
as a metric of tolerance when evaluating treatment efficacy.  
2.5 Developing the T/R framework 
Collectively, the T/R framework presents a reproducible approach with a number of 
applications (e.g. testing the therapeutic efficacy of an intervention strategy). However, this 
framework can also be expanded to tackle additional challenges. One application of the T/R 
framework includes the elucidation of pathogenic circuits that underlie the development of 
cancer cachexia, an often studied but poorly understood manifestation of cancer pathology, 
affecting up to 80% of patients with advanced-stage cancer (Ramos et al., 2004) and accounting 
for about 20% of all cancer-related fatalities (Loberg et al., 2007; Tisdale, 2002). Current 
failure to identify suitable markers are often ascribed to “population stratification, variable 
linkage disequilibrium and genotype misclassification” (Tan et al., 2011). In turn, a lack of 
markers preclude candidate targets to treat cancer cachexia. Consequently none of the current 
therapies provides a lasting improvement and there is an ongoing search for effective 
therapeutic targets (Tan et al., 2014). However, we suspect that two additional factors may 
contribute to the lack of suitable markers. 
Firstly, disease may be driven by either tumour load, or the intrinsic noxious phenotype of the 
cancer. Indeed, mice xenograft models have demonstrated that cancer cells can differ 
profoundly in their ability to induce cachexia (Mori et al., 1991). This might be a major 
confounding factor, as a large tumour load may be driving a cachectic phenotype in one patient, 
whereas the noxious nature of the cancer may be a more prominent factor in another. However, 
the T/R framework allows for a finer resolution of the disease state and presents a method for 
identifying cancers that are more prone to inducing pathology. 
Second, immunologists have taken note that much of the difficulty in identifying genetic 
markers for pathogen susceptibility could relate to the fact that pathogen heterogeneity is often 
taken for granted (Hill, 2012): Host susceptibility towards a pathogen is not only dependent on 
host genotype, but also that of the pathogen, implying that disease is a bigenomic phenomenon. 
As an example, innate resistance towards HIV infections observed in certain individuals is 
dependent on the host genotype as well as the strain of HIV (Saez-Cirion et al., 2009; Stephens, 
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2005). Similarly, there is a growing appreciation that cancer cachexia manifests as an 
“interaction between the host and cancer cells” (Gallagher et al., 2016): cancer-associated 
pathology may depend on the unique nature of stress a given tumour imposes as well as the 
ability of the host to accommodate such a particular stress. As an example, a highly glycolytic 
tumour may induce lactic acidosis in an individual with a set of metabolic polymorphisms, 
resulting in a decreased capacity to metabolise lactate. However, in another individual with 
normal metabolic capacity, a highly glycolytic tumour would not induce such pathology since 
adequate reserve capacity in lactate metabolism would buffer against such stress. Thus, the 
manifestation of pathology is dependent on both cancer (i.e. the nature of stress imposed) and 
the ability of the host to accommodate the specific stress imposed by cancer. 
The T/R framework have been pointed out to be “host centric” (Råberg et al., 2009). In order 
to emphasise a demarcation between host-derived versus cancer-derived factors that impact on 
disease, two additional terms will be implemented. Firstly, the host contributes by either 
resisting the infection or tolerating a tumour. In turn, cancer cells exhibit a level of adaptation 
to the host environment that allows the spread and dissemination within the host, an ability that 
will be referred to as virulence, while also imposes stress on homeostatic mechanisms, i.e. 
exhibiting pathogenicity. Consequently, the disease progression depends on the resultant 
interaction between these factors (Figure 2.4): host resistance antagonise pathogen virulence, 
thus impacting on pathogen load. Similarly, the marginal cost of enduring a given pathogen 
load is dependent on the host ability to tolerate a particular pathogenic phenotype of a cancer. 
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Figure 2.4. Schematic summary of how tolerance, pathogenicity, resistance and virulence affect the 
disease state. 
In summary, the interaction between cancer and host factors dictates the disease trajectory 
(Figure 2.5). An interaction between host- and cancer-derived factors dictate the immediate 
disease trajectory in terms of directionality (pathogen load and health status providing 
‘coordinates’) as well as magnitude of effect (how swiftly the disease would progress). 
Considering the disease state as a bigenomic phenotype implies that certain tolerance circuits 
may only exert a protective effect on health status in the face of a particular challenge and 
similarly, certain pathogenic factors would only manifest in pathology when placed in the 
context of a given host. Furthermore, host-derived factors need not be independent –a process 
that promotes tolerance may also promote resistance or alternatively, act antagonistically. 
Similarly, pathogen-derived factors may also exhibit pleiotropic effects. 
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Figure 2.5. The impact on health status by both host and pathogen within the context provided by 
both interacting genomic landscapes (i.e. genetic and epigenetic modifications present within 
cancer and host). 
2.6 Cancer Tolerance Pathways  
It has also been demonstrated that the genetic alteration in cells that develop into cancer often 
induces an upregulation of the inflammatory response which is associated with aggressive 
malignancy and metastasis (Borrello et al., 2005). This is of interest since genes involved with 
immunology are typically highly polymorphic (Abi-Rached et al., 2011; Balkwill and 
Mantovani, 2001; Maizels, 2009; Robinson et al., 2013; Seruga et al., 2008; Smith and 
Humphries, 2009). Indeed, polymorphisms in various cytokines have long been known to be 
associated with the development and prognosis of cancer (Balkwill and Mantovani, 2001; 
Howell and Rose-Zerilli, 2007; Seruga et al., 2008). It is conceivable that certain individuals 
would exhibit an ‘inflammatome’ that would render them more resilient or susceptible to the 
development of inflammatory-associated pathologies. It is thus likely that numerous genetic 
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polymorphisms within genes regulating immune aspects can have an impact on the disease 
trajectory via the dominating effect of immune modulators on other systems. Similarly, 
metabolic polymorphisms are also likely to play a prominent role in mediating host tolerance 
to cancer. Polymorphisms in genes encoding glucose metabolism have already been shown to 
associate with clinical outcome in pancreatic cancer (Dong et al., 2011). Indeed, much of the 
diversity observed among the numerous metabolic interactions (>8 700) and concentrations of 
metabolites (~16 000) is brought about by underlying genetic variation (DeBerardinis and 
Thompson, 2012). However, metabolic anomalies may also manifest from host-cancer 
metabolic interactions (DeBerardinis and Cheng, 2009; Hensley et al., 2013; Martinez-
Outschoorn et al., 2011; Rattigan et al., 2012).  
It thus seems likely that metabolism, as affected by immune effectors such as cytokines, 
presents an excellent candidate system for exploring the complexities of cancer tolerance. 
Indeed, a metabolic-immunologic crosstalk is exemplified by cancer cachexia (Tsoli and 
Robertson, 2013). Furthermore, numerous polymorphisms within metabolic and immune 
structures provide a rich source of variation, potentially explaining much of the heterogeneous 
disease trajectories observed. Addressing this complexity, “candidate atrogenes”, expression 
signatures of sets of genes involved in muscle wasting during cancer cachexia, have been 
identified in an omics approach (Gallagher et al., 2016). Carefully designed experiments, 
capturing necessary data (pathogen load and accurate metrics of health) may identify candidate 
systems that would point the way towards novel treatment strategies. 
2.7 Investigating cancer tolerance and pathogenicity 
Considering the disease state as a bigenomic phenotype imply that two distinct hosts (different 
genotypes) may respond differently to an identical cancer, since pathology does not only 
manifest from the stress imposed by the cancer, but also as a result of the host response to such 
a stress. This view is indeed supported in rodent models, where different strains of rodents 
respond differently to identical tumours. As an example, similar tumours in different animal 
strains (Walker carcinoma on Sprague-Dawley and Wistar Rats (Jensen and Muntzing, 1970), 
illustrated variation in resistance to cancer across strains. Conversely, challenging similar 
strains of mice with different tumours demonstrate variation in cancer pathogenicity. In this 
regard, Mori and co-workers (Mori et al., 1991) transplanted four different melanoma tumours 
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into nude mice, observed that certain tumours rapidly induced weight loss with the 
manifestation of cachexia-like symptoms whereas others did not. 
These observations suggest that cancer pathology is dependent on host genotype (i.e. rodent 
strain) as well as cancer ‘genotype’. If the developing pathology associated from cancer is 
dependent on resilience of the host to the stress imposed by the cancer, markers for the 
developing pathology should match: a susceptibility marker would only become apparent in a 
host susceptible to a given stress. Thus, the current approach for identifying “cachexia prone 
genotypes” based on association of host genotype with cachectic phenotype (Johns et al., 2014) 
neglect the fact that the particular genotype of the cancer also impact on the development of 
cancer cachexia. As a hypothetical example, a tumour excreting high levels of TNF will affect 
two different hosts with different TNF receptor polymorphisms differently. In particular, the 
effect of TNF on cachexia will only be apparent (and relevant) in hosts that express a receptor 
with high affinity to TNF. It is thus a necessity to evaluate the role of cancer markers in context 
of the host genotype. 
A more structured approach can be followed to identify host markers that would render a host 
susceptible to a particular cancer. As an example, the contributing effect of a given cytokine 
(e.g. TNF) can be investigated by upregulating cytokine expression in cancer cells, and 
transplanting these cancer cells in hosts either lacking a given receptor (e.g. TNFR -/- mice), or 
are receptor positive (TNFR+/+ mice). This approach is illustrated by a simplified experiment 
(Figure 2.6) consisting of two mice populations, arbitrarily designated as ‘+/+’ and ‘-/-’ to 
demarcate distinctive genotypes (e.g. TNFR polymorphism), as well as two different cancer 
cell lines (CCL), ‘A’ and ‘B’ (e.g. denoting TNF expression). Note that, whether a host or 
cancer derived attribute is being studied depends on the origin of variation within the system:  
host derived attributes (tolerance and resistance) are evaluated by comparing different host 
performances to similar CCL. In contrast, pathogenicity and virulence are cancer-derived traits 
and are therefore inspected when comparing CCL A and B within a similar host-context. Thus, 
the relative pathogenicity of a cancer cell in a mouse strain can be expressed as the slope of a 
regression line obtained from plotting a health metric (e.g. bodyweight) against tumour volume. 
For example, if CCL A induces greater pathology in +/+ mice than CCL B, CCLA would be 
considered more pathogenic. IF -/- mice develop less pathology to CCL B than +/+ mice, -/- 
mice would be considered more tolerant.  
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Figure 2.6. Experimental setup:  discriminating between host- and pathogen-derived factors. 
This approach can be used to investigate the pathogenic effects of a candidate gene (e.g. 
comparing pathogenicity of cancer cells expressing a candidate gene with an identical cell line 
in which the gene of interest has been knocked out) or be exploited in a data-driven approach 
(e.g. by mutagenizing a population of cancer cells, comparing pathogenicity between 
populations, and correlating genotype with phenotype (Chen et al., 2015). Similarly, instead of 
evaluating the effect of host genotype on tolerance and resistance, therapeutic interventions 
could be evaluated (Figure 2.2). Two chemotherapeutic agents may be equally effective at 
eradicating cancer cells, but differ in their toxicity. For example, leukaemia resistance can be 
measured by the number of circulating blast (a proxy for cancer load), whereas anaemia (or 
related blood count) provides a metric of tolerance. In this context, efficacy can be expressed 
as the T/R ratio, i.e. the number of mature blood cells divided by the number of blasts. In 
particular, similar to the comparison between host and cancer (TNF expression by cancer and 
host receptor affinity), intervention therapy may exhibit a cancer-specific efficacy (that is, a 
particular therapy’s effectiveness depends on the cancer cell type).  
2.8 Implications of T/R framework 
The T/R framework argues for a more in-depth approach to cancer pathology. It is likely that 
the poor performance in identifying good markers for cancer pathologies such as cachexia may 
result from the way the disease state is viewed. The T/R framework provides the operational 
resolution to distinguish between pathology manifesting from extensive tumour burden, versus 
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cancers intrinsically expressing a more pathogenic phenotype. In addition, considering the 
disease state as a bigenomic phenotype implies that certain tolerance mechanisms may only 
exert a protective effect on health status in the face of a particular challenge and similarly, 
certain pathogenic factors may only manifest in pathology when placed in the context of a 
given host. Taking these factors into consideration, we hypothesise that the T/R framework 
may provide a novel methodology in studying the nature of cancer pathology. In addition, 
therapies aimed at enhancing host tolerance would not have a negative impact on cancer fitness 
and as such do not invoke counter-evolutionary innovation (Roy and Kirchner, 2000). 
Similarly, therapies decreasing pathogenicity should also avoid evolutionary strategies that 
undermine therapeutic intervention. As such, tolerogenic and anti-pathogenic therapies would 
be expected to remain effective for longer. 
Furthermore, reducing the adverse effects associated with neoplastic infection would be likely 
to enhance patients’ survivability. Indeed, health status as reflected in weight loss has long 
been realized to be a powerful prognostic factor (Dewys et al., 1980). Additionally, therapies 
aimed at increasing tolerance in effect also help to reinforce reserve capacity of the patient and 
open additional potential therapeutic options, such as second- or third-line therapy. This is of 
particular relevance in more pathogenic cancers such as pancreatic tumours where patients 
seldom possess sufficient reserve capacity to endure the toxic side-effects of second-line 
therapies (Hidalgo, 2010). Similarly, recent development of immunotherapy (Larkin et al., 
2015) has again brought attention to the possibility of mobilising the immune system in treating 
cancer. However, the immune system is often particularly adversely affected by chemotherapy 
(Zitvogel et al., 2011). This is no surprise as activated immune cells share common metabolic 
circuits often observed in cancerous cells (Maciver et al., 2008). In this regard, the T/R 
framework may aid in quantifying the detrimental effect of a given treatment modality by using 
an immunological metric (e.g. immune cell count) instead of health. 
2.9 Conclusion 
The fine-scale resolution on the disease state provided by the T/R framework points towards a 
number of interesting applications. Novel therapeutic interventions promoting tolerance or 
targeting cancer pathogenicity may enhance the survivability of patients or indeed even aid in 
redefining therapeutic endpoints. This is not to supplant current efforts on finding a cure for 
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cancer. Rather, T/R represents an augmented approach to a complex disease. Understanding 
how host–cancer interactions take shape may also aid in discovering novel biomarkers. Indeed, 
the T/R framework stresses the need to associate host-derived biomarkers with that of a cancer-
specific factor. This undoubtedly implies greater effort with more refined study designs. 
However, this approach also holds the potential of providing biomarkers of unprecedented 
accuracy. In this regard, it has become clear that metabolic circuits are profoundly influenced 
by immunological structures – a crosstalk between systems that are likely to yield many 
mechanisms by which cancer pathology manifests. Accordingly these systems should enjoy 
top priority in research on cancer tolerance and pathology.  
2.10 Future perspective 
The primary goal of antineoplastic intervention is the complete elimination of cancer. 
However, being able to endure a large tumour load may hold therapeutic advantages where 
curative endpoints are not realistically perusable. Indeed, some have speculated that a potential 
future strategy might be in treating cancer “as a chronic manageable disease, such as diabetes 
and heart disease” (Folkman and Kalluri, 2004) and that “instead of focusing exclusively on a 
glorious victory, [we] should address the possible benefits of an uneasy stalemate in 
appropriate situations” (Fillon, 2012). Similarly, others “foresee a future in which the 
prevention of metastatic cancer will become a mainstream practice by managing MRD [i.e. 
minimal residual disease], and effective therapeutic agents and strategies will be available to 
turn fatal metastatic disease into a chronic condition” (Wan et al., 2013). Redefining the 
therapeutic endpoint as such would necessarily imply that the host must be more tolerant to the 
neoplastic infection and chemotherapeutic interventions. In addition, the T/R framework 
provides a mechanism by which therapeutic efficacy can be described by comparing the 
reduction in tumour load (resistance) versus the health cost (tolerance) of a given intervention. 
As an example, novel immuno-oncology interventions leading to an upregulation of the 
immune system often induce a range of adverse effects. Indeed, adverse effect caused 
discontinuation of therapy in 7.7% of the patients receiving nivolumab, 14.8% on ipilimumab 
and 36.4% of patients on both (Larkin et al., 2015). In this regard, the T/R framework represents 
a tool for evaluating therapeutic interventions that do more harm than good. Indeed, since 
chemotherapy is generally associated with cumulative side-effects, reducing tumour load at an 
excessive ‘cost’ in terms of health (or well-being) would be counterproductive. 
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3.   Chapter 3 
This chapter outlines the first study to investigate the role of tolerance and resistance within 
an oncological setting. By inoculating mice with similar tumours, a comparison between 
cancers in terms of the tolerance and resistance effect can be assessed directly. 
Alternatively, the T/R framework can also be applied to investigate the effects of 
therapeutic intervention. As proof of this concept, both these approaches were implemented 
in this study. 
3.1 Study design 
The current study made use of 60 female C57BL/6 mice (five groups with n = 12), the 
chemotherapeutic agent doxorubicin (DXR) and two syngeneic cancer cell lines: EO771 
mammary carcinoma and B16 melanoma (Figure 3.1). Two experiments were conducted. 
First, the effect of DXR on mice tolerance and resistance was investigated. This experiment 
involved a comparison between tumour (EO771) bearing mice receiving three cycles of high 
(5 mg/kg), low (2 mg/kg) dose DXR or vehicle control (Hanks balanced salt solution) once 
tumours were palpable (Figure 3.2). The second experiment compared the tolerance and 
resistance of C57BL/6 mice to EO771 mammary tumours versus B16 melanoma. Note that no 
chemotherapy was involved in the second experiment. 
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Figure 3.1. Study design and intervention groups. 
 
 
Figure 3.2. Experimental time line. DXR was not administered to mice injected with B16. 
3.1.1 Routine cell culture: EO771 and B16  
The EO771 cells (a generous gift from Fengzhi Li, Roswell Park Cancer Institute, Buffalo, New 
York, USA) and B16 cells (kindly provided by Prof. Lester M. Davids, University of Cape 
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Town, Cape Town, RSA) were maintained in similar conditions. Glutamax-DMEM (Celtic 
Molecular Diagnostics, Cape Town, South Africa) was supplemented with 10% foetal bovine 
serum (Sigma Chemical Co., St Louis, MO, USA). Cells grown as monolayer were incubated at 
37°C in a humidified atmosphere (95% air and 5% CO2) in T75 flasks (Greiner Bio One, 
Germany) to ~80% confluence. Cells were split (1:3) by washing cells in pre-warmed (37°C) 
Hanks balanced salt solution (HBSS) before incubating cells with 4 ml trypsin/EDTA (Sigma 
Chemical Co., St Louis, MO, USA) at 37°C for 7 minutes. 
3.1.2 Animal husbandry 
Weaning-age (4-5 weeks old) female C57BL/6 mice, reared under specified-pathogen-free 
conditions, were obtained from University of Cape Town's Research Animal Facility. Acquired 
mice were housed at the Animal Unit, Stellenbosch University, in individually ventilated cages 
(6-8 mice in a cage) at 22°C under 12-h light/dark cycle. Mice were allowed a one week 
acclimatisation period before being subjected to experimental procedures, with ad lib access to 
food and tap water. Ethical clearance had already been obtained for this project from the 
Research Ethics Committee: Animal Care and Use of Stellenbosch University (SU-ACUM13-
00027). 
3.1.3 Mice inoculation with EO771 and B16 cancer cells 
The protocol that was implemented in this study was adapted from (Ewens et al., 2006), in 
which Matrigel™ was used instead of HBSS, and was performed for both EO771 and B16 cells. 
Matrigel™ consists of a range of extracellular proteins and growth factors that are derived from 
Engelbreth-Holm-Swarm mouse tumour cells (Fridman et al., 2012). Though Matrigel™ is not 
necessary for the engraftment of either B16 or EO771 cancer cells this procedure is often 
deployed as it is argued that it more accurately recapitulates the extracellular context of cancer 
cells.  
Both the EO771 (mammary adenocarcinoma) and the B16 cell line (melanoma) are derived 
from C57BL/6 background and readily form tumours in these mice. For the purpose of 
inoculating mice with cancer cells, cells were grown to ~70% confluence to ensure the cells 
were in an exponential growth phase. Cells were trypsinised, centrifuged, and re-suspended in 
ice-cold mixture (1:1) of PBS and Matrigel™ (9.2 mg/ml protein, BD Biosciences) at 2.5×106 
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cells/ml in sterile 1.5 ml Eppendorf tubes. Since Matrigel™ congeals above 4°C (Fridman et al., 
2012), cell suspension was kept on ice continuously after re-suspension. 
There are a number of benefits associated with subcutaneous (s.c.) injection as opposed to injection 
into the mammary fat pad (i.e. orthotopic transplantation). Firstly, subcutaneously injected cancer 
cells seldom metastasise (Workman et al., 2010). Thus, subcutaneous injection would avoid the 
stochastic nature of metastasis and also decrease morbidity as well as mortality. In addition, 
tumours that grow subcutaneously can continuously be monitored, and tumour volume can be 
measured directly. Finally, EO771 are adenocarcinoma of the mammary gland, whereas B16 are 
melanomas. Thus ‘orthotopic’ transplants for EO771 would not recapitulate the native micro-
environment of B16 and consequently may introduce the differences in adaptation to micro-
environment as a confounding factor. Consequently, the s.c. injections simplified operations, and 
provided a more standardised model. 
Prior to injection, ~0.8 ml of the cell suspension was drawn-up into a syringe, where after a 23-
gauge needle was fitted. Each mouse was inoculated subcutaneously at the second inguinal nipple 
(Figure 3.3) with 100 µl cell suspension (i.e. 2.5×105 cells). By gently raising the inserted needle, 
a small subcutaneous ‘lacuna’ was formed into which the cell suspension was injected. After 
discharging 100 µl of the cell suspension, the needle was slowly withdrawn in order for the injected 
Matrigel to be heated up by the body heat of the mice. This caused the Matrigel to become more 
viscous, thereby minimising leakage once the syringe was retracted. The needle was slowly 
retracted with a rotating motion. 
 
Figure 3.3. Diagram indicating the site of injection. Mice were injected subcutaneously above the 
second mammary fat pad (left, inguinal group). 
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3.1.1 Tumour volume and DXR injection 
Tumour volume and body weight were measured every second day. Tumour volume was calculated 
by the formula 1/2×(Length×Width2), as measured by digital callipers. Once tumours became 
palpable (1~2 weeks after inoculation) mice were given three injections of HBSS, or DXR 
(Doxorubicin hydrochloride, Sigma) over a one week period (i.e. two days between injections, 
Figure 3.2). Dose of DXR to be administered was calculated according to the body weight 
measured the preceding day, and a stock solution of DXR was diluted in HBSS to produce a 
final volume of 100 μl. 
3.1.2 Endpoints and tissue harvesting 
Mice where sacrificed when tumours reached a volume of approximately 400 mm3. First, mice 
were anesthetised with isoflurane (Safeline Pharmaceuticals), using a 5% (v/v) isoflurane/oxygen 
mixture for induction, followed by a maintenance mixture of 1.5% isoflurane/oxygen. While the 
mice were anesthetised, blood samples were obtained through cardiac puncture, and allowed to clot 
at room temperature (22°C) in a serum clotting tube, followed by certification (1000×g for 15 min). 
The serum fraction was then aliquoted into 500 µl tubes and immediately frozen at -80°C for later 
analysis. Muscularis Gastrocnemius (GAS) was harvested, and fixed in neutral-buffered 10% 
formalin solution (Sigma, HT501128). Liver tissue was washed in ice-cold Hank’s balanced salt 
solution. While submerged in buffer, excess blood from the liver lobes was removed by rapidly 
compressing and releasing (i.e. by the repeated ‘squishing’ of liver lobes) with pliers, before the 
liver lobes were snap-frozen in liquid nitrogen an stored at -80°C. 
3.2 Muscle cross-sectional area 
After fixing GAS muscle in formalin, muscle samples were placed in an embedding cassette 
and embedded with paraffin wax (see Appendix I) using TISSUE TEK III (model 4640B, Miles 
Laboratories Inc, Napervile, IL). Embedded samples were mounted on a rotary microtome 
(Reichert Jung, Heidelberg, Austria) and sectioned at 5 µm thickness. Sections were then 
dewaxed in preparation for haematoxylin and eosin (H&E) staining (Appendix I). After 
allowing sections to be air-dried, a mounting medium was added and a coverslip was placed 
over the sections. Images of the muscle cross-sectional area (MCA) was taken on a Nikon 
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Eclipse E400 microscope equipped with a Nikon DXM1200 colour at ×20 magnification. The 
MCA was calculated using ImageJ software (Figure 3.4). 
 
Figure 3.4. Histological cross-section of gastrocnemius muscle. (A) After calibrating the pixel 
distance to the scale, the ‘Freehand’ tool was used to outline the perimeter of muscle cross-section. 
(B) Double counting was avoided by marking measured fibres using the ‘Find Edges’ function. 
Though mouse muscles exhibit predominantly glycolytic fibre types, the GAS muscle consists 
of mixed fibres, thus providing a more general effect of DXR, and avoiding any effect that may 
be attributed to fibre type. Due to the small size of the GAS muscle of the mice, and the fact 
that a small section of muscle was harvested for a parallel study, a representative histological 
section was not available for all mice. As a result, the counted fibres were pooled, with the 
tumour control (TC) group having n = 513 fibres counted, for low-dose (LD), n = 550, and for 
high dose (HD), n = 323 fibres. Muscle cross-sectional area was calculated in ‘pixel-area’, 
standardised to the pixel distance of the scale bar, and expressed in arbitrary units. 
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3.3 Statistical analysis 
Statistical analysis was performed in R (version 3.3), using a variety of software packages 
including ggplot2, psych, and car. To compare slopes, an updated one-way ANCOVA model 
was implemented (using Fisher’s LSD post hoc test) which included an interaction term 
between the covariate and predictor variable: for resistance Time:Group and for tolerance, 
log(tumour volume):Group interaction terms were used. Significance in the interaction terms 
signify a violation of the assumption that regression slopes are homogenous (i.e. slopes are 
significantly different).1 In cases where comparisons between two groups were conducted, 
analysis was performed as previously described (Paternoster et al., 1998), according to the 
formula: 
𝑍 =  
𝑏1 − 𝑏2
√(𝑆𝐸𝑏1)2 +  (𝑆𝐸𝑏2)2
 
where 𝑏1 and 𝑏2 represent the regression coefficients (i.e. slopes) and similarly, 𝑆𝐸𝑏1 and 𝑆𝐸𝑏2 
the respective standard deviation associated with each groups. The homogeneity of variance 
was tested using Levene’s test, whereas the Shapiro-Wilk test was used to test whether data 
conformed to a normal distribution. Where applicable, a robust ANOVA was conducted using 
the WRS2 package (confidence intervals calculated by 2000 bootstrap samples, and samples 
means 10% trimmed). For all tests, a p-value of < 0.05 was considered significant. 
3.4 The effect of DXR on resistance of mice to EO771  
Resistance was measured by fitting a regression line with logged tumour volume (mm3) as a 
function of time (Figure 3.5). As evident from the regressions summary, the slope of tumour 
control (TC: 0.0988) is shallower than the low concentration DXR group (LD: 0.1346), with 
the high concentration DXR group being steepest (HD: 0.145). Surprisingly, this suggests that 
DXR treatment increased tumour growth. 
                                                 
1 Details of this approach are provided by Fields, Miles and Zoë in Discovering statistics using R (Chapter 
11, pp 483-484). 
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Figure 3.5. Linear regression model of logged tumour volume plotted against time. HD: high dose 
group; LD: low dose group; TC: tumour control. All mice were inoculated with EO771 cancer cells. 
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Next, a test for homogeneity of regression slopes was performed to investigate if there were 
any differences in slopes between groups. This analysis indicated that the slopes were indeed 
significantly (Time:Group, p< 0.001) different (Figure 3.6). 
 
Figure 3.6. Homogeneity of regression slopes. The Time:Group interaction is significant, indicating a 
violation of the assumption of homogeneity of regression slopes (i.e. slopes are significantly 
different). 
In conclusion, these observations indicate, unexpectedly, that the DXR significantly increased 
tumour growth. Interestingly, DXR had previously been shown to enhance tumour motility and 
metastatic potential in another mouse mammary carcinoma, the 4T1 cancer cells, as well as in 
human MDA-MB-231 cancer cells (Bandyopadhyay et al., 2010). Evidence suggests that DXR 
might mediate this effect by upregulating transforming growth factor-beta (TGF-β) signalling 
in cancer cells. Similarly, others (Formelli et al., 1986) have noted that B16 cells repeatedly 
selected for DXR resistance occasionally demonstrated an “enhancement in metastasis 
formation not associated with an increase in survival time”, suggesting that underlying cellular 
mechanisms by which cells undergo adaptation to doxorubicin may also have an impact on 
tumour growth.  
Collectively, these results suggest a cell-autonomous mechanism by which DXR may enhance 
tumour growth: TGF-β is also known to play a role in the ability of cells to manipulate their 
micro-environment and enhance metastatic potential (Massagué, 2008). In addition, as tumour 
cells ‘spread out’, competition among cells for resources will be relaxed, consequently 
enhancing the growth potential of cancer cells. However, it is also possible that DXR may 
promote cancer growth via its impact on the host. As an example, tissue damage caused by 
DXR may promote the release of growth factors in order to initiate tissue repair. It is also 
possible that DXR may increase tumour growth by inhibiting the immune system directly, as 
monocytes/macrophages are known to “represent a major target of doxorubicin” (Krysko et al., 
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2011). Similarly, DXR may have a negative impact on other immune cell such as NK cells, 
thus promoting tumour growth by preventing immune surveillance. 
3.5 The effect of DXR on tolerance of mice to EO771 
In order to assess the effect of DXR on tolerance of mice to EO771 tumour cells, a regression 
curve was fitted to a plot with body weight as response variable and tumour volume as predictor 
variable (both tumour volume and body weight were log-transformed) (Figure 3.7). 
Implementing the same statistical analysis as discussed above, it was found that slopes were 
indeed significantly (p < 0.01) different. The tumour control group (TC) exhibited a positive 
regression coefficient whereas both DXR groups (LD and HD) presented negative slopes.  
Of note, the R2 values are very low, indicating that tumour volume had little predictive effect 
on health status. This would suggest that most of the effect on health status may relate to the 
group to which mice had been assigned (i.e. depending on whether mice received DXR or not). 
Indeed, EO771 tumours did not induce weight loss (as indicated by the positive slope of the 
TC group), indicating that these tumours were well tolerated. Also, only the TC group exhibited 
a significant slope. However, pooling TC and HD groups, and comparing the slopes from 
pooled samples to TC (i.e. comparing mice that received DXR versus tumour control) 
demonstrated a significant (Z = 23.886, p < 0.01) difference between mice receiving DXR and 
the TC group. 
  
Stellenbosch University  https://scholar.sun.ac.za
   
 
     44 
 
 
Figure 3.7. Linear regression model of the logged tumour volume plotted against time. HD: high dose 
group; LD: low dose group; TC: tumour control. Only the TC slope (i.e. regression coefficient) was 
significant. 
 
Group TC Std. Error t value p value
Intercept: 2.98132 0.05295 56.306 <2e-16 ***
Slope: 0.02259 0.01041 2.169 0.0324 *
R² 0.0441
Group LD Std. Error t value p value
Intercept: 3.15425 0.05757 54.794 <2e-16 ***
Slope: -0.01454 0.01124 -1.294 0.199
R² 0.01663
Group HD Std. Error t value p value
Intercept: 3.147542 0.050106 62.82 <2e-16 ***
Slope: -0.014753 0.009772 -1.51 0.134
R² 0.02296
F-statistic: 4.705 on 1 and 102 DF,  p-value: 0.03239
F-statistic: 1.674 on 1 and 99 DF,  p-value: 0.1987
F-statistic: 2.279 on 1 and 97 DF,  p-value: 0.1344
Regression summary: Tolerance (Dox)
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Since pathology may manifest in the absence of any discernible decrease in body weight, MCA 
was determined as a secondary measure of tolerance. As expected, TC had a higher average 
MCA in comparison to mice in the HD group. However the difference between TC and LD 
was not significant (p = 0.248). 
 
Figure 3.8. The muscle cross sectional area (MCA) in EO771 tumour bearing mice treated with low 
and high dose DXR. HD: high dose group; LD: low dose group; TC: tumour control.  
The results from the MCA thus partially support the tolerance measured by body weight. As 
expected, mice receiving a high dose of DXR exhibited a significantly lower MCA than the 
other groups. The lack of significance between the LD and TC groups (despite the decrease in 
tolerance slopes) may be explained by the fact that data demonstrated large variance. In 
particular, the site of tumour inoculation might have induced another source of variance: as the 
tumour grew, the gait of the mice might have altered, resulting in the mice shifting workload 
on to the unimpeded leg. In turn, a higher work load might have led to muscle hypertrophy and 
a subsequent increase in MCA. 
3.6 Resistance of mice to B16 and EO771  
The same statistical analyses were performed to test the tolerance and resistance of C57BL/6 
mice against the two syngeneic cancer cell lines, EO771 and B16. As illustrated below (Figure 
3.9), the B16 cells (M) grew much faster than EO771 (TC). Quantitatively, the mice exhibited 
lower resistance to B16 (slope of 0.2591) compared to EO771 (slope of 0.0998). In addition to 
differences in slopes, R2 was also higher for B16 tumours than EO771 (0.72 vs 0.40). The 
comparatively lower R2 for EO771 cells could imply that tumour growth is only partially 
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predicted by time, and is more influenced by other factors. As an example, B16 cancer cells 
may be more effective in controlling their local environment, whereas EO771 cells may be 
more dependent on random factors (e.g. proximity to arteries for blood supply). 
 
 
Figure 3.9. Linear regression model of log tumour volume plotted against time. M: B16; TC: (tumour 
control) EO771. 
Group TC Std. Error t value p value
Intercept: 4.27254 0.10695 39.948 <2e-16 ***
Slope: 0.09883 0.01189 8.309 4.36E-13 ***
R² 0.4036
Group M Std. Error t value p value
Intercept: 5.9841 0.11908 50.25  <2e-16 ***
Slope: 0.25917 0.02281 11.36 1.38E-15 ***
R² 0.7169
Regression summary: Resistance  (EO771 vs B16) 
F-statistic: 69.03 on 1 and 102 DF,  p-value: 4.357e-13
F-statistic: 3.071 on 1 and 51 DF,  p-value: 0.08572
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3.7 Tolerance of mice to B16 and EO771  
Mice inoculated with B16 cells demonstrated a significantly lower tolerance compared to mice 
bearing EO771 tumours (Figure 3.10): Mice bearing EO771 tumours exhibited a positive 
growth (slope = 0.02259), whereas B16 tumours induced weight loss (B16 = -0.02109). The 
larger body weight (i.e. higher intercept on the y axis) of the TC group (EO771 mice) resulted 
from the vastly reduced lag phase before tumours become measurable: since all inoculated 
mice were young (4-5 weeks old) and still growing, a shorter lag time in the B16 resulted in 
these mice being measured at a younger age (and thus lower initial body weight). Hence, the 
discrepancy between intercepts (i.e. initial body weights) reflects the ±two weeks of additional 
growth that the TC group underwent before tumours became measurable. 
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Figure 3.10. Linear regression model of log tumour volume plotted against time. TC: tumour control 
EO771 cancer cells. M: B16 melanoma cells. The slope of the M group is not significant. 
 
However, quantifying tolerance by differences in MCA did not reveal a significant difference 
between B16 and EO771 cancer cells (Figure 3.11). 
Group TC Std. Error t value p value
Intercept: 2.98132 0.05295 56.306 <2e-16 ***
Slope: 0.02259 0.01041 2.169 0.0324 *
R² 0.0441
Group M Std. Error t value p value
Intercept: 3.01724 0.08664 34.826  <2e-16 ***
Slope: -0.02109 0.01204 -1.752 0.0857 .
R² 0.05679
F-statistic: 4.705 on 1 and 102 DF,  p-value: 0.03239
F-statistic: 3.071 on 1 and 51 DF,  p-value: 0.08572
Regression summary: Tolerance (EO771 vs B16) 
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Figure 3.11. The muscle cross sectional area (MCA) in mice bearing EO771 and B16 tumours. M: 
Melanoma (B16 tumour cells); TC: tumour control (EO771 tumour cells). 
At first glance, the lower tolerance of mice to B16 cells may be attributed to the observation 
that these mice are also less resistant to this cancer cell line, suggesting that a form of metabolic 
exhaustion may be driving pathology. Yet, the R2 values are very low (i.e. the correlation 
between body weight and tumour volume is low, an observation also noticed for EO771 
tumours). This may suggest that it is not tumour volume as such that is driving the decline in 
health, but rather the type of tumour. In turn, this would suggest that B16 cells induce pathology 
(weight loss) through mechanisms that are influenced by the noxious phenotype of the tumour 
and not only tumour load. However, the slopes for B16-bearing mice are not significant, and 
similarly, the MCA did not differ significantly. 
3.8 Discussion 
3.8.1 Effect of DXR on tolerance and resistance 
The first notable finding of the current study is the observation that DXR enhanced tumour 
growth (Figure 3.5). Though this result is counter-intuitive, DXR has previously been shown 
to enhance tumour motility and metastatic potential in another mouse mammary carcinoma, 
the 4T1 cancer cells, as well as in human MDA-MB-231 cells (Bandyopadhyay et al., 2010). 
Similarly, it was previously (Formelli et al., 1986) demonstrated that B16 cells repeatedly 
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selected for doxorubicin resistance eventually developed an “enhancement in metastasis 
formation not associated with an increase in survival time”, suggesting that the underlying 
cellular mechanism by which cells undergo adaptation to doxorubicin may also have an impact 
on tumour growth. Thus, although our results are unexpected, similar findings have been 
observed in both human and mouse cancer cells. 
DXR may enhance tumour growth through either its effect on cancer cells (i.e. virulence), or 
by altering host physiology in a manner that is more conducive to tumour growth (i.e. 
resistance). A virulence mechanism by which DXR may enhance tumour growth is through the 
up-regulation of TGF-β signalling in cancer cells (Bandyopadhyay et al., 2010). TGF-β is 
known to play a role in the ability of cells to manipulate their micro-environment and enhance 
metastatic potential (Massagué, 2008). In addition, as tumour cells ‘spread out’, competition 
among cells for resources will be relaxed, consequently enhancing the growth potential of 
cancer cells. However, DXR may also have an impact on the micro- or macro-environment 
(i.e. affect host resistance). As a plausible example, tissue damage caused by cytotoxic DXR 
may result in the subsequent release of growth factors to promote tissue repair. Similarly, it is 
also possible that DXR could increase tumour growth by inhibiting the immune system 
directly, as monocytes/macrophages are known to “represent a major target of doxorubicin” 
(Krysko et al., 2011). It is thus not possible to conclude if DXR decreased resistance (i.e. 
inhibited host ability to attenuate tumour growth) or enhanced tumour virulence (enhance 
cancer cells ability to growth within host). 
Regressing tumour volume against time (Figure 3.5) resulted in a higher R2 value of mice 
receiving DXR (R2 = 0.661 in high dose and 0.646 in low does DXR) compared to the TC 
group (R2 = 0.404), suggesting that in mice receiving DXR, time were a better predictor of 
tumour growth. This might imply that DXR eliminated other sources of variance that might 
impact on tumour growth (i.e. additional sources of variance that predict tumour growth other 
than time). The underlying biological reason for this is unclear. However, DXR-induced tissue 
damage may result in the release of systemic growth factors that promote tissue repair. In turn, 
the release of growth factors may not only promote tumour growth, but allow a tumour to grow 
at the maximum rate, and thus, a more consistent rate. Similarly, systemic factors may decrease 
dependency on the tumour micro-environment (e.g. the infiltration of immune cells, the release 
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of danger signals by ischaemic and dying cells), thus removing a stochastic element of tumour 
development (e.g. the proximity to major blood vessels, or the formation of necrotic centres). 
Not only does a reduction of muscle mass carry great prognostic value (Martin et al., 2013), 
but DXR has also been shown to induce a loss of extensor digitorum longus muscle mass in 
mice receiving 20 mg/kg DXR – a dose similar to the HD group (Gilliam et al., 2009). Thus, 
as expected, administration of DXR resulted in lower tolerance slopes. However, this 
difference only reached significance after pooling results from both high- and low-dose DXR 
groups. Also, a lower MCA was only observed for mice receiving a high dose of DXR. The 
fact that MCA did not completely correlate with tolerance slopes (i.e. that LD and HD had 
similar tolerance slopes, as measured by body weight, but HD exhibited lower MCA compared 
to LD) indirectly suggests that a decrease in body weight does not completely correlate with a 
decrease in muscle mass.  
This small discrepancy between MCA and tolerance slopes may result from a number of 
factors. Firstly, the decrease in body weight is not only dependent on a decrease in muscle 
mass, but may also result from the depletion of glycogen or fat stores, a decrease in bone 
mineral density, or atrophy of other organ systems. Secondly, it is also possible that a more 
pronounced decrease in body weight in HD mice is ‘masked’ by weight gained from 
pathological manifestations. As an example, an accumulation of fluids, e.g. ascites resulting 
from liver, kidney or heart failure, may mask a decrease in body weight. However, no overt 
signs of pathology were observed in the mice during tissue harvesting. Thirdly, it should be 
noted that a decrease in muscle mass and muscle quantity does not necessarily correlate with a 
decrease in MCA. As an example, in response to muscle damage caused by DXR, muscle fibres 
may split – a process that promotes the expansion of muscle mass by hyperplasia (instead of 
hypertrophy). Here, smaller muscle fibres may in fact represent a form of adaptation and not 
pathology. Also, DXR may affect different fibre types differently. For example, (Hydock et 
al., 2011) found that in rats, DXR exerted a more pronounced adverse effect of muscle function 
in soleus muscle, which consist of more oxidative fibre types compared to GAS. Finally, it 
could be deduced that the myotoxicity effect of DXR may be counteracted by the increase in 
‘resistance training’ of the muscle, as the tumour caused the mice to shift their weight to the 
non-tumour-bearing side (i.e. their right side), as mentioned earlier. Since the position and 
dimensions of growth differ from one tumour to another, mice would also vary in the extent to 
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which body weight is shifted onto the right hind limb and consequently, the effect of muscle 
loading. This introduces another source of variance in the data set, dampening the effect.  
3.8.2 Comparative tolerance and resistance between B16 and EO771 tumours 
Tumours developing from B16 cells grew at a greater pace than those that developed from 
EO771. Consequently, fewer data points were recorded for regression analysis. Nevertheless, 
the resistance slope for B16 was significantly higher. Interestingly, despite fewer data points, 
the linear model fitted the M group more accurately compared to the TC group (R2 for TC 
group 0.4 vs 0.7 for M group). This may suggest that the growth trajectory of EO771 cells is 
more stochastic, depending on factors other than time. The biological basis for this more 
‘predictable’ growth of B16 cells is not clear, but as mentioned, it may suggest that B16 cells 
are more able to control the micro environment, thus ensuring consistent growth. 
With regard to tolerance, B16 appear to be less tolerant, though the slope of the regression line 
was not significant. Similarly, a decrease in MCA was also not significant between tumour 
control (TC, EO771 cells) and melanoma (M, B16 cells) groups. The non-significance may 
relate to the fact that, due to the rapid growth of B16 tumours, fewer data points were recorded 
for regression analysis. Further complicating interpretation of results, B16-bearing mice were 
sacrificed at a younger age (due to rapid tumour growth), rendering a direct comparison 
between EO771 and B16 in terms of tolerance more difficult. As an example, age of the mice 
may influence the distribution of muscle fibre types, and, since muscle fibre type also relates 
to MCA, age may alter the MCA independent of tumour load. Also, in young, growing mice, 
tolerance may manifest as a lack of growth, rather than a negative slope. This would suggest 
that mice are indeed even less tolerant to B16 tumours than predicted.  
3.9 Conclusion 
In conclusion, it was found that as a result of the lower tolerance associated with DXR, together 
with the fact that DXR enhances tumour growth, DXR therapy was not effective in our mice 
model system. This finding illustrates the efficacy of implementing the T/R framework in 
exposing the driver of pathology as manifesting from low resistance or low tolerance, but also 
points out a number of surprising findings, and highlights some challenges. Although the result 
from MCA does corroborate the results from T/R slopes, this effect may be even more 
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pronounced in different muscle types. This observation also raises the possible problem that 
may emerge when different metrics of tolerance exhibit contradicting results. A major 
challenge in comparing T/R of different cancer cells is that cancer cells grow at different rates, 
and subsequently any comparison must also take into account that mice will be sacrificed at 
different ages. The problem is particularly acute when comparisons are being made between 
full-grown versus juvenile mice. Age-matches controls for each group may not be practical, 
but using fully grown mice may at least avoid the complication of interpreting results. 
We hypothesised that the higher R2 value of mice receiving DXR may be explained by the 
systemic release of growth factors, resulting in maximum (and therefore constant) tumour 
growth. Systemic factors may also hint at the possible mechanism of pathology. As an example, 
inflammatory cytokines may cause muscle atrophy. In this regard, implementing a multiplex 
system (Luminex™ assay), the changes in different serum cytokines/growth factors was 
measured, but results obtained for seven out of the eight growth factors/cytokines were below 
the detectable range (data not shown) and discarded.  
As an alternative, we focused on the pathology of DXR as mediated by altered hepatic function. 
Most research has focused on the well-established cardio-toxicity of DXR (Octavia et al., 
2012). However, DXR also exhibits hepatotoxicity (Kalender et al., 2005) suggesting that liver 
damage may contribute to the manifestation of pathology. In addition, rapidly dividing tumour 
cells may increase metabolic load on the liver. In this regard, pathology may manifest as a form 
of ‘metabolic exhaustion’ – particular relevant in young mice that are still growing. 
Consequently, the remainder of the research investigated the manifestation of pathology as a 
result of DXR treatment, focusing on the liver. However, the surprising observation that DXR 
can induce tumour growth could also suggest that cancer cell phenotype may be altered by 
DXR in a manner that would promote tumour growth. The following chapter focuses on the 
effect of DXR on cancer cell growth. 
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4.  Chapter 4 
The unexpected finding that DXR increased tumour growth promoted subsequent analyses 
to elucidate the underlying cell signalling events implicated in this phenomena. Here, 
findings from western blot analyses are provided. 
4.1 Introduction 
Doxorubicin (DXR) exerts its cytotoxic effect via a number of mechanisms. One key 
mechanism is the binding and inactivation of DNA topoisomerase II, resulting in covalently 
bound topoisomerase to DNA, resulting in single and double strand breaks in DNA (Tewey et 
al., 1984). In turn, DNA damage initiates the DNA damage response, and ultimately induces 
apoptosis (Li et al., 2016). It has also been noted that, although DXR preferentially binds to 
topoisomerase II (Zhang et al., 2012), DXR-induced cardiotoxicity might be mediated by 
inhibition of mitochondrial topoisomerase (Khiati et al., 2014). Cardiac tissue maintains high 
levels of oxidative respiration, with a corresponding high level of mitochondrial content. The 
DXR-mediated cardiotoxicity might thus directly relate to the increased mitochondrial damage 
inflicted by DXR on mitochondrial topoisomerase (Khiati et al., 2014). In addition to 
cardiotoxicity, DXR also adversely affects other rapidly dividing cells, and myeloid toxicity 
resulting in neutropenia as well as anaemia has long been noted (Dessypris et al., 1986).  
However, it is generally acknowledged that DXR also mediates its toxic effects through 
topoisomerase-independent mechanisms (Gewirtz, 1999; Mukhopadhyay et al., 2009). Another 
key mediator of DXR-associated toxicity includes oxidative stress resulting from radical 
formation (Doroshow and Davies, 1986). However, anti-oxidants as well as iron chelating 
agents have thus far not been effective in attenuating the toxic effects of DXR (Ghigo et al., 
2016). Recently, it has been shown that DXR, intercalating with DNA, can result in histone 
eviction, resulting in a deregulated transcriptome (Pang et al., 2013). A deranged transcriptome 
might indeed impose a novel form of cellular stress, yet it remains to be explained why such a 
mechanism would be particularly toxic to cardiac tissue. In this regard, it has been noted that 
mitochondrial DNA (mtDNA), though lacking histones, also interact with proteins that protect 
mtDNA against radiation and free radicals (Guliaeva et al., 2006). It is thus tempting to 
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speculate that the intercalation of DXR with DNA that results in histone eviction might 
similarly inhibit the binding of protective proteins to the mtDNA, which rendering mtDNA 
more susceptible to oxidative stress. 
It is likely that a combination of these toxic effects might be at play, or that one mechanism 
predominates in certain cellular contexts (Kato et al., 2000). The range of mechanisms by 
which DXR mediates its toxicity might also explain why DXR is used to treat a vast array of 
both solid and haematological malignancies. Yet, the fact that DXR is effective against many 
cancers, in conjunction with the diverse mechanism of toxicity, renders the finding that DXR 
enhanced tumour growth all the more surprising.  
From a tolerance/resistance perspective, DXR could promote tumour growth by either 
decreasing host resistance, or by enhancing tumour virulence. As an example, DXR might 
enhance tumour growth by adversely affecting immune cells, compromising the host’s ability 
to eliminate cancer cells through immune editing. However, such a hypothesis is not easily 
testable, given the complex nature of measuring immune surveillance and the anti-cancer 
activity of the immune system. Alternatively, DXR may alter cancer-intrinsic processes that 
may promote tumour growth. In this chapter, efforts to evaluate the effect of DXR on cancer 
virulence (i.e. the ability of DXR to promote tumour growth by enhancing cell-intrinsic 
mechanisms) are reported. 
4.2 Cell Signalling 
4.2.1 Apoptotic signalling 
Apoptosis can be initiated via either intrinsic or extrinsic pathways (Figure 4.1). The extrinsic 
pathway is often activated by immune cells, e.g. cytotoxic T cells, as well as Natural Killer 
cells (Wilson et al., 2009) or signalling effectors such as Tumour Necrosis Factor (TNF) (Wang 
and El-Deiry, 2003). In contrast, the intrinsic pathway is typically activated by cell stress such 
as DNA damage, oxidative stress, or as part of the endoplasmic reticulum (ER) stresses 
(unfolded protein response), and is characterised by the important role played by the release of 
key mitochondrial proteins such as cytochrome C (Cyt C) (Fulda and Debatin, 2006). 
Intrinsic activation of p38 protein kinase (by various cell stressors such as DNA damage) 
results in the activation of p53 (Bulavin et al., 1999). In turn, p53 regulates the expression of 
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the pro-apoptotic proteins, Bid (Sax et al., 2002) and Bax (Chipuk et al., 2004). Similarly, p53 
can also induce apoptosis via a transcription-independent mechanism, including the direct 
activation of Bax [(Basu and Haldar, 1998; Chipuk et al., 2004), which promotes mitochondrial 
permeability and the formation of the apoptosome. The intrinsic and extrinsic pathways also 
intersect. Caspase 8, activated by the extrinsic pathway, can cleave cytosolic Bid, rendering the 
activated truncated Bid (tBid) (Li et al., 1998). The truncated Bid translocates from the cytosol 
to the mitochondria where it mediates the release of Cyt C (Tan et al., 2014). Once released, 
Cyt C forms a complex with caspase 9 and Apaf-1, known as the apoptosome, which 
subsequently activates executioner caspases (caspase 3, 6 and 7), and ultimately induces 
apoptosis (Cain et al., 2002; Garrido et al., 2006). In addition, these executioner caspases can 
also be activated through proteolytic cleavage of caspase 12 (Liu et al., 2014) or caspase 8 
(Fernandes-Alnemri et al., 1996). 
 
Figure 4.1. The intrinsic and extrinsic pathways of apoptosis. Various intrinsic stressors such as DNA 
damage, ROS or ER stress induce apoptosis via the intrinsic pathway, where death receptor 
activation (e.g. by TNF) induces apoptosis through the extrinsic pathway. 
Since an increase in tumour growth could be mediated by a decrease in cell death, cell death 
pathway proteins such as the cleavage (i.e. activation) of various caspases (3, 8 and 9) as well 
as initiators (e.g. p38 and caspase 12) of the apoptotic pathway are investigated in the current 
study. The expression of Bcl-2 was also assessed, since this protein is often upregulated during 
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cell stress and prevents the induction of apoptosis through the inhibition of Cyt C being released 
from the mitochondria (Cory et al., 2003). Furthermore, Bcl-2 is also and occasionally 
associated with the development of chemo-resistance (Sartorius and Krammer, 2002). 
4.2.2 Cell growth and pro-survival signalling 
The raf/MAPK/ERK and PI3K/PTEN/Akt/mTOR pathways play a key role in promoting cell 
growth and proliferation (Figure 4.2). Indeed, altered expression or mutations of genes 
involved in these pathways are often associated with both cancer development and chemo-
resistance (Steelman et al., 2011). As an example, the application of mTOR inhibitors in 
treating certain tumours has also been proposed (Pópulo et al., 2012). Similarly, most tumours 
exhibit mutations in signalling proteins which occur upstream of ERK (Samatar and 
Poulikakos, 2014). Also, activation of Akt signalling pathways antagonises various mediators 
of apoptosis (Avan et al., 2016). It is thus likely that altered expression and activation status of 
key proteins involved in these pathways may explain the observed DXR resistance and tumour 
growth observed in mice in our study. 
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Figure 4.2. Cell-signalling pathways involved in cell growth and proliferation. 
External stimuli such as growth factors (GF) bind to the receptor tyrosine kinase (RTK) where 
after subsequent receptor auto-phosphorylation creates binding sites that then recruit IRS, an 
adaptor protein for phosphoinositide 3-kinase (PI3K). Activated PI3K mediates the 
phosphorylation of phosphatidylinositol (4,5)-bisphosphate (PIP2) to generate membrane-
bound phosphatidylinositol (3,4,5)-trisphosphate (PIP3). Pleckstrin homology (PH) domains in 
Akt and phosphoinositide dependent protein kinase-1 (PDK1) recognize PIP3 and translocate 
to the membrane. In turn, PDK1 phosphorylates the activation loop of Akt on the threonine 
residue, thus partially activating Akt (Hemmings and Restuccia, 2012). Subsequent 
phosphorylation of Akt on the serine residue by mTORC2 (mechanistic target of rapamycin 
complex 2) fully activates Akt, which initiates downstream mitogenic cell-signalling events, 
and antagonises cell-death pathways (Avan et al., 2016; Manning and Cantley, 2007) 
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Furthermore, Akt activates mTORC1 which upregulates biosynthetic pathways (Avan et al., 
2016; Manning and Cantley, 2007).  
Similarly, GF binding activates RTK auto-phosphorylation, generating binding sites for the 
SHC and GRB2 adaptor molecules that recruit SOS, the RasGEF (GTPases exchange factor) 
to the membrane. SOS catalyses Ras GTP exchange and Ras-GTP then recruits Raf to the 
membrane, where it gets activated (Weber et al., 2001). Raf activates MEK and MEK activates 
ERK via activation loop phosphorylation (Sasaki et al., 2003). The activated ERK translocates 
to the nucleus where it regulates the expression of various proteins including proteins involved 
in cell proliferation (Lidke et al., 2010; Zhang and Liu, 2002).  
Key regulators which oppose these signalling cascades include Jun amino-terminal kinases 
(JNK) and Phosphatase and tensin homolog (PTEN). The activity of PTEN is controlled on 
various levels including transcriptionally (methylation status, miRNAs or the presence of 
transcription factors), by posttranslational modifications and various interactions with other 
proteins (Song et al., 2012). PTEN is a well-established anti-cancer protein which is often 
mutated or inactive in various types of cancers (Cully et al., 2006). This function is also 
signified by the fact that other anti-apoptotic proteins such as p53 plays a key role in the 
transcription of this protein (Stambolic et al., 2001). Mechanistically, PTEN antagonises the 
PI3K-Akt pathway by catalysing the hydrolysis of PIP3 to PIP2, thereby opposing the function 
of PI3K (Georgescu, 2010).  
JNK can exert contrasting effects, depending on the cellular context. Earlier studies have 
implicated JNK as a key mediator of the cellular stress response. This is also exemplified by 
JNK’s alternative name – stress-activated protein kinase. Indeed, inflammatory cytokines such 
as TNF are known to activate the JNK-signalling pathway (Liu et al., 1996). In line with JNK’s 
function during cellular stress, JNK rapidly inhibits protein synthesis (Banerjee and Kyriakis, 
1994). JNK can also antagonise the mutagenic-signalling cascades by inhibiting the Akt-
signalling pathway (Sunayama et al., 2005). Furthermore, constitutive activation of JNK can 
lead to the induction of apoptosis through both transcriptionally dependent and independent 
mechanisms (Chen et al., 1996; Donovan et al., 2002; Donovan et al., 2002; Shen and Liu, 
2006). In fruit flies the activation of JNK can act as a switch between signalling cascades, 
moving from apoptotic to mutagenic pathways (Ryoo et al., 2004). Similarly, in cancer cells 
lacking PTEN, an upregulation of both JNK and Akt promote cell proliferation, and the 
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anchorage-independent growth of cancer cells (Vivanco et al., 2007). The ultimate function of 
JNK activation is thus dependent on the cell type, and in particular with reference to an 
oncological context, dependent on the genomic lesions carried by the cancer cells. 
4.3 Study outline 
Western blot analysis was conducted on key signalling proteins in order to identify the 
signalling circuits activated in tumours in response to DXR (Figure 4.3). For each group (either 
tumour control, mice receiving low dose DXR, or mice receiving high dose DXR) a total of 8 
mice were randomly selected.  
 
Figure 4.3. Study design to identify key singling proteins in tumour samples. Tumour samples from 
8 mice in each group were subjected to Western Blot analysis. 
4.4 Materials and methodology 
Harvested cancer tissue was thawed on ice and lysed by adding radioimmunoprecipitation 
assay (RIPA) buffer (0.1% SDS, 5 mM EGTA, 5 mM EDTA, 65 mM Tris, NP-40, 1% Na-
deoxycholate and 154 mM NaCl at pH 7.4), freshly supplemented with protease and 
phosphatase inhibitors (Aprotinin, Leupeptin and Benzamidine at 1 µg/ml, and NaF, Na3VO4 
and PMSF at 1 mM). Tissue samples were subsequently homogenised (KineMatica Polytron™ 
PT2100 homogeniser, Fisher Scientific), and left on ice for 2 hours prior to being centrifuged 
(12000 rpm for 20 min) at 4°C, where after the supernatant was collected and stored at -80°C 
for later analysis. 
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Protein concentration was determined using the Bradford method (Bradford, 1976). Briefly, a 
×5 stock solution (500 mg G-250 Coomassie Brilliant Blue dissolved in a solution consisting 
of 250 ml 95% ethanol and 500 ml phosphoric acid, filled to 1L with distilled water) was 
diluted to a ×1 stock solution and filtered to remove any undissolved Coomassie particles. A 
standard curve was generated from a two-fold serial dilution (blank, followed by a 2-20 µg 
protein gradient) of 100 µl bovine serum albumin (BSA, Roche) added to 900 μl Bradford 
reagent. Protein samples (5 μl each) were diluted in distilled water (95 μl), where after Bradford 
reagent (900 μl) was added. The protein concentration was spectrometrically determined by 
measuring the absorbance spectra at a wavelength of 595 nm (Cecil CE 2021 
spectrophotometer, Cecil Instruments). Proteins samples above the linear absorbance range 
were diluted with RIPA buffer. 
Protein lysates were denatured with Laemli’s sample buffer (working solution consisting of 
5% beta-mercaptoethanol, 4% SDS, 10% glycerol, 0.03% bromophenol blue and 62.5 mM 
Tris, pH 6.8) prior to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 
Based on Bradford protein quantification results, samples were diluted with Laemli’s sample 
buffer to 50 μg of total protein. Samples were frozen at -80 °C. These samples were later 
thawed on ice, vortexed, and heated to 95°C for 5 minutes before use. The molecular weights 
of bands were established from the BLUeye Prestained Protein Ladder (Genedirex). After 
loading the samples, gels were run for 10 min at 100 V, where after the voltage was increased 
(150 V) and samples were run until the dye-front approached the end of the gel (~90 minutes) 
in Tris/Glycine/SDS running buffer (Bio-Rad). Proteins were separated using a TGX Stain-
Free FastCast™ Acrylamide kit (12% acrylamide gel, Bio-Rad).  
Protein was referred to a membrane using Trans-Blot® Turbo™ RTA Mini PVDF Transfer 
Kits (Bio-Rad) according to the manufacturer’s specifications: PVDF membranes were 
submerged in methanol (100%) for 10 seconds, and subsequently incubated, along with 
blotting paper, in transfer buffer (supplied with kit) for 2 min. Proteins were transferred to the 
membrane on a Trans-Blot Turbo Transfer System (Bio-Rad) for 10 minutes (25V, 2.5 A). 
After transferring the proteins onto membranes, the proteins were fixed by bathing membranes 
in 100% methanol where after they were air-dried. Membranes were subsequently re-
submerged in methanol and washed in TBS-T (tris-buffer saline: 20 mM tris, 137 mM NaCl, 
0.1%Tween-20 and pH 7.6). 
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The TGX Stain-Free FastCast™ gels are infused with trihalo compounds which interact with 
tryptophan amino acids, which then provide a fluorescent signal at the 300 nm wavelength and 
provides a means for quantifying total protein content, and allow the subsequent normalisation 
of protein content. Visualisation of total protein was performed using the ChemiDoc™ MP 
System (Bio-Rad) by exposing gels to UV light for 150 seconds. 
Membranes were incubated in 5% skimmed milk (diluted with TBS-T) for 1 hour in order to 
avoid non-specific binding of antibodies on the membrane, and subsequently rinsed in TBS-T 
to remove excess milk. Primary antibody incubation was performed overnight at 4°C (see 
Table 4.1 for summary of antibodies used). Following incubation, membranes were again 
washed with TBS-T and incubated with the secondary antibody at room temperature for 1 hour. 
Membranes were washed again before being developed using Clarity™ ECL Substrate (Bio-
Rad) on the ChemiDoc™ MP system. 
Table 4.1. Primary and secondary antibodies used in this study.  
 
Normalisation of protein content was conducted on Bio-Rad Image Lab™ software (version 
5.1) and exported to Microsoft Excel. Groups were compared using a one-way ANOVA 
followed by Bonferroni post hoc comparison for significant (p <0.05) changes between groups 
PTEN 54 Cell Signalling 9559 Rabbit 1:1000 1: 10 000
p-PTEN (Ser380) 54 Cell Signalling 9551 Rabbit 1:1000 1: 10 000
PI3K p85 85 Abcam ab86714 Mouse 1:1000 1: 10 000
p-PI3Kp85 (Tyr458) 85 Elabscience ENP0224 Rabbit 1:1000 1: 10 000
Akt 60 Abcam ab32505 Rabbit 1:1000 1: 10 000
p-Akt (Ser473) 60 Cell Signalling 4060 Rabbit 1:1000 1:10 000
p-Akt (Thr308) 60 Cell Signalling 9275 Rabbit 1:1000 1:10 000
PDK1 58-68 Cell Signalling 3062 Rabbit 1:1000 1: 10 000
p-PDK1 (Ser241) 58-68 Cell Signalling 3061 Rabbit 1:1000 1: 10 000
mTOR 289 Abcam ab51089 Rabbit 1:1000 1:5000
p-mTOR (Ser2448) 289 Abcam ab84400 Rabbit 1:1000 1:5000
cRaf 74 Cell Signalling 9422 Rabbit 1:1000 1: 10 000
p-cRaf (Ser259) 74 Cell Signalling 9421 Rabbit 1:1000 1: 10 000
ERK1/ERk2 42, 44 Cell Signalling 4695 Rabbit 1:1000 1: 10 000
p-ERK1/ERK2 (Thr202/Tyr204) 42,44 Cell Signalling 4370 Rabbit 1:1000 1: 10 000
p38 43 Cell Signalling 9212 Rabbit 1:1000 1: 10 000
p-p38 (Thr180/Tyr182) 43 Cell Signalling 9211 Rabbit 1:1000 1: 10 000
JNK 46, 54 Cell Signalling 9252 Rabbit 1:1000 1: 10 000
p-JNK (Thr183/Tyr185) 46, 54 Cell Signalling 9251 Rabbit 1:1000 1: 10 000
Bcl-2 26 Santa Cruise 130308 Mouse 1:1000 1:5000
Caspase 9 51 Cell Signalling 9508 Mouse 1:1000 1: 10 000
Caspase 8 57 Abcam ab25901 Rabbit 1:1000 1: 10 000
c-Caspase 8 18 Abcam ab25901 Rabbit 1:1000 1: 10 000
Caspase 3 35 Cell Signalling 9665 Rabbit 1:1000 1: 10 000
c-Caspase 3 17, 19 Cell Signalling 9664 Rabbit 1:1000 1: 10 000
2° AB DilutionPrimary Antibody (1° AB)
Molecular 
weight (kDa)
Vendor Catalogue # Species 1° AB Dilution
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compared. Statistical analysis was performed in GraphPad Prism (version 5.0) and R using the 
car package.  
4.5 Results: Pro-survival signalling 
4.5.1 cRaf phosphorylation 
DXR did not significantly alter cRaf phosphorylation between groups: There was no significant 
increase in total or phosphorylated cRaf, and similarly, no increase in the ratio between p-cRaf 
and total cRaf (Figure 4.4). 
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Figure 4.4. The effect of low and high DXR concentration on cRaf protein phosphorylation status. 
(A) Phosphorylated-cRaf1 (p-cRaf) (B) Total cRaf expression. (C) Ratio between p-cRaf and total cRaf 
was not significant different between groups (Control: 1.0 ± 0.17; LD-DXR: 1.13 ± 0.17; HD-DXR: 1.09 
± 0.2). Results are expressed as mean ± SEM. 
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4.5.1 ERK phosphorylation 
The ratio between total and p-ERK was significantly different between the HD-DXR and 
control groups (Control: 1.0 ± 0.16; LD-DXR: 1.58 ± 0.16; HD-DXR: 1.71 ± 0.18), as 
demonstrated by the significant increase in the p-ERK:ERK ratio in the HD-DXR group 
(Figure 4.5). 
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Figure 4.5. The effect of low and high DXR concentrations on ERK protein phosphorylation status. 
(A) Phosphorylated-ERK (p-ERK). (B) Total ERK expression. (C) Ratio between p-ERK and total ERK. 
Results are expressed as mean ± SEM.  
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4.5.2 p38 MAPK 
There was no significant increase in total or phosphorylated p38, and similarly, no increase in 
the ratio between p-p38 and total p38 (Figure 4.6) (Control: 1.0 ± 0.17 versus HD group: 1.27 
± 0.25). 
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Figure 4.6. The effect of low and high DXR concentration on p38 protein phosphorylation status. (A) 
Phosphorylated-p38 (p-p38). (B) Total p38 expression. (C) Ratio between p-p38 and total p38. 
Results are expressed as mean ± SEM.  
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4.5.3 JNK 
There was no significant increase in either total or phosphorylated JNK, and similarly, no 
increase in the ratio between p-JNK and total JNK (Figure 4.7): DXR did not significantly 
alter JNK phosphorylation between groups (Control: 1.0 ± 0.47 versus HD group: 0.9 ± 0.41). 
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Figure 4.7. The effect of low and high DXR concentration on JNK protein phosphorylation status. (A) 
Phosphorylated-JNK (p-JNK). (B) Total JNK expression. (C) Ratio between p-JNK and total JNK. 
Results are expressed as mean ± SEM. 
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4.5.4 PTEN 
There was no significant increase in either total or phosphorylated PTEN (Control: 1.0 ± 0.05 
versus HD group: 1.12 ± 0.07) and similarly, no increase in the ratio between p-PTEN and total 
PTEN (Figure 4.8). 
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Figure 4.8. The effect of low and high DXR concentration on PTEN protein phosphorylation status. 
(A) Phosphorylated-PTEN (p-PTEN). (B) Total PTEN expression. (C) Ratio between p-PTEN and total 
PTEN. Results are expressed as mean ± SEM. 
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4.5.5 PI3Kp85 
There was no significant increase in either total or phosphorylated PI3Kp85, despite a slight 
increase in the HD group (Control: 1.0 ± 0.1 versus HD group: 1.2 ± 0.27). Similarly, no 
increase in the ratio between p- PI3Kp85 and total PI3Kp85 was observed (Figure 4.9). 
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Figure 4.9. The effect of low and high DXR concentration on PI3Kp85 protein phosphorylation status. 
(A) Phosphorylated-PI3Kp85 (p-PI3Kp85). (B) Total PI3Kp85 expression. (C) Ratio between p-
PI3Kp85 and total PI3Kp85. Results are expressed as mean ± SEM. 
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4.5.6 PDK1 
Despite a slight decrease in the HD group (Control: 1.0 ± 0.11 versus HD group: 0.96 ± 0.11), 
DXR did not significantly alter PDK1 phosphorylation status (Figure 4.10). 
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Figure 4.10. The effect of low and high DXR concentration on PDK1 protein phosphorylation status. 
(A) Phosphorylated-PDK1 (p-PDK1). (B) Total PDK1 expression. (C) Ratio between p-PTEN and total 
PDK1. Results are expressed as mean ± SEM.  
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4.5.1 Akt (phosphorylated at thr308) 
Despite a slight increase in the HD group (Control: 1.0 ± 0.2 versus HD group: 1.74 ± 0.44), 
no significant difference in phosphorylation (thr308) was observed (Figure 4.11). 
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Figure 4.11. The effect of low and high DXR concentration on Akt protein phosphorylation status 
(thr308). (A) Phosphorylated Akt (thr308). (B) Total Akt expression. (C) Ratio between p-Akt (thr308) 
and total Akt. Results are expressed as mean ± SEM. 
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4.5.2 Akt (phosphorylated at ser473) 
DXR did not significantly alter Akt phosphorylation (ser473) between groups (Figure 4.12), 
as a slight increase in the phosphorylation of Akt remained non-significant (Control: 1.0 ± 0.2 
versus HD group: 1.74 ± 0.44).   
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Figure 4.12. The effect of low and high DXR concentration on Akt protein phosphorylation status 
(ser473). (A) Phosphorylated Akt (ser473). (B) Total Akt expression. (C) Ratio between p-Akt (ser473) 
and total Akt. Results are expressed as mean ± SEM. 
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4.5.3 mTOR 
There were no significant differences in either total or phosphorylated mTOR, and 
correspondingly, also no increase in the ratio between p-mTOR and total mTOR (Figure 4.13), 
despite a slight increase in the LD group (Control: 1.0 ± 0.38 versus LD group: 1.18 ± 0.24).  . 
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Figure 4.13. The effect of low and high DXR concentration on mTOR protein phosphorylation status. 
(A) Phosphorylated-mTOR. (B) Total mTOR expression. (C) Ratio between p-mTOR and total mTOR. 
Results are expressed as mean ± SEM. 
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4.5.4 Bcl-2 
There were no significant differences in the expression of Bcl-2 between groups (Figure 4.14) 
(Control: 100.0 ± 12.5; LD group: 94.62 ± 9.16; HD group: 84.46± 13.09). 
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Figure 4.14. The effect of low and high DXR concentration on Bcl-2 expression. Results are expressed 
as mean ± SEM. 
4.6 Results: Apoptotic markers 
4.6.1 Caspase 9 
Expression of caspase 9 was not significantly different between groups (Figure 4.15) (Control: 
100.0 ± 12.08; LD group: 115.4 ± 10.81; HD group: 108.3 ± 8.87). 
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Figure 4.15. The effect of low and high DXR concentration on caspase 9 expression. Results are 
expressed as mean ± SEM. 
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4.6.2 Caspase 8 
DXR did not significantly alter the ratio between cleaved and un-cleaved caspase 8 between 
groups (Figure 4.16). This is despite a dramatic (almost 5-fold) increase in the HD group above 
the control group, which is most likely due to the high SEM in the HD group (Control: 1.0 ± 
0.14; LD group: 2.04 ± 0.89; HD group: 5.78 ± 2.95). 
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Figure 4.16. The effect of low and high DXR concentration on caspase 8 cleavage. Results are 
expressed as mean ± SEM. 
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4.6.3 Caspase 3 
There was no significant difference in the ratio between total and cleaved caspase 3 between 
groups (Figure 4.17). 
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Figure 4.17. The effect of low and high DXR concentration on caspase 3 cleavage. Results are 
expressed as mean ± SEM. 
4.7 Discussion 
Although various trends were evident, the only significant change that was observed relates to 
the increase in ERK phosphorylation (Figure 4.5). The lack of significance (e.g. caspase 8 – 
Figure 4.16) is likely because of the greater variance in the data set, as well as the fact that 
Bonferoni is a conservative post hoc test. Caspase 8 activation is mediated via the extrinsic 
pathway by factors such as TNF (Beaudouin et al., 2013) or immune cell activation (Waring 
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and Müllbacher, 1999). TNF might be increased as a result of DXR-induced tissue damage, or 
might be expressed by tumour cells as a result of the hostile micro-environment (e.g. hypoxic 
tumour centres resulting from rapid cell division outpacing vascularisation). However, none of 
the other caspases showed evidence of an increase in cleavage (a marker for the induction of 
apoptosis), suggesting that DXR did not increase cell death. 
ERK, as a member of the mitogen-activated protein kinase super family, antagonises apoptotic 
signals and promotes cell division (Mebratu and Tesfaigzi, 2009). The downstream targets of 
ERK are diverse: ERK1/2 regulates more than 600 proteins (Steelman et al., 2011). ERK 
phosphorylation is induced by growth factors which might be derived from different sources. 
As an example, cancer cells induce the paracrine release of various growth factors by stromal 
cells (Caplan and Dennis, 2006). Similarly, cancer cells themselves can also release trophic 
factors in an autocrine fashion (Hoelzinger et al., 2007). Alternatively, following tissue damage 
resulting from DXR, an increase in circulating growth factors might occur to promote tissue 
repair. In this regard, attempts were made to measure various serum markers using a Luminex 
Bead-based Multiplex Assay platform. Unfortunately, results were below the detectable range, 
likely as a result of experimental error2. 
The mechanism by which DXR promotes tumour growth is thus not clear. One possibility is 
that DXR compromised the immune system of mice, resulting in lower levels of immune 
surveillance. Indeed, the fact that mice exhibited lower tolerance toward DXR demonstrated 
the susceptibility of mice to DXR. Accordingly, the DXR reduced host resistance by 
eliminating immune cells that would otherwise induce cancer cell death. However, this 
argument is not supported by the fact that apoptotic signalling was not observed. Alternatively, 
cell-autonomous mechanisms in cancer cells might explain the increased tumour growth. The 
inability of DXR to induce apoptosis might be a result of an increased expression of efflux 
proteins. As an example, the over-expression of ABC transporters, known to export xenobiotic 
compounds such as DXR (Elliott and Al-Hajj, 2009), is a known mechanism of drug resistance 
in cancer cells. This would imply that DXR did not directly alter cancer cell growth since intra-
                                                 
2 Samples were analysed on the same day as samples from another study, which also generated data below 
the standard curve, suggesting experimental or assay failure rather than a legitimate decrease in serum 
markers. 
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cellular DXR concentrations would be low. However, chemoresistance does no directly explain 
the increase in tumour growth.  Rather, tumour growth might be promoted by the release of 
growth factors after DXR has been cleared or it might have resulted from an increase in serum 
nutrients which might promote cell growth. Collectively, these observations indicate that DXR 
did not alter apoptotic pathways, but could decrease resistance as host reasons to DXR-mediate 
tissue injury. Growth factors released during the resolution phase could have led to the 
activation of ERK pathway in tumour cells, promoting tumour growth, thereby explaining 
lower resistance. 
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5.   Chapter 5 
Both tumour load and chemotherapy are likely to impact on host tolerance and resistance. 
Given the cardinal role played by the liver in energy homeostasis, immunomodulation 
functions and detoxification of xenobiotic, efforts were directed at investigating the effects 
of tumour load (EO771 vs B16) and chemotherapy on hepatic autophagy and cell 
death/survival markers. 
5.1 Introduction 
Various anatomical features, unique to the liver, highlight the key role of the liver as a major 
‘filtering’ organ. While the hepatic arteries provide oxygenated blood, the liver also receives 
blood via the portal vein which derives its blood supply directly from the gastrointestinal tract. 
The portal system thus ensures that any substrate ingested is first ‘filtered’ by the liver before 
entering systemic circulation. Also, the liver exhibits a low blood pressure as a result of various 
hepatic sinusoids, where the slow blood flow provides more time for liver cells to clear toxins 
and foreign bodies. In fact, the liver can contain approximately a quarter of the total cardiac 
output in humans (Dhainaut et al., 2001). Consequently, the liver plays a key role in 
metabolising xenobiotics: the liver expresses a battery of enzymes capable of metabolising 
noxious substrates into less noxious compounds (Shimada, 2006). The liver also performs 
housekeeping functions such as the synthesis of various biological compounds for both local 
and systemic supply, as well as the removal of excess metabolites. Moreover, recent evidence 
indicates that the liver, as opposed to the spleen, might represent the primary organ for the 
removal of damaged erythrocytes (Theurl et al., 2016). The liver also represents the major site 
for vitamin A storage (Blomhoff et al., 1990). 
Another housekeeping function of the liver is the production of primary bile acids by 
hepatocytes, which play an indisputably critical role in the digestion of lipids and the absorption 
of hydrophobic vitamins in micelles. Bile acids are formed by conjugating an amino acid, such 
as taurine, to a cholic acid (a steroid moiety). The polarity and hydrophobicity of the bile acid 
is thus dependent on the moiety conjugated to cholic acid. Hence, the consequence that dietary 
fats has an impact on the type of bile acid produced. As an example, long chain fatty acids are 
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more likely to induce the secretion of more hydrophobic bile acids since these fatty acids are 
less water soluble than short chain fatty acids. Interestingly, the amphiphilic nature of bile acids 
makes it possible for these molecules to disrupt bacterial membranes (Taranto et al., 2006), 
suggesting that bile might also play a role in preventing bacterial overgrowth of the small 
intestine. Conversely, the differential ability of certain bacteria to metabolise bile salts has also 
been implicated in the ontology of dysbiosis between host and intestinal biota. As an example, 
in mice, the introduction of a diet rich in milk fats stimulates the increased production of 
taurine-conjugated bile salts, which in turn promotes the growth of anaerobic bacteria, 
Bilophila wadsworthia, which use the sulphur in taurine as a terminal electron acceptor 
(Devkota et al., 2012). Also, biliary excretion of various xenobiotics can represent a major 
route for the systemic clearance of toxins. As an example, in an isolated perfused rat liver 
model system, almost a third of DXR was cleared by the biliary secretion of unmodified DXR 
(Ballet et al., 1987). Finally, bile salts, either modified by intestinal biota, or unmodified 
entering circulation (being very effectively reabsorbed post-prandially), can bind to various 
nuclear receptors and influence a host of cell types (recently reviewed elsewhere (Kuipers et 
al., 2014; Li and Chiang, 2013). Bile secretion thus has an impact on the population of intestinal 
biota, nutrient absorption and clearance of xenobiotics, and it influences immune and metabolic 
parameters by binding to nuclear receptors. 
The liver also has an important immunological function. Kupffer cells in the liver represent the 
largest population of tissue-resident macrophages (Dhainaut et al., 2001). In response to 
inflammatory stimuli, the liver represents a major site for the production of cytokines, initial 
phase proteins and various pro-thrombotic factors (Dhainaut et al., 2001). However, the liver 
has also been shown to play a role in clearance of such inflammatory mediators (Andus et al., 
1991). In fact, Kupffer cells also play a crucial role in clearance of bacteria (Katz et al., 1991) 
and inflammatory mediators such as lipopolysaccharides (LPS) (Mathison and Ulevitch, 1979). 
As an example, impairment in liver function decreases the ability of the liver to clear bacteria 
(Ashare et al., 2009). Similarly, two hours following a 90% hepatecomy, rats demonstrated 
bacteraemia (Wang et al., 1993). It should however be noted that an increase in bacteria 
entering circulation is not only a result of decreased liver clearance, but also results from an 
increase in the growth of bacteria in the small intestine (Wang et al., 1993). Also, others (Cani 
et al., 2009) have shown that inflammatory mediators could increase gut permeability and 
enhance bacterial translocation, suggesting that the accumulation of bacteria is not only a result 
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of decreased clearance, but also due to an increase in bacteria translocation as a result of 
increased gut permeability.  
As a major site for glycogen storage, along with an extensive capacity for gluconeogenesis, the 
liver plays a key role in glucose homeostasis (Pilkis and Granner, 1992). The role of the liver 
in maintaining energy homeostasis is particularly relevant during an infection, or in response 
to an inflammatory stimulus in general, as the elevated blood glucose during severe infections 
is largely driven by gluconeogenesis in the liver (Dahn et al., 1995; Hirasawa et al., 2009). In 
turn, elevated glucose levels play a key adaptive role: in the mitochondrial matrix of rapidly 
dividing cells (e.g. cancerous as well as non-transformed cells such as rapidly proliferating 
immune cells), glucose is converted to acetyl-CoA which is subsequently fluxed into 
biosynthetic pathways (Vander Heiden et al., 2009). This observation is also supported by the 
finding that the differentiation of monocytes into mature macrophages is inhibited by the 
inactivation of fatty acid biosynthetic pathways (Ecker et al., 2010). In turn, fatty acid synthesis 
drives the production of phospholipids, which is required for mature macrophages to perform 
immune functions (e.g. increased phospholipids for the formation of filopodia as well as 
various organelles such as lysosomes) (Ecker et al., 2010). Finally, tissue rich in phagocytic 
cells such as the liver, spleen and lung consistently show an increase in glucose uptake in a rat 
caecal ligation and puncture model of sepsis (Maitra et al., 2000), demonstrating the increase 
glucose utilisation of immune cells during a bacterial challenge. These observations also 
illustrate the important role of maintaining elevated glucose levels during immune cell 
activation. The key role of the liver in supplying glucose during an infection is exemplified by 
the observation that primary hepatic dysfunction results in a decrease in glucose levels and the 
development of lactic acidosis (Dhainaut et al., 2001).  
Patients in intensive care invariably exhibit a range of anomalous hepatic functional parameters 
(Jenniskens et al., 2016). Some of them might represent manifestations of pathology (i.e. 
pathogenicity) whereas other changes in liver function might in fact be directed to tolerance 
during the challenge, or aimed at resisting an infection. For example, an increase in glucose 
levels has been observed to be an “independent risk factor for increased hospital mortality” 
(Krinsley, 2003). Yet, hyperglycaemia might not be a cause of mortality, but might rather 
reflect a more severe infection. Likewise, other anomalies in liver function might not 
necessarily reflect pathology, but an adaptive response. As an example, hyperbilirubinemia has 
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similarly been described as “a common complication of sepsis” and a predictor of mortality 
during sepsis (Zhai et al., 2009). Yet, bilirubin is a potent antioxidant and could play an 
important role in protecting cells against oxidative stress (Jansen and Daiber, 2012). In this 
regard, the T/R framework might be applied in order to elucidate the physiological relevance 
of various ‘anomalous’ liver functional parameters. 
Various operational aspects of the liver discussed are likely to play a role in response to DXR 
and tumour load. Rapidly dividing cancer cells might induce lactic acidosis (Sillos et al., 2001). 
Disrupted vascular architecture of tumours might induce anaemia as more blood becomes 
pooled in the poorly formed vascular bed (Nagy et al., 2009). Necrotic centres might provide 
a constant supply of sterile inflammatory mediators as intracellular content is spilled into the 
extracellular milieu (Lotze and Tracey, 2005; Trautmann, 2009). Similarly, DXR has been 
shown to increase release of inflammatory cytokines such as prostaglandin E2, and interleukin 
1β and 8 (Kang et al., 2013). Accordingly, targeting cytokine-signalling cascades has been 
proposed as a potential intervention for limiting the toxic effect of DXR (Wong et al., 2013). 
Thus, in addition to the role of the liver in metabolising DXR (Le Bot et al., 1988) and the 
excretion of DXR via bile flow (Ballet et al., 1987), the liver may also play a key role in altering 
metabolic parameters in response to DXR-induced cytokine release. 
Both tumour load and DXR are thus likely to impose stress on the hepatic system. Regarding 
the critical role of the liver in managing the challenge posed by DXR and tumour load, a 
reduction of liver operational capacity will have a great impact on the host’s ability to tolerate 
tumour load and DXR. Accordingly, the aim of this study was to investigate the role of tumour 
load on key hepatic proteins involved in cell survival as well as autophagy, a generic cell stress 
response, in an attempt to explain the observed difference between B17 and EO771 cells. 
5.2 Molecular markers 
Autophagy is a generic cellular stress response that is upregulated in response to a variety of 
cellular insults (Kroemer et al., 2010). Autophagy has been implicated in the removal of 
damaged proteins (Kroemer et al., 2010)  as well as defective cellular organelles such as 
mitochondria (Ward et al., 2016). Since DXR has been implicated in oxidative stress, which 
results in protein and organelle damage (Zhou et al., 2001), it is likely that autophagy may play 
a pivotal role in mediating host tolerance to chemotherapeutic agents such as DXR. 
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Autophagy plays an indispensable role in energy homeostasis by supplying cells with nutrients 
from the breakdown of non-essential cellular components (Kuma et al., 2004). Autophagy is 
also involved in the mobilisation of stored fat (Ward et al., 2016) and glycogen (Zirin et al., 
2013). Rapidly dividing cells could introduce low-level energy stress which might become 
compounded by the toxic effects of DXR. 
Autophagy has also been implicated as a mechanism for cell death, though such claims have 
caused considerable controversy. The role of autophagy in response to cell stress implies that 
autophagy is often upregulated parallel to cell-death pathways similarly activated in response 
to the same stressor. However, a number of observations now implicate autophagy as a 
legitimate cell-death mechanism (‘autosis’) at least under certain conditions (Liu and Levine, 
2015). Similarly, the consequence of an upregulation of autophagy in response to DXR is 
controversial with conflicting results being reported (Dirks-Naylor, 2013). As an example, in 
rats, suppression of autophagy with 3-methyladenine increased cardiovascular performance 
after a DXR challenge, implicating autophagy in the development of cardiovascular disease 
(Lu et al., 2009). Conversely, in mice, inhibition of autophagy with bafilomycin resulted in 
increased mortality, whereas induction of autophagy with rapamycin attenuated the 
development of cardio-toxicity (Sishi et al., 2013). The role of autophagy is thus not fully 
understood.   
Autophagy also plays a key role in modulating inflammatory pathways, where it has been 
implicated in the secretion of activated Il-1β as well as the degradation of pro-Il-1β (Harris et 
al., 2011). Similarly, autophagy has also been implicated in the degradation of inflammasomes 
(Yuk and Jo, 2013). Since the liver hosts a large population of tissue-resident macrophages 
(Kupffer cells), it is likely that autophagy might play a key role in either increasing or 
attenuating inflammatory signalling pathways. Finally, hepatic autophagy might also have an 
important function in removing translocated bacteria, or LPS entering circulation (Katz et al., 
1991; Mathison and Ulevitch, 1979).  
Taken together, these observations demonstrate a number of cellular activities by which hepatic 
autophagy may impact on host tolerance and resistance (Figure 5.1). DXR treatment could 
damage mitochondria, induce the production of radicals which subsequently damage proteins. 
Since DXR damage rapidly dividing cells, including the rapidly dividing stem cells forming 
the intestinal epithelium (Dekaney et al., 2009), it is possible that translocated bacteria might 
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enter circulation where the liver may play an important function in removing pathogens as well 
as noxious factors such as LPS. In addition, removal of apoptotic bodies formed by liver cells 
destroyed by DXR could prevent secondary apoptosis and subsequent inflammation. 
Autophagic activity might also be implicated in an inflammatory signalling context, by 
targeting the inflammasome for degradation, or through the non-canonical secretion of 
inflammatory mediators such as IL-1β. In addition, the role of autophagy in mobilising energy-
rich substrates also suggests that this pathway might have an impact on host resistance, since 
an increase in circulating nutrients might fuel tumour growth.  
 
Figure 5.1. Hepatic autophagy plays a major role in a number of physiological functions. 
In the current study two accepted markers for autophagy activity, p62 and LC3B-II were 
assessed (Figure 5.2). LC3 is cleaved by ATG4 (autophagy-related gene 4) forming LC3-1. In 
turn, cytosolic LC3-I is activated by ATG7 cleavage of a small peptide fragment and 
subsequent lipidation, rendering the active LC3B-II protein witch is membrane-bound, and in 
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turn, is recruited to the autophagosomal membrane (Tanida et al., 2008). The scaffold protein 
p62 can bind to both ubiquitin (Ub) and LC3, thus designating ubiquitinated proteins for 
autophagy degradation (Komatsu et al., 2007). Also, western blot analysis was conducted in 
order to investigate the activation status of mTOR (by phosphorylation on Ser2448) since 
mTOR activation is a strong suppressor of autophagy (Kim et al., 2011). Finally, liver damage 
is also likely to compromise hepatic function, and consequently, pro-survival (e.g. Akt 
phosphorylation status) as well as pro-apoptotic markers (cleavage of caspase 3 and PARP) 
were also assessed by western blot analysis. 
 
Figure 5.2. Both p62 and LC3 play indispensable roles in autophagy. 
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5.3 Study outline 
As outlined in Chapter 3, mice were divided into six groups (Figure 5.3), in order to (a) 
evaluate the effect of DXR on liver parameters in mice bearing EO771 tumours, and (b) to 
determine the effect of B16 versus EO771 tumours on liver function. For western blot analysis, 
liver samples were pooled3: for each group consisting of 12 mice, three liver samples were 
randomly pooled in order to generate four pooled samples for each group.  
 
Figure 5.3. Study design. Liver samples from 12 mice in each groups were pooled (3 mice per sample) 
and subsequently used for western blot analyses. 
                                                 
3 Detailed motivation for pooling samples is detailed in Chapter 6. 
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5.4 Materials and methodology 
Harvested liver samples were thawed on ice and lysed by adding lysis buffer (Table 5.1). 
Tissue samples were subsequently homogenised (KineMatica Polytron™ PT2100 
homogeniser, Fisher Scientific), and left on ice for 2 hours prior to being centrifuged (12 000 
rpm for 20 min) at 4°C, where after the supernatant was collected and stored at -80°C for later 
analyses. 
Table 5.1. Constituents of lysis buffer used for western blot analysis. 
 
Protein concentrations were determined using the Bradford method (Bradford, 1976). Briefly, 
a ×5 stock solution [500 mg G-250 Coomassie Brilliant Blue dissolved in a solution consisting 
of 250 ml 95% ethanol and 500 ml phosphoric acid (filled to 1L with distilled water)] was 
diluted to a ×1 stock solution and filtered to remove any undissolved Coomassie particles. A 
standard curve was generated from a two-fold serial dilution (blank, followed by a 2-20 µg 
protein gradient) of 100 µl bovine serum albumin (BSA, Roche) added to 900 μl Bradford 
reagent. Protein samples (5 μl each) were diluted in distilled water (95 μl), where after Bradford 
reagent (900 μl) were added. The protein concentration was spectrophotometrically determined 
by measuring the absorbance spectra at 595 nm (Cecil CE 2021 spectrophotometer, Cecil 
Instruments). Protein samples above the linear absorbance range were diluted with RIPA 
buffer. 
Protein lysates were denatured with Laemli’s sample buffer (working solution consisting of  
5% beta-mercaptoethanol, 4% SDS, 10% glycerol, 0.03% bromophenol blue and 62.5 mM 
Tris, pH 6.8) prior to sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
Stock 10 ml 20 ml 30 ml 50 ml
20 mM Tris-HCl 200 mM
1 mM EGTA 10 mM
1 mM EDTA 100 mM 100 μl 200 μl 300 μl 500 μl
150 mM NaCl 1 M 1.5 ml 3 ml 4.5 ml 7.5 ml
1 mM β-glycerophosphate - 0.002 g 0.004 g 0.006 g 0.01 g
2.5 mM tetra-Na-Pirophosphate - 0.01 g 0.02 g 0.03g 0.05 g
1 mM Na3VO4 10 mM 1 ml 2 ml 3 ml 5 ml
50 μg/ml PMSF 100 mM 30 μl 60 μl 90 μl 150 μl
10 μg/ml Leupeptin - 10 μl 20 μl 30 μl 50 μl
10 μg/ml Aprotinin - 10 μl 20 μl 30 μl 50 μl
0.1% SDS 10% 100 ul 2 ml 3 ml 5 ml
1 ml 2 ml 3 ml -
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PAGE). Based on Bradford protein quantification results, samples were diluted with Laemli’s 
sample buffer to 50 μg of total protein. Samples were frozen at -80°C. These samples were 
later thawed on ice, vortexed and heated to 95°C for 5 minutes before use. Molecular weights 
of bands where established from BLUeye Prestained Protein ladder (Genedirex). After loading 
the samples, gels were run for 10 minutes at 100 V, where after the voltage was increased (150 
V) and samples run until the dye-front approached the end of the gel (~90 minutes) in 
Tris/Glycine/SDS running buffer (Bio-Rad). Proteins were separated using a TGX Stain-Free 
FastCast™ Acrylamide kit (12% acrylamide gel, Bio-Rad).  
Proteins were transferred to a membrane using Trans-Blot® Turbo™ RTA Mini PVDF 
Transfer Kits (Bio-Rad) according to the manufacturer’s specifications: PVDF membranes 
were submerged in methanol (100%) for 10 seconds, and subsequently incubated, along with 
blotting paper, in transfer buffer (supplied with kit) for 2 minutes. Proteins were transferred to 
the membrane on a Trans-Blot Turbo Transfer System (Bio-Rad) for 10 minutes (25V and 2.5 
A). After transferring proteins onto membranes, proteins were fixed by bathing membranes in 
100% methanol where after it was air-dried. Membranes were subsequently re-submerged in 
methanol and washed in TBS-T (tris-buffer saline: 20 mM tris, 137 mM NaCl, 0.1%Tween-20 
and pH 7.6) 
The TGX Stain-Free FastCast™ gels are infused with trihalo-compounds which interact with 
tryptophan amino acids, which then provide a fluorescent signal at the 300 nm wavelength, and 
provide a means for quantifying total protein content, and allow the subsequent normalisation 
of protein content. Visualisation of total protein was performed using the ChemiDoc™ MP 
System (Bio-Rad) by exposing gels to UV light for 150 seconds. 
Membranes were incubated in 5% skimmed milk (diluted with TBS-T) for one hour in order 
to avoid non-specific binding of antibodies on the membrane, and subsequently rinsed in TBS-
T to remove excess milk. Primary antibody incubation was performed overnight at 4°C (see 
Table 5.2 for summary of antibodies used). Following incubation, membranes were again 
washed with TBS-T and incubated with the secondary antibody at room temperature for 1 hour. 
Membranes were washed again before being developed using Clarity™ ECL Substrate (Bio-
Rad) on the ChemiDoc™ MP system. 
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Table 5.2 Primary and secondary antibodies used.  
 
Normalisation of protein content was conducted on Bio-Rad Image Lab™ software (version 
5.1) and exported to Microsoft Excel. Groups were compared using a one-way ANOVA 
followed by Bonferroni post hoc comparison for significant (p <0.05) changes between groups 
compared. Statistical analysis was performed in GraphPad Prism (version 5.0). Significance 
among groups compared are indicated with by ‘*’ for significant with regard to control; ‘#’ for 
significant with regard to B16, and ‘$’ for significance resulting from comparison with the 
tumour/EO771 group. 
5.5 Results: Effect of DXR on liver 
5.5.1 Markers of autophagy 
a) Expression of p62 
There were no significant differences in the expression of p62 between groups (Control: 1 ± 
0.16; Tumour: 1.22 ± 0.05; LD-DXR: 1.10 ± 0.23; HD-DXR: 1.11 ± 0.17) (Figure 5.4). 
p62 62 Cell Signalling 8025 Rabbit 1:1000 1:10 000
mTOR 289 Abcam ab51089 Rabbit 1:1000 1:5000
p-mTOR (Ser2448) 289 Abcam ab84400 Rabbit 1:1000 1:5000
Caspase 3 35 Cell Signalling 9665 Rabbit 1:1000 1:10 000
c-Caspase 3 17, 19 Cell Signalling 9664 Rabbit 1:1000 1:10 000
Akt 60 Abcam ab32505 Rabbit 1:1000 1:10 000
p-Akt (Ser473) 60 Cell Signalling 4060 Rabbit 1:1000 1:10 000
p-Akt (Thr308) 60 Cell Signalling 9275 Rabbit 1:1000 1:10 000
PARP 116 Abcam ab191217 Rabbit 1:1000 1:10 000
c-PARP 89 Cell Signalling 9541 Rabbit 1:1000 1:10 000
LC3B-II 14,16 Cell Signalling 3868 Rabbit 1:1000 1:10 000
2° AB DilutionPrimary Antibody (1° AB)
Molecular 
weight (kDa)
Vendor Catalogue # Species 1° AB Dilution
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Figure 5.4. The effect of low and high DXR concentrations on p62 expression. Results are expressed 
as mean ± SEM. 
 
b) LC3B-II 
Tumour-bearing mice exhibited a marked increase in LC3B-II, being significantly higher 
(p >0.05) than in mice receiving no DXR, or high dose DXR (Control 1 ± 0.18; Tumour 2.45 
± 0.36; LD-DXR 1.73 ± 0.35; HD-DXR 1.13 ± 0.18) (Figure 5.5). 
 
Figure 5.5. The effect of low and high DXR concentrations on LC3B-II. Results are expressed as mean 
± SEM (*: significant with regard to Control; #: significant with regard to Tumour group) 
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5.5.2 Markers of cell growth and proliferation 
a) Akt (phosphorylated at Ser473) 
There was no significant difference in the phosphorylation status of Akt between groups 
(Figure 5.6). 
 
Figure 5.6. The effect of low and high DXR concentrations on Akt(Ser473) phosphorylation. Results 
are expressed as mean ± SEM. 
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b) Akt (phosphorylated at Thr308) 
There were no significant differences in the phosphorylation status of Akt between groups 
(Figure 5.7). 
 
Figure 5.7. The effect of low and high DXR concentrations on the phosphorylation status of 
Akt(Thr308). Results are expressed as mean ± SEM. 
c) Phosphorylation of mTOR 
Tumour-bearing mice not receiving DXR exhibited a significant (p >0.05) increase in mTOR 
phosphorylation status compared to tumour-bearing mice receiving DXR (Figure 5.8). Low-
dose DXR exhibited a decrease in mTOR phosphorylation compared to control, however, the 
ratio between total and phosphorylated mTOR increased in both groups receiving DXR 
(Control: 1.0 ± 0.13; Tumour: 1.52 ± 0.09; LD-DXR: 0.89 ± 0.13; HD-DXR: 0.84. ± 0.18). 
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Figure 5.8. The effect of low and high DXR concentrations on mTOR phosphorylation. Results are 
expressed as mean ± SEM (*: significant with regard to Control; #: significant with regard to Tumour 
group) 
5.5.3 Markers for apoptosis 
a) Caspase 3 cleavage 
Tumour-bearing mice not receiving DXR exhibited a significant increase (p <0.05) in caspase 
3 cleavage (Control: 1.0 ± 0.19; Tumour: 3.52 ± 0.63; LD-DXR: 2.4 ± 0.57; HD-DXR: 2.47 ± 
0.24) (Figure 5.9). 
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Figure 5.9. The effect of low and high DXR concentrations on caspase 3 cleavage. Results expressed 
as mean ± SEM. (*: significant with regard to Control) 
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b) PARP 
Groups did not differ significantly with regard to cleavage of PARP (Figure 5.10). 
 
Figure 5.10. The effect of low and high DXR concentration on PARP cleavage. Results expressed as 
mean ± SEM. 
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5.6 Results: Comparison between B16 and EO771 tumours 
5.6.1 Markers of autophagy 
a) Expression of p62 
Mice bearing B16 tumours exhibited a marked increase in p62 expression (Control: 1 ± 0.15; 
EO771: 1.27± 0.14; B16: 2.49 ± 0.14) (Figure 5.11). 
 
Figure 5.11. The effect of tumour type on p62 expression. Results are expressed as mean ± SEM. (*: 
significant with regard to Control) 
b) LC3B-II 
Mice bearing B16 tumours exhibited levels of LC3B-II significantly higher than both EO771 
and B16 (Control: 1 ± 0.23; EO771: 1.48 ± 0.37; B16: 2.97 ± 0.17) (Figure 5.12). 
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Figure 5.12. The effect of tumour type on LC3B-II. Results expressed as mean ± SEM (*: significant 
with regard to Control; #: significant with regard to B16 tumour group) 
 
5.6.2 Markers of cell growth and proliferation 
c) Akt (phosphorylated at Ser473) 
Though there was a significant difference in Akt expression (Figure 5.13), a marked increase 
in phosphorylation of Akt (Ser 473) in mice bearing EO771 tumours which were significantly 
higher in EO771 compared to either control or B16 mice (Control: 1 ± 0.18; EO771: 4.01 ± 
0.95; B16: 0.24 ± 0.11). 
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Figure 5.13. The effect of tumour type on Akt(Ser473) phosphorylation. Results are expressed as 
mean ± SEM. (*: significant with regard to control; $: significant with regard to EO771 tumour 
group). 
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d) Akt (phosphorylated at Thr308) 
There was no significant differences in the phosphorylation status of Akt (Thr308) between 
groups (Figure 5.14). 
 
Figure 5.14. The effect of tumour type on Akt(Thr308) phosphorylation. Results ae expressed as 
mean ± SEM. 
  
Stellenbosch University  https://scholar.sun.ac.za
   
 
     106 
c) Phosphorylation of mTOR 
Neither EO771 nor B16 tumours differed significantly from the control mice (Figure 5.15). 
However, mice bearing EO771 tumours exhibited lower expression of mTOR compared to 
mice with B16 tumours (Control: 1 ± 0.15; EO771: 1.27 ± 0.14; B16: 2.49 ± 0.14).  
 
Figure 5.15. The effect of tumour type on mTOR phosphorylation. Results are expressed as mean ± 
SEM (#: significant with regard to B16 tumour group). 
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5.6.3 Markers for apoptosis 
a) Caspase 3 cleavage 
Caspase 3 levels were comparable between groups (Figure 5.16). Compared to EO771, B16 
tumours exhibited a significant decrease in caspase 3 cleavage (Control: 1 ± 0.27; EO771: 0.98 
± 0.06; B16: 0.41 ± 0.04). 
 
Figure 5.16. The effect of tumour type on caspase 3 cleavage. Results expressed as mean ± SEM. ($: 
significant with regard to EO771 tumour group). 
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b) PARP 
Although PARP expression was significantly higher in EO771 mice compared to B16 and 
control mice (Control: 1 ± 0.2; EO771: 2.71 ± 0.14; B16: 1.29 ± 0.08), no significant 
differences were observed in the ratio between total and cleaved PARP (Figure 5.17) 
 
Figure 5.17. The effect of tumour type on PARP cleavage. Results are expressed as mean ± SEM. (*: 
significant with regard to Control; $: significant with regard to EO771 tumour group) 
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5.7 Comparison between DXR groups 
The phosphorylation status of mTOR (Figure 5.8) indicated that the mice bearing EO771 
tumours exhibited higher p-mTOR/mTOR ratio, suggesting that the activated mTOR might 
inhibit autophagy in tumour bearing mice. This is somewhat unexpected since, higher 
metabolic demand placed on mice as a result of tumour load could be expected to increase 
hepatic autophagy. However, DXR groups with significantly lower p-mTOR/mTOR ratio 
(compared to tumour groups) would suggest that the DXR challenge re-introduced the need to 
upregulate autophagy. However, autophagy is also regulated by mTOR- independent 
mechanism (Chen et al., 2016). As such, these results should be viewed in context of other 
findings. 
Indeed an increase in LC3B-II observed in tumour groups (Figure 5.5) could suggest an 
increase in autophagic activity. This interpretation would contradict results from p-
mTOR/mTOR (Figure 5.8) ratio which was elevated in the tumour group and suggest a 
decrease of autophagy. Alternatively, an increase in LC3B-II could also occur if the pool of 
autophagic vesicles are increased, but degradation of vesicle are not increased (i.e. if 
autophagic flux was not increased). This raises concerns regarding the reason why autopahgic 
flux would be inhibited by DXR. Finally, p62 levels did not differ between groups (Figure 
5.11). Since p62 is degraded with the phagosome vesicle content, an increase in p62 might 
indicate an increase in vesicle formation, or a decrease in vesicle degradation. The observation 
that p62 did not change is consistent with an interpretation that autoaphgic flux did not increase. 
Taken together, immunoblotting results are inconclusive with regards to autophagic activity. 
Activated mTOR does not only inhibit autophagy, but also induce a host of anabolic processes 
reflective of growth and proliferation (McCarthy and Esser, 2010). Mice receiving DXR might 
undergo liver damage, with would decrease the activity of mTOR. However, this interpretation 
is challenged by other results. Firstly, Akt activation did not differ between groups (Figure 
5.13 & 5.14). Moreover, only the tumour group (not receiving DXR) demonstrated a significant 
increase in the apoptotic marker, cleaved caspase 3 (Figure 5.9). It is hard to reconcile an 
increase in mTOR activity (which is anabolic signalling cascade) in context of an elevated 
apoptotic marker. Similarly, it is unclear why mice receiving DXR would have lower cleaved 
caspase 3 compared to mice inoculated with only tumour cells. However, it should be noted 
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that cleaved PARP did not differ between groups (Figure 5.15). Thus, apoptosis is inferred 
from a single marker and should be treated with caution. 
In conclusion, the immunoblotting results are largely inconclusive. It should be noted that the 
liver is metabolically dynamic tissue and highly responsive to feed-fasting cycles (Komatsu et 
al., 2005). In this regard, it is possible that the cellular content of structures involved in 
autophagy is comparative between groups, but that autophagic processes are implemented in 
different ways. As an example, autophagic proteins used to mobilise glycogen might also be 
up regulated in response to DXR-induced stress. Extending the range of proteins evaluated 
might resolve discrepancies observed between groups. 
5.8 Comparison between cancer types 
Interestingly, both p62 (Figure 5.11) and LC3B-II (Figure 5.12) was significantly elevated in 
the B16 melanoma group. While LC3B-II levels might suggest an increase in autophagosomal 
pool size, the increase in p62 would imply a failure to degrade these vesicles. In other words, 
these results are suggestive of lysosomal dysfunction. It is tempting to speculate that a 
compromised autophagy apparatus might contribute to the low tolerance observed in mice 
bearing B16 tumours (Chapter 3). Indeed, lysosomal failure are is usually associated with an 
increase in cell death (Loos and Engelbrecht, 2009). However, this interpretation is not 
supported by the observation that caspase 3 cleavage was lower in the B16 group compared to 
the EO771 group (Figure 5.16), and that PARP cleavage was not significantly different 
between groups (Figure 5.15). Another context where LC3B-II is increased with p62 is during 
pathogen subversion of autophagy processes (van Niekerk et al., 2016): Many viruses, bacteria 
and protozoans inhibit lysosomal fusion with autophagic vesicles, since these pathogens make 
use of the vesicles to avoid immune detection. Although mice did not show any overt signs of 
infection, this possibility cannot be ruled out.  
Prosurvival signaling (Akt phosphorylation) did not differ significantly: although Akt 
phosphorylation on Ser473 was significantly higher in the EO771 group (Figure 5.12), 
phosphorylation at Thr308 was not significantly elevated. Similarly, though PARP levels was 
significantly elevated in EO771 group, cleaved PARP was not (Figure 5.14), and possibly 
related to non-apoptotic function of these uncleaved proteins (Schwerk and Schulze-Osthoff, 
2003). However, B16 mice exhibit suppressed levels of cleaved caspase 3 (Figure 5.16). Since 
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B16 cancer cells also exhibited the lowest tolerance (Chapter 3), this observation would suggest 
that increased apoptosis might be reflective of increased liver pathology. In conclusion, the 
main finding of this study was that mice bearing B16 tumours might exhibit signs of 
dysfunctional autophagy, since p62 and LC3B-II where concomitantly elevated, suggesting 
that lysosomal function and degradation of vesicle content could not be executed.  
5.9 Conclusion 
Comparison between groups receiving DXR did not demonstrate an expected increase in 
autophagy: although LC3B-II was elevated in the tumour group compared to DXR, no other 
marker indicated an increase in autophagy. The elevated p-mTOR/mTOR ratio in the tumour 
group compared to DXR might be reflective of increased cell proliferation or protein synthesis 
rather than an inhibition of autophagy. This interpretation would describe the lower p-
mTOR/mTOR ratio in mice receiving DXR compared to tumour group as a result of cellular 
stress (i.e. in mice receiving DXR, cells disengaging anabolic activities usually activated by 
suppressing mTOR activation). Yet, this interpretation is not corroborated by increased caspase 
3 cleavage in the tumour group as it is not clear why cells expressing apoptotic markers, would 
activate mTOR signalling. 
In contrast, there was suggestive evidence that mice bearing B16 tumours might exhibit signs 
of a compromised autophagic process. The increase in LC3B-II suggest an increase in vesicle 
formation, whereas the elevated p62 imply that vesicle content (and the p62 inside the vesicle) 
does not undergo degradation, thus suggesting an inability of lysosomal vesicles to fuse with 
autophagosomes. Regarding the various functions of autophagy (Figure 5.1), an inability to 
fully execute the entire autophagic process to completion could explain the lower tolerance in 
mice bearing B16 tumours. 
Measuring autophagy with western blotting is challenging as it provides a ‘snap shot’ of a 
dynamic process. In this regard, transgenic mice models have been introduced to measure 
autophagic activity in vivo (Castillo et al., 2013). Also, only a few proteins playing an 
executioner role (i.e. not induction) was measured and it is therefrom not possible to point out 
the purpose of autophagy in these cells. As an example, autophagic machinery upregulated in 
response to nutritional stress (fasting) might be subsequently repurposed for other functions 
such as cell-autonomous defence against pathogens (van Niekerk et al., 2016). Thus, high basal 
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levels of autophagy in both control and DXR groups might be comparable, suggesting 
autophagy is not an important response to a DXR challenge. Yet, this does not preclude the 
possibility that autophagy was differentially implemented in pursuit of diverging needs 
(clearance of damaged mitochondria in DXR groups, versus mobilisation of energy rich 
substrate in control groups). Expanding the range of proteins investigated might highlight such 
differences. In this regard, a study was subsequently conducted making use of a proteomic 
analysis (Chapter 6) in order to resolve the ambiguous results obtained in this chapter.  
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6.  Chapter 6 
Based on the inconclusive results from western blot analyses, subsequent proteomic 
analyses were performed. This chapter outline key findings from bioinformatics analyses 
implementing a gene ontology approach to describe biological relevance of deferentially 
regulated proteins between groups of mice. 
6.1 Proteomic study design 
Two key technical challenges in proteomics analysis are the complexity of the protein sample 
(i.e. the range of proteins expressed by tissue/cell sample) and the dynamic range (i.e. 
variability in the expression range) of proteins. As an example, protein abundance in plasma 
samples can vary across a 1012-fold range, whereas the sensitivity of most proteomic platforms 
is within three to four orders of magnitude (Wasinger et al., 2013). Inter-sample variation can 
thus be substantial, and rapidly inflate variance and decrease statistical power. To address this 
concern, liver samples were pooled prior to proteomic analysis in order to ‘level out’ inter-
mice variability: for each group, three mouse liver samples were randomly pooled, forming 
four samples which were submitted for proteomic analysis (Figure 6.1). Thus, from a total of 
12 mice, 4 samples (containing liver samples from three mice) were used for proteomic 
analysis.  
 
Figure 6.1. Pooling of liver samples. 
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Snap-frozen liver samples were wrapped in tin foil (pre-cooled in liquid nitrogen) and crushed 
between two spoons (also pre-cooled). It is not practical to add identical amounts of liver 
samples since water vapour condenses on frozen tissue samples, increasing the weight. 
Therefore, a similar, but not exact amount of liver samples were pooled. It was not desirable to 
re-generate batches of pooled liver samples, since the representative amount of liver tissue each 
mouse contributed would differ between batches. Thus, the same samples were used for both 
western blot and proteomic analyses. This facilitated comparison between analytic platforms 
(western blot and proteomic results). Pooled-liver samples were sonicated in lysis buffer 
(Table 6.1) and frozen at -80°C until analysed. 
Table 6.1. Constituents of lysis buffer used for proteomic analysis. 
Finally, an attempt was made to compare our results to published data. Unfortunately, no study 
has yet performed either proteomic or transcriptomic analysis on mouse liver following DXR 
treatment. However, published data is available for HepG2 cells exposed to DXR. These cells 
are a human-derived hepatocellular carcinoma that was treated with DXR (Hammer et al., 
2010). This publicly available proteomic data was also analysed using (where applicable) the 
same set of analytic procedures employed in the bioinformatics pipeline. 
6.2 Mass spectrometry 
Liquid chromatography mass spectrometry was performed by the Centre for Proteomic & 
Genomic Research (CPGR), an ISO 9001:2008 certified facility. Analysis was performed using 
a Dionex Ultimate 3000 nano-HPLC system followed by peptide analysis on a Q-Exactive 
quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific, USA) in positive ion mode. 
Stock 10 ml 20 ml 30 ml 50 ml
20 mM Tris-HCl 200 mM
1 mM EGTA 10 mM
1 mM EDTA 100 mM 100 μl 200 μl 300 μl 500 μl
150 mM NaCl 1 M 1.5 ml 3 ml 4.5 ml 7.5 ml
1 mM β-glycerophosphate - 0.002 g 0.004 g 0.006 g 0.01 g
2.5 mM tetra-Na-Pirophosphate - 0.01 g 0.02 g 0.03g 0.05 g
1 mM Na3VO4 10 mM 1 ml 2 ml 3 ml 5 ml
50 μg/ml PMSF 100 mM 30 μl 60 μl 90 μl 150 μl
10 μg/ml Leupeptin - 10 μl 20 μl 30 μl 50 μl
10 μg/ml Aprotinin - 10 μl 20 μl 30 μl 50 μl
0.1% SDS 10% 100 ul 2 ml 3 ml 5 ml
1 ml 2 ml 3 ml -
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Relative quantification of protein abundance was performed using the Progenesis QI 
(Nonlinear, UK) software suit. Identified peptides were matched to proteins in the UniProt 
database using Byonic algorithm (Proteinmetrics, San Carlos, CA, USA; version PMI-Byonic-
Com:v2.5.6). Proteins were included if at least two unique peptides were observed for a 
corresponding protein. A minimal 2-fold change in protein abundance with a significance 
threshold of p < 0.05 (ANOVA) was used as the cut-off criterion for inclusion in the final list 
of regulated proteins. Principal component analysis was used to identify outliers (analysis part 
of service provided by CPGR). Since four liver samples were run, outliers identified were 
omitted, thus, for some groups n = 3 and not 4. 
6.3 Proteomic results 
Regulated protein samples that adhered to the selection criteria (see preceding section) are 
tabulated in Appendix I. Protein abundance was normalised to control mice (i.e. no tumour or 
DXR). Briefly, mice bearing EO771 tumours exhibited 143 differentially regulated proteins, 
low dose DXR 176 and high dose 145, and mice with B16 melanoma exhibited 186 regulated 
proteins. Proteomic results from the published study (Hammer et al., 2010) revealed 85 
regulated proteins. It is likely that this lower protein abundance results from the fact that liver 
samples are complex, consisting of multiple cell types, as well as from the fact that in vivo 
systems are more complex (a more dynamic environment than typical for monocultured cells) 
and are thus expected to provide a more complex data set with greater variation. 
The end product of proteomic analysis is a long list of regulated proteins and not very useful. 
Subsequent analysis includes a bioinformatics approach to identify sets of regulated proteins 
involved in a particular biological function (i.e. enrichment analysis). To ascertain meaning 
from the proteomic profile, a gene ontology (GO) approach was implemented in our research.  
6.4 Gene ontology approach 
The Gene Ontology Consortium oversees a collaborative effort to assign a standardised 
functional description to genes and their protein products. These ‘functional descriptions’ are 
divided into three different domains (ontologies): (1) biological process, (2) cellular 
components and (3) molecular function. A cellular component is part of a cell such as an 
organelle or part of another structure (e.g. ribosomal subunit being part of a ribosome). The 
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molecular function refers to a molecular ‘action’ such as binding or catalysing substrates. In 
contrast, a biological process describes a series of events (e.g. a ribosomal protein is involved 
in the biological process ‘translation’). Of note, gene ontology (GO) does not describe 
biological entities such as a protein or a metabolic pathway, but focuses on the characteristics 
and functionality of a gene or the protein product. Thus, as an example, an enzyme is not an 
ontology, but the enzymatic function is. Similarly, a ‘cellular component’ is defined by the 
cellular structure into which the component fits, and not by the component itself. Therefore, 
‘cytochrome c’ is not an ontology, but a ‘component of electron transport chain’ is an ontology.  
These GO terms are arranged in a hierarchical manner (Figure 6.2), with parent terms carrying 
less detail than the child term. As an example, the term ‘cellular response to gamma radiation’ 
is more detailed than ‘cellular response to ionizing radiation’ since gamma radiation is simply 
one source of ionising radiation. Thus, child terms are more informative than parent terms.  
 
Figure 6.2. GO terms exhibits a hierarchical ordering, with parent terms being more general (i.e. 
being less informative) than child terms. 
 
The interaction between GO terms is defined in a manner similar to the way in which a GO 
term itself is defined. Thus, GO does not only attempt to collapse complex interaction into a 
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simple hierarchy; rather, GO terms are semantically expressed (Figure 6.3) by ‘controlled 
vocabularies’ that describe the relationship between GO terms. As an example, the relationship 
between GO terms often takes on the form ‘X is a Y’, where X might be a ‘response to stimulus’ 
and Y a ‘response to abiotic stimulus’. In this example, a response to a stimulus is a type of 
response that includes a response to abiotic factors. The edge connecting the parent term 
(‘response to stimulus’) with the child term (‘response to abiotic stimulus’) is logically defined 
by the ‘is a’ relationship. Various interactions are possible (e.g., ‘part of’ or ‘has part’) with 
varying levels of detail.  
 
Figure 6.3 Semantic similarity between GO terms (generated in AmiGO2). 
The interaction between GO terms can give rise to complex graphs since ‘many-to-many’ 
interactions are possible (Figure 6.4). Firstly, one parent term can have multiple child terms 
(Figure 6.4A – dark grey box). Here, the parent term ‘protein binding’ maps to multiple 
specific child terms (‘enzyme binding’, ‘calcium dependent protein binding’, ‘receptor 
binding’ etc.) Similarly (Figure 6.4B – light grey box), the child term ‘G-protein coupled 
receptor binding’ has two parent terms (‘glutamate receptor binding’ and ‘G-protein coupled 
Stellenbosch University  https://scholar.sun.ac.za
   
 
     123 
receptor binding’). Thus, topologically, GO terms can be described as nodes that are connected 
by semantic operators such as ‘is a’ or ‘part of’ which represent the edges to the graph.  
 
 
Figure 6.4. Interaction between GO terms gives rise to a directed acyclic graph (generated with 
GOrila). 
The GO approach thus allows for complex descriptions of biologically relevant processes. 
There are currently ~35 000 GO terms with ~65 000 term-term interactions (Dutkowski et al., 
2013) from which graphs of varying degrees of complexity can be generated. In turn, a variety 
of freely available packages are available for analysing lists of GO terms, including FatiGO 
(Al-Shahrour et al., 2004), GOrila (Eden et al., 2009), agriGO (Du et al., 2010), AmiGO 
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(Carbon et al., 2009), GoMiner (Zeeberg et al., 2003), and BiNGO (Maere et al., 2005). In this 
study, GO analysis is primarily reported from REVIGO which make use of the ‘semantic 
similarity’ between GO terms to collapse GO terms into ‘the most informative common 
ancestor’ for a set of GO terms (Supek et al., 2011). 
6.5 Bioinformatics pipeline 
For each group, the list of regulated proteins was divided into ‘up-’ (i.e. expressed higher in 
intervention group than control group) and ‘down-’ (i.e. protein levels are lower in intervention 
group compared to control) regulated proteins. Lists were then submitted to DAVID (Database 
for Annotation, Visualization and Integrated Discovery) version 6.8, a freely available online 
analytic tool set for bioinformatics analyses (Huang et al., 2009). Among the various 
functionalities provided by DAVID are the assignment of GO terms, with corresponding p-
values (Benjamini-Hochberg corrected for multiple testing), to a list of proteins. The list of GO 
terms, with their corresponding p-values, was then submitted to REVIGO. REVIGO 
implements the user-supplied p-value to collapse GO terms into clusters that remove 
redundancies (e.g. overlap between parent and child terms). The data presented is then depicted 
in various graphic formats. Data is inspected according to the three ontologies (biological 
process, cellular component and molecular function). 
REVIGO often provides clusters of GO terms that require more detailed analysis. In 
performing the enrichment analysis, a number of additional recourses were used (Figure 6.5). 
DAVID provides easy access to the KEGG (Kyoto Encyclopedia of Genes and Genomes) and 
the Reactome Pathway Browser where the role of a group of proteins assigned a given GO term 
can be inspected within the context of a metabolic or signalling pathway. DAVID also provides 
a 2-D viewer were protein-protein interactions within a group can be inspected. BioVenn was 
used to identify sets of GO terms that are unique to an intervention group, or shared across all 
groups. Also, most platforms only accommodate a set number of gene/protein identifiers. In 
particular, a UniProt database was used to convert UniProt accession numbers to a number of 
alternative formats compatible with BioVenn (e.g. Ensembl gene identifiers). 
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Figure 6.5 Basic outline of enrichment analyses. 
Unless stated otherwise, all analyses were performed using default settings. A notable 
exception was analysis on HepG2 cells, where inclusion criteria and selection parameters were 
more relaxed. This is because HepG2 cells are not formally analysed, but mainly used as a 
broad reference. As an example, GO enrichment analyses have indicated the upregulation of 
proteins not typically associated with the liver (e.g. proteins involved with sarcomeres). Here, 
a comparison between the proteomes of liver samples and published data on HepG2 cells 
assisted with the interpretation of data. 
In total, analyses were performed on five samples sets: High dose DXR (HD), Low dose DXR 
(LD), tumour control (T), B16 melanoma (M) and published data for HepG2 cells. For each 
group, proteins were classified as up- or downregulated, resulting in 10 lists of regulated 
proteins (5 groups × up- or downregulated = 10). These 10 sets were subsequently analysed 
according to three ontologies: biological process, cellular components and molecular function. 
Thus, a total of 30 analyses were performed. In the following section, a detailed overview of 
the analytic procedure and data interpretation is provided. This overview is followed by a brief 
description of each group and a review of the main differences and similarities between groups. 
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6.6 Effect of high dose DXR on the hepatic proteome 
Despite the large number of GO terms identified as downregulated, REVIGO collapsed most 
of the GO terms into few clusters. Only ontology terms downregulated include biological 
processes (Figure 6.6). The size of the nodes (‘bubbles’) describes the specificity of the terms: 
large nodes imply less specific terms (i.e. the larger the node, the more GO terms are collapsed 
within it). Nodes (GO terms) are connected via edges that are based on the hierarchical 
relationship between GO terms. The shade of red represents the significance of the term (‘deep 
red’ more significant). However, all nodes are significant (-log[p-value] > 1.3 which translates 
to p-value less than 0.05). 
 
Figure 6.6 Biological processes downregulated in HD group.  
A downregulation in various biological processes observed in REVIGO was also observed by 
Functional Annotation Clustering (FAC) in DAVID. As an example, a decrease in cytoskeletal 
processes (‘regulation of actin filament-based process’) was again observed to cluster together 
in DAVID (Figure 6.7), despite the fact that the two software environments make use of 
different clustering algorithms. The observation that cytoskeletal processes (‘regulation of 
actin filament-based process’) are downregulated might have a number of implications. As an 
example, an upregulating of cytoskeletal functions might also reflect the infiltration of various 
cells into damaged liver. This might include mobilised hepatic stellate cells, as well as immune 
cells (Amieva and Furthmayr, 1995). 
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Figure 6.7 2-D viewer in DAVID of proteins (horizontal) and their functional relationship (vertical) 
involved in cytoskeletal organisation (downregulated). Notice, DAVID uses a different clustering 
algorithm from REVIGO, and also does not distinguish between different ontologies (e.g. biological 
process or a cellar component). 
However, altered cytoskeletal activity might also reflect a number of additional cellular 
activities and events, including energy homeostasis. As an example, actin plays a role in 
trafficking of organelles as well as organelle structures and also in mitochondrial fission/fusion 
events (De Vos et al., 2005; Wu et al., 2011). Thus, altered expression in proteins involved in 
mediating cytoskeletal structure may in fact signify altered mitochondrial function, and 
consequently have an impact on cellular energy homeostasis. In this regard, a downregulation 
of proteins implicated in cellular glucose homeostasis might in fact relate to altered 
mitochondrial structure and functionality. However, DAVID did not specifically cluster 
proteins involved in glucose homeostasis. Similarly, the node ‘cellular glucose homeostasis’ 
identified in REVIGO is small, indicating few GO terms are included by the category cellular 
glucose homeostasis. Nevertheless, the observation that cytoskeletal elements (‘regulation of 
actin filament-based process’) share functionality with organelle organisation (‘negative 
regulation of organelle organisation’), in conjunction with the observation that metabolic 
components are downregulated (‘cellular glucose homeostasis’) could imply alterations in 
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mitochondrial fission/fusion events. Mitochondrial alteration may account for altered glucose 
metabolism as well as an alternation in organelle size: mitochondrial stress, such as oxidative 
stress, results in altered fission/fusion dynamics (Wu et al., 2011).  
The oxidation-reduction processes might also at first seem to be related to energy homeostasis 
since oxidative respiration is a typical process that also involves an oxidation-reduction 
process. This is also partially corroborated by Functional Annotation Clustering (FAC) in 
DAVID (Figure 6.8). As an example, Hao1 (hydroxyacid oxidase 1) has been implicated in 
metabolism of phytanic acid (a fatty acid) which cannot be metabolised in β-oxidation but 
undergoes α-oxidation exclusively in peroxisomes (Jones et al., 2000). The relevance of a 
downregulation of hydroxyacid oxidase 1 is not clear. Phytanic acid can be produced by 
bacterial fermentation, suggesting that a downregulation might imply a decrease in bacteria-
derived phytanic acid. Interestingly, Sept11 that was also downregulated (Figure 6.7) has 
previously been implicated in cell-autonomous defence against invading pathogens (Mostowy 
et al., 2009). Collectively, the downregulation of these proteins suggests a possible shift in the 
interaction between the host and intestinal biota. As an example, damage to the intestinal lining 
caused by DXR-induced toxicity (Dekaney et al., 2009) might result in gut permeability which 
might increase circulating lipopolysaccharides (LPS). Since the liver performs a filtering 
function, increased circulating LPS might induce an upregulation of defence mechanisms in 
hepatocytes. The role of Phyhd1 (Phytanoyl-CoA Dioxygenase Domain Containing 1) is also 
not obvious, in part because the protein function is not fully understood: no study has detailed 
the function of this protein since its initial discovery from a mouse cDNA library (Strausberg 
et al., 2002). 
Stellenbosch University  https://scholar.sun.ac.za
   
 
     129 
 
Figure 6.8. 2-D viewer in DAVID of proteins (horizontal) and their functional relationship (vertical) 
involved in oxidation/reduction processes downregulated. 
However, in addition to identifying metabolic proteins, FAC also identified a number of genes 
suggesting that a decrease in oxidation-reduction processes might also include, unexpectedly, 
a decrease in antioxidant capacity such as lower levels of Prdx6 (encoding peroxiredoxin 6, 
also known as antioxidant protein 2). The antioxidant activity of Prdx6 is exemplified by the 
observation that mice lacking Prdx6 exhibit higher levels of protein oxidation (Wang et al., 
2003). Similarly, peroxiredoxin 4 has also been implicated in ROS scavenging (Nabeshima et 
al., 2013). Consequently, a decrease of peroxiredoxin 6 is surprising in light of the fact that 
DXR is widely believed to induce ROS production (Injac and Strukelj, 2008; Nayak et al., 
2013). 
One possibility for the observed decrease in proteins involved in radical scavenging is that this 
observation represents a ‘refractory response’ that occurs after a dramatic upregulation of 
antioxidant capacity in response to the initial DXR-induced oxidative damage. Following the 
clearance of DXR, antioxidant capacity needs to be re-equilibrated, since ROS also plays a role 
in a number of important cell-signalling events (Schieber and Chandel, 2014). In addition, it is 
of interest that supplementation with antioxidants as well as iron chelators (iron generates more 
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reactive radical species from H2O2 via Fenton reactions) has failed to provide protection against 
DXR (Šimůnek et al., 2009). In fact, mitochondrial-derived H2O2 results in the oxidation of 
PTEN, which results in an increase in Akt-signalling pathways (Connor et al., 2005). This 
suggests that a decrease in radical scavenging proteins might be a response to optimise and re-
equilibrate radical signalling in the context of tissue repair processes. 
6.7 Upregulation of proteins induced by high dose DXR 
In contrast to the number of downregulated GO terms, a number of biological processes were 
upregulated in response to DXR (Figure 6.9). Many of these nodes represent biological 
activities involved in catabolic processes such as macromolecule catabolism and proteolysis. 
An increase in proteolytic processes might be placed in context of nutrient deprivation: DXR, 
like many other chemotherapeutic agents, likely induced a decrease in feeding behaviour, 
necessitating the breakdown of proteins for gluconeogenesis in the liver. Alternatively, higher 
proteolytic activity might result from the need to degrade proteins damaged by free radical 
damage post DXR treatment. Also of interest, certain GO terms assigned to downregulated 
proteins were also present in the set of upregulated proteins. As an example, oxidation-
reduction processes were both downregulated and upregulated. 
 
Figure 6.9. Biological processes upregulated in the HD group (HD: High dose DXR). 
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The observation that GO terms assigned to downregulated proteins again appear in the set of 
upregulated proteins, appears contradictory. However, many GO terms are generic, including 
proteins that might perform the same biological function, but in vastly deferent contexts. As an 
example, proteolytic reactions are not only relevant to catabolic processes but also play a cell 
signaling role (e.g. cleaving PARP). Similarly, the seeming paradoxical observation that 
similar processes are both up- and downregulated (e.g. as observed for oxidation-reduction 
processes) can be explained by the fact that these reactions are activated in different contexts. 
This is also exemplified in the data for upregulated proteins (Figure 6.10). In particular, many 
of the proteins implicated in ‘oxidation-reduction processes’ play detoxification roles or are 
involved in biosynthetic pathways, whereas the downregulated ‘oxidation-reduction processes’ 
(Figure 6.8) were enriched for proteins implicated in radical scavenging.  
Of note, however, is that certain radical scavenging proteins (e.g. glutathione peroxidase (Lei, 
2002)) were indeed upregulated. The reason why certain antioxidant mechanisms are 
upregulated, whereas others are simultaneously downregulated is unclear. One possibility 
might be that different antioxidant mechanisms are invoked, based on the origin and species of 
radicals produced (e.g. H2O2 versus OH
-). As a plausible example, excessive mitochondrial 
ROS might need to be curbed, while minimising the impact on cytosolic ROS that might play 
various cell-signalling functions (Ray et al., 2012). 
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Figure 6.10. 2-D viewer in DAVID of proteins involved in oxidation/reduction processes. Biological 
function (horizontally) and their functional relationship (vertical). 
An upregulation of ribonucleoside monophosphate biosynthesis (Figure 6.9) may suggest a 
form of nucleotide stress, since ribonucleotide inosine 5'-monophosphate is a purine precursor 
of Guanosine 5'-monophosphate (GMP) and adenosine 5'-monophosphate (AMP). DXR causes 
a halt in replication by inhibiting topoisomerase (Tewey et al., 1984). In this regard, a stalled 
replication process might activate a response similar to nucleotide depletion (Zeman and 
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Cimprich, 2014). This would suggest that an upregulating of proteins involved in purine 
biosynthesis might reflect a response to replication stress induced by nucleotide depletion. 
Alternatively, an increase in nucleotide production might demonstrate a physiological 
adaptation: after the removal of the DXR insult, replication of cells takes place in order to 
replace damaged tissue which might increase the systemic demand for nucleotides (used in 
RNA and DNA). As an example, the myelo-suppressive effects of DXR have long been 
appreciated (Bally et al., 1990), suggesting that the replacement of hepatocytes following DXR 
might increase the demand for nucleotides. Finally, extracellular ATP and ADP have a well-
established role in immune signalling (Idzko et al., 2014), whereas cyclic AMP and GMP play 
various cell-signalling roles (Fajardo et al., 2014). The significance of an increase in nucleotide 
synthesis can have a number of implications. 
An upregulating of steroid metabolism as well as lipid biosynthesis was also observed with 
FAC analysis (Figure 6.11). One plausible explanation is that these activities might include 
that replicating cells require more steroids to be incorporated into membranes. This narrative 
is in line with the preceding argument that nucleotide synthesis might be upregulated to 
accommodate tissue expansion of certain organ systems. However, all proteins are reasonably 
central in the biosynthesis pathway (Figure 6.12), rendering it impossible to exclude other 
possibilities (e.g. the use of steroids as hormone precursors or in the synthesis of bile acids). 
The fact that DXR can damage intestinal lining (Dekaney et al., 2009), as well as its immune-
suppressive effect (Hui-Chou et al., 2012) might cause the expansion and invasion of intestinal 
biota that is usually regulated by the immune system (Maynard et al., 2012). Since bile acids 
exhibit anti-microbial properties (Sung et al., 1993), an increase in bile acids might represent a 
strategy to prevent bacterial overgrowth in DXR treated (i.e. immune-compromised) mice. 
Finally, the biliary excretion of DXR represents an important route through which the body 
may remove this noxious substance (Ballet et al., 1987). Thus, an increase in bile flow might 
represent a strategy to enhance the clearance of DXR. 
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Figure 6.11. 2-D viewer in DAVID of proteins involved in lipid and steroid biosynthesis. Biological 
function (horizontally) and their functional relationship (vertical). 
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Figure 6.12. Proteins involved in xenobiotic metabolism. Upregulated proteins are indicated by red 
stars (★). Diagram from KEGG (diagram abridged). Numbers indicate proteins, according to 
International Union of Biochemistry and Molecular Biology Enzyme Nomenclature. 
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Finally, it is also interesting that both catabolic and anabolic processes are upregulated (Figure 
6.10). As an example, proteolysis and macromolecular catabolism is upregulated, whereas 
cellular nitrogen compound biosynthesis is also co-currently upregulated. Furthermore, these 
cellular activities are functionally integrated, with nodes being either directly or indirectly 
linked with edges (i.e. have functional components). This might seem to invoke a possible 
futile cycle, with both catabolic and anabolic processes operating simultaneously in the same 
tissue. However, cells are capable of spatially partitioning biological processes. A key example 
is the activation of autophagy (a process long appreciated to be involved in catabolic functions) 
along with the upregulation of biosynthetic pathways (Kaur and Debnath, 2015; Narita et al., 
2011). The need to activate catabolic and anabolic processes simultaneously is also relevant to 
the liver. As an example, during an inflammatory insult, the liver is involved in catabolic 
processes (e.g. gluconeogenesis from proteins) as well as in the synthesis of immune 
modulators and effectors (initial phase proteins and thrombotic factors) (Robinson et al., 2016).  
The upregulation of proteins involved in xenobiotic metabolism (Figure 6.9) was confirmed 
by FCA. Interestingly, two proteins upregulated, xanthine dehydrogenase and guanine 
monophosphate synthase (indicated as 1.17.32 and 6.3.52 respectively in Figure 6.13) are 
involved in the metabolism of azathioprine (brand name Imuran, used as an immune 
suppressor) which, like DXR, exerts a therapeutic effect by halting DNA replication in rapidly 
dividing immune cells (Nielsen et al., 2001). Similarly, a protein (UDP-
glucuronosyltransferase 1-9, indicated as 2.4.1.17) involved in irinotecan (also an anti-cancer 
agent that, like DXR, inhibits topoisomerase) was also upregulated (2.4.1.17). Collectively, the 
upregulating of these enzymes is likely reflective of the hepatic processing of DXR.  
 
Figure 6.13. Proteins involved in xenobiotic metabolism.  Upregulated proteins are indicated by red 
stars (★).  
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The upregulation of GO terms associated with cellular components (Figure 6.14) supports the 
interpretation that DXR treatment results in an alteration in cellular metabolism, including 
increasing protein catabolism, as well as altered mitochondrial function. As an example, 
components of the proteasome complex were upregulated, whereas numerous mitochondrial 
proteins were also upregulated. There is also evidence of vesicle formation or an increase in 
vesicle trafficking (e.g. proteins involved in the formation of membrane envelopes, as well as 
endoplasmic reticulum). The upregulating of cytoskeletal proteins (‘regulation of actin 
filament-based processes’ – Figure 6.6) might suggest an increase in vesicle trafficking. In 
turn, an increase in vesicle trafficking may also reflect biological processes. As an example, 
damaged mitochondria may ‘bud off’ (i.e. undergo mitochondrial fission) and subsequently be 
sequestered in autophagic vesicles prior to fusion with lysosomal vesicles (Twig et al., 2008). 
However, proteins involved in autophagic processes were not upregulated in our sample, a 
result also confirmed by western blot analyses (Chapter 5).  
 
Figure 6.14. Cellular components upregulated in the HD group. Components described as obsolete 
(e.g. ‘vesicular fraction’) are components that form structures in other species (in this case, yeast 
cells). In REVIGO, GO terms were specified to be derived from mice, and are thus designated as 
‘obsolete’ if GO term is relevant to a different organism (e.g. yeast). 
Similarly, the upregulation of processes involved in detoxification and synthesis of cholesterol 
is also supported by the observation that elements contributing to microbody formation were 
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upregulated. Microbodies are peroxisomes and glyoxysomes which play a role in α- and β-
oxidation, processing of radicals, and detoxification of xenobiotics (Faust and Kovacs, 2014). 
Though peroxisomes are also formed from ER components (Ma et al., 2011), the upregulating 
of ER processes did not share elements with peroxisomes (i.e. there were no edges connecting 
GO terms in the node ‘endoplasmic reticulum’ with node ‘microbody’ – Figure 6.14). 
Inspection of GO terms associated with molecular function (Figure 6.15) affirmed the 
preceding observations that catabolic processes such as the proteasomal pathway might be 
upregulated, and that mitochondrial remodelling was taking place. GO terms involved in 
electron transport, as well as cofactor binding suggest that mitochondrial activity was indeed 
altered. Also, proteins with peptidase activity were similarly upregulated, supporting the role 
of catabolic processes. Yet, there was an increase in protein components of ribosomes, 
contrasting with the finding that processes involved in translation were downregulated (Figure 
6.6). The significance of this finding is not clear. 
 
Figure 6.15. Molecular functions upregulated in the HD group (HD: High dose DXR). 
6.8 Summary: High DXR group 
Many observations, such as the increased expression of proteins involved in the detoxification 
of xenobiotics in the HD group, were as expected. Similarly, the response to gamma radiation 
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might correspond to the fact that many chemotherapeutic agents, including DXR, can lead to 
‘radiation recall’, inducing tissue damage similar to exposure to radiation (Burris and Hurtig, 
2010). Alterations in mitochondrial fission and fusion activities in response to DXR have also 
previously been reported (Ashley and Poulton, 2009). However, the relevance of some findings 
is less obvious. An interesting observation is the concurrent up- and downregulation of certain 
proteins involved in radical scavenging. This might suggest the need to scavenge particular 
radical species, or the special compartmentalisation of radicals (e.g. the need to decrease 
mitochondria-derived ROS, while saving cytosolic ROS to perform normal functions). This, in 
turn, raises the possibility of exploring tolerance therapies that aim to either target particular 
ROS species, or compartmentalise the distribution of antioxidants. 
The unexpected impact of the host’s intestinal biota on the chemotherapeutic outcome has only 
recently been appreciated (Karin et al., 2014). This is likely also true in the context of DXR. 
The immune system plays a key role in managing the composition of intestinal biota (Kato et 
al., 2014; Lee and Mazmanian, 2010), and conversely, the immune system is also altered by 
the intestinal biota (Bauer et al., 2006). Since DXR attenuates the host’s immune system 
(Bhinge et al., 2012), it is likely that the relationship between the host and intestinal biota would 
be affected. In fact, proteomic results indicated a number of regulated processes that might 
have an impact on host-symbiont interactions. As an example, an increase in bile flow (possible 
consequence of increase steroid metabolism) might prevent bacterial overgrowth in DXR-
treated (i.e. immune-compromised) mice. The reduction of hydroxyl-acid oxidase 1, necessary 
for the metabolism of bacteria-derived phytanic acid, suggests that bacteria are either not 
fermenting substrate, or that the bacterial load in the intestines is low. Similarly, Septin-11, 
known to play a role in host defence against bacteria was also observed. It remains to be seen 
how populations of intestinal biota are altered in response to chemotherapy, and more 
importantly, what the consequence and effect may be of a ‘re-negotiated’ equilibrium between 
the host and its symbionts.  
Interestingly, only a few immune-modulating agents such as cytokines were observed. A 
possible reason for this is an interplay between two factors. Firstly, immune modulators such 
as cytokines are often small and usually only present in low quantities. Being small, a cytokine 
would generate fewer peptides compared to larger proteins; being low in abundance only 
confounds the low counts of cytokine-derived peptides. The second factor is the pooling of 
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mouse liver samples. Mice were sacrificed based on tumour size, and not according to the date 
on which DXR was administered. Consequently, the liver proteome of some mice would 
exhibit an acute response to DXR, whereas other mice might exhibit a liver proteome reflective 
of a ‘resolution phase’ where tissue repair is taking place (e.g. mice that received DXR earlier, 
but were sacrificed at a later date). Some observations in the proteomic results support this 
argument, such as the increased expression of proteins involved in vascularisation (‘placental 
blood vessel development’ – Figure 6.9) while the response to xenobiotics was concurrently 
elevated. 
Nonetheless, the proteomic data highlighted a number of unexpected pathways activated in the 
HD groups. As an example, higher cholesterol synthesis might suggest that these compounds 
might play an important role during the resolution phase, post chemotherapy. However, many 
of the observations might not relate to the effect of DXR, but may result from the tumour. As 
an example, increased glycolysis in tumour cells might increase the hepatic clearance of lactate, 
thus explaining the observed increase in proteins involved in glucose homeostasis (Figure 6.6). 
It is thus import to compare the HD group to the tumour group (T) in order to make these kinds 
of distinctions. In the following section, a comparison between groups is presented. Details of 
data analysis have been omitted. 
6.8.1 Comparison between DXR groups: Procedural outline 
The preceding discussion provided an example of how data was analysed. However, proteomic 
alterations are more insightful if comparisons are drawn between groups. As an example, a 
comparison between tumour group (T) and the high dose DXR group (HD) could allow for the 
identification of regulated pathways in response to DXR versus tumour. 
After assigning GO terms to regulated proteins, BioVenn was use to generate an area-
proportional representation of GO terms that were either unique or shared by intervention 
groups (Figure 6.16). Interestingly, the majority of downregulated proteins were shared 
between groups, whereas the upregulation of GO terms was unique to each intervention group. 
This would suggest that downregulation of proteins may represent a more generic response to 
hepatic stress (arising from DXR or tumour load), whereas the upregulation of proteins resulted 
from unique responses.  
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Figure 6.16. Differential enrichment of GO terms between mice receiving DXR. Diagram generated 
in BioVenn. (HD: High dose Dox; LD: Low dose Dox; T tumour control).  
For each group, GO terms were analysed by applying the same procedure as implemented for 
the HD group. However, since groups are compared (and not simply described), another 
procedure was introduced: From BioVenn, the GO terms that were identified as unique to each 
group, or shared universally, were imported to REVIGO. This allowed for identification of 
processes that were common between groups or unique to a particular group. However, because 
many GO terms are shared between groups (particular with reference to the downregulated 
proteins), the p-value for each term was not included, in order to identify processes likely to be 
implicated. Thus, excluding p-values allowed REVIGO greater scope to collapse GO terms 
into the most informative common ancestor between GO terms. However, lacking a formal 
statistical description of significance (i.e. p-value), results cannot be considered definitive. 
Rather, the goal was to provide a broad overview of processes of interest (i.e. which are 
universal or specific) that might assist in interpreting results (which are generated for each 
group in a manner similar to the example for the HD group); therefore, this was an exploratory 
procedure. 
As an example, biological processes that were upregulated highlighted many unique GO terms 
(Figure 6.17). With regards to the previously analysed HD group, many of the processes 
unique to the HD group were again observed to be uniquely upregulated, including regulation 
of the cytoskeleton, and organelle organisation. This would suggest that these processes are 
unique to the HD group. Similar procedures were implemented for the analysis of the other 
groups. 
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Figure 6.17. Upregulated GO terms unique to each group (comparison between DXR groups). Nodes 
are blank to indicate that terms are not assigned significance values. (HD: High dose DXR; LD: Low 
dose DXR; T: Tumour control). 
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6.8.2 Comparison between DXR groups: Results 
Both HD and LD had similar underlying trends in the enrichment of GO terms. As an example, 
the LD group, like the HD group, demonstrated alteration of mitochondrial architecture 
(Figure 6.18). However, many of the similarities are not directly evident. As an example, 
instead of cytoskeletal processes, contractile fibres collapsed into ‘sarcomere’ and ‘contractile 
fibre’. These results might seem strange since sarcomeres are usually associated with 
contractile tissue such as muscle. However, hepatic stellate cells have previously been shown 
to express sarcomere proteins (Ogata et al., 1993). Similarly, proteomic analysis of Hep2G cell 
revealed an upregulation of contractile fibres as well as sarcomeres (Figure 6.19). The 
expression of contractile proteins, in conjunction with the anatomical position of hepatic 
stellate cells and responsiveness to vasomodulators such as angiotensin II and endothelin I have 
implicated these cells in the maintenance of  vascular tone within the liver (Hellerbrand, 2013). 
Indeed, the liver contains a large portion of the total blood volume (up to 30%), of which a 
large fraction can be expelled to maintain systemic blood pressure in case of rapid blood loss 
(Lautt, 2009). Tumour vasculature is typically chaotic and often results in a haemorrhagic 
tumour, which cause lower blood pressure. (As a personal observation, this seems particularly 
true for EO771 tumours.) This might suggest that an increase in contractile fibres may represent 
a strategy to constrict haptic blood volume. Alternatively, the significance of increased 
sarcomeric proteins is possibly related to fact that, after liver injury, stellate cells take on a 
myofibroblast-like phenotype (Hellerbrand, 2013). The increase in contractile proteins might 
suggest an expansion and activation of these cells in response to liver injury. 
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Figure 6.18. Upregulated GO terms (in LD mice) associated with cellular components. 
 
 
Figure 6.19. Upregulated GO terms associated with cellular components (Hep2G cell line). 
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There was also evidence suggesting that a DXR-detoxification response in the LD group was 
upregulated. However, instead of collapsing GO terms into ‘response to gamma radiation’ (as 
was seen in the HD group), LD GO terms clustered into groups ‘cellular response to stress’ 
which was connected to ‘response to organic substance’ (anthracyclines, of which DXR is one, 
are all organic compounds). GO terms associated with cholesterol synthesis were not 
significantly enriched, though there was an increase in lipid metabolism (e.g. upregulation of 
two-carbon metabolic pathways, which include enzymes that are involved in acetyl-coenzyme 
A metabolism). Yet, the cytochrome P450 family of enzymes is involved in various 
detoxification as well as biosynthetic pathways. Some of these enzymes are involved in both 
fatty acid and cholesterol biosynthesis. As an example, FAC grouped CYP51 with fatty acid 
biosynthesis (Figure 6.20), yet this enzyme has also been implicated in cholesterol 
biosynthesis as well as in modulating cellular sterol content (Fink et al., 2005). Nevertheless, 
the HD group exhibited more unique GO terms (Figure 6.16), suggesting that the lack of a 
lower expression of proteins involved in cholesterol metabolism might be a very legitimate 
difference between LD and HD groups. 
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Figure 6.20. 2-D viewer in DAVID of proteins (horizontal) and their functional relationship (vertical) 
involved in fatty acid and lipid metabolism (upregulated). 
The tumour control (T) group exhibited a number of GO terms shared with other groups, 
including antioxidant enzymes (e.g. peroxiredoxin 4), stress proteins such as heat shock 
proteins (e.g. expression of Hspa1b) and pitrilysin metallepetidase (Pitrm1). A range of 
metabolic proteins were also upregulated in the T group (Figure 6.21). Also similar to the HD 
and LD groups, a number GO terms identified are mitochondrial components, thus again 
reflecting an alteration in the metabolic activity in T group (Figure 6.22). GO terms unique to 
the T group suggest that ‘glycolytic processes’ might have been uniquely upregulated in this 
group (Figure 6.17), though these results are only indirectly supported by the number of 
regulated GO terms associated with mitochondrial function (Figure 6.22). As an example, the 
observation that pyruvate dehydrogenase complex (PDC) was upregulated, in conjunction with 
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the possible alteration to mitochondrial function pathways, collectively supports the 
observation that proteins involved in glycolytic functions might have been upregulated. 
Similarly, the upregulation of glucokinase (Figure 6.21), an enzyme predominantly expressed 
by hepatocytes and β-cells (Matschinsky, 1990), implicates glucose homoeostasis as being a 
regulated pathway unique to the T group. 
 
Figure 6.21. 2-D viewer in DAVID of proteins (horizontal) and their functional relationship (vertical) 
involved in mitochondrial function and structure (upregulated regulated). 
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Figure 6.22. Upregulated GO terms associated with biological processes upregulated in the tumour 
control group. 
An upregulation of proteins involved in glucose metabolism can have two effects. The end 
product of glycolysis is pyruvate, which can be converted to either lactate, or acetyl-coenzyme 
A. An upregulation of pyruvate dehydrogenase complex may thus play a key role in lactate 
clearance. In fact, mutations associated with proteins involved in the pyruvate dehydrogenase 
complex often results in fatal lactic acidosis (Brown et al., 1994; Ferriero et al., 2013). The 
liver plays an important role in the conversion of lactate back to glucose, a process referred to 
as the Cori cycle. The fact that two moles of ATP are generated from one mole of glycolysis, 
compared to the 6 moles of ATP required to recycle glucose, means this process operates at a 
net loss of 4 moles of ATP. It seems unlikely that hepatocytes would increase glycolysis, thus 
producing lactate, which is then subsequently recycled back to glucose (a futile cycle). Indeed, 
since many tumours exhibit high levels of glycolysis despite sufficient oxygen, the so called-
Warburg effect (Vander Heiden et al., 2009), it is expected that livers of tumour-bearing mice 
would experience a higher metabolic burden as a result of the increased recycling of lactate. 
Alternatively, acetyl-coenzyme A may enter the citric acid cycle or it can be used in various 
biosynthetic processes. In fact, many rapidly dividing cells, such as activated immune cells 
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(Palsson‐McDermott and O'neill, 2013; Vander Heiden et al., 2009) or cancer cells 
(Hatzivassiliou et al., 2005), increase glycolysis (irrespective of oxygen levels) in order to 
direct metabolic intermediates (e.g. acetyl-coenzyme A) towards biosynthetic processes such 
as lipid synthesis. This suggests that glycolytic intermediates might be fluxed into biosynthetic 
pathways. Indeed, a flux of glucose intermediates into biosynthetic pathways is also supported 
by the upregulation of Acetyl-CoA carboxylase 2 (Figure 6.21), which catalyses the 
conversion of acetyl-CoA to malonyl-CoA, which is subsequently used in fatty acid synthesis 
(Hardie, 1989; Kim et al., 1989). Collectively, these arguments suggest that the upregulation 
of proteins implicated in glycolytic functions (Figure 6.17) might rather be linked to 
biosynthetic pathways or the clearance of lactate. 
Also of interest was the unique upregulation of proteins involved in exosome formation. These 
vesicles often contain a variety of cellular cargo, including microRNA that regulates 
transcription. However, the significance of this finding is not clear, since it is the cargo of these 
vesicles that determines biological significance. However, it does pose the interesting 
possibility that such vesicles and their content might be used as markers for liver phenotypic 
changes (Sato et al., 2016). 
6.9 The effect of DXR on the liver proteome of tumour-bearing 
mice 
Most of the downregulated genes were common among all groups. Similarly, many processes 
that were upregulated between groups exhibited similar molecular functions. As an example, 
all groups exhibited some form of stress response (upregulation of heat shock proteins, and 
certain enzymes implicated in radical scavenging activities). However, at least some of the 
observed processes were unique to each group. The observation that downregulated proteins 
appear to be shared suggests that a decrease in gene expression is a more generic response to 
stress, whereas the upregulated genes are unique. 
Also of interest was the absence of proteins involved in autophagy. Since DXR is likely to 
stress hepatocytes, e.g. by the induction of oxidative stress (Injac and Strukelj, 2008; Nayak et 
al., 2013), it would be expected that a generic stress response such as an upregulation of 
autophagy should be evident, yet this was not the case, a result also observed with 
immunoblotting (Chapter 5). One possibility is that autophagy was already elevated, and 
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subsequently ‘repurposed’ from a metabolic function, to a stress response. Mice have a high 
metabolic rate, and are very dependent on autophagy during fasting periods. In fact, mice 
lacking key autophagic proteins do not survive the postnatal feed-fasting cycles (Liu et al., 
2013). Hence, it is possible that control mice exhibited high basal levels of autophagy. This 
might explain the lack of listed autophagic proteins: during DXR-challenge, the autophagic 
machinery might be ‘repurposed’ to deal with damaged organelles. Thus, autophagy might 
indeed play a key role in managing the consequence of DXR despite the absence of autophagy 
proteins. Alternatively, the liver, as a key regulator of energy homeostasis, might not increase 
autophagy as a defence mechanism. In the context of DXR-induced cardiotoxicity, a recent 
review (Dirks-Naylor, 2013) pointed out that many studies implicate an upregulation of 
autophagy in cardiac tissue as promoting the pathology. Thus, not increasing autophagy above 
basal levels might promote tolerance in hepatocytes. 
All groups also expressed various proteins associated with contractile function. This might 
include activities such as vesicle transport, original structural changes, cell division, and the 
contractile function of hepatic stellate cells (possible in response to a decrease in blood 
volume). Similarly, in the T group, the observed upregulation of proteins involved in spindle 
formation might suggest an increase in cell proliferation, though proteins involved in cell 
growth, proliferation or cell cycle regulation were not identified. 
All groups exhibited alterations in proteins involved in mitochondrial function and alteration 
in metabolic activities. A number of enzymes implicated in glycolysis may in fact play the key 
function of fluxing metabolic intermediates towards biosynthetic processes. As an example, 
liver proteomes of mice in the T group exhibited an increase in lipid synthesis. In mice 
receiving DXR, biosynthesis was possibly channelled more towards cholesterol synthesis, 
though anabolic processes such as an upregulation of proteins involved in the proteasomal 
pathway was observed. The relevance of an increased expression of cholesterol is not clear, 
since the position of the enzymes in this pathway was not close enough to an end product to 
identify the main role of synthesised cholesterol. Cholesterol is a key component of cell 
membranes, and consequently, all cells are capable of synthesising cholesterol. In the liver, 
cholesterol plays a role in the formation of bile. If DXR induced a loss of appetite, a decrease 
in the demand for bile would be expected. However, an increase in bile production during DXR 
treatment might be followed by an upregulating of cholesterol-synthesising enzymes in order 
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to meet the renewed increase in the demand for bile acids. High synthesis of cholesterol might 
also decrease DXR tolerance, since chronic hypercholesterolemia is associated with pathology 
beyond arteriosclerosis. As an example, higher cholesterol may impair membrane function, 
altering the flow of ions in cardiac myocytes (Wu et al., 1995). Clearly, the significance of 
cholesterol production during DXR treatment needs to be further investigated. 
Proteomic results also highlight mechanisms that might have an impact on the interaction 
between host and intestinal biota. Not only is bile acids’ amphiphilic molecule capable of 
disrupting microbial membranes (Begley et al., 2005), but the conjugation of amino acids to 
cholesterol can also have an impact on the composition of intestinal populations. The amino 
acids to which bile is bound influences the polarity of bile, with the result that dietary fat 
influences the species of bile acids secreted (i.e. the amino acid to which the cholesterol is 
conjugated). As an example, mice receiving milk-derived fat secrete bile acids conjugated to 
taurine (a sulfonic acid), which promotes the growth of certain anaerobic bacteria (Devkota et 
al., 2012). Mechanistically, these bacteria are adapted to metabolising bile, and in particular, 
liberating the sulphur from taurine and using it as a terminal electron acceptor (instead of 
oxygen). Therefore, altering not only the volume but also the composition of bile acids may be 
a strategy to select for, or against, certain strains of intestinal bacteria. 
Some of the data hints at a possible role of intestinal biota in mediating host tolerance in the 
HD group. This is inferred from the downregulation of Sept11. Yet, Septin 11 has also been 
demonstrated to play a role in establishing cellular architecture. As an example, in rat neurons 
Septin 11 has been found to play a key role in regulating cytoskeletal structure at the synapses 
of at GABAergic neurons (Li et al., 2009). Similarly, a related protein, Septin 7, which was 
also upregulated, played a key role in mice during meiosis (Li et al., 2012) – another process 
implicated in cellular structure and motility. This would suggest that the upregulating of Septin 
11 might not be directly linked to immune function, but possibly related to cellular architecture. 
The upregulation of proteins involved in nucleotide synthesis in the HD group remains to be 
established. Since nucleotides such as cyclic GMP and ATP play various roles in intracellular 
signalling functions, whereas extracellular nucleotides have an important function in mediating 
inflammatory signalling (Riteau et al., 2010). It therefore appears as if an upregulation of 
nucleotides might have an impact on various signalling events. Nucleotides are also important 
in transcription and cell replication as they form building blocks of RNA/DNA. This suggests 
Stellenbosch University  https://scholar.sun.ac.za
   
 
     152 
that an upregulation in nucleotide synthesis might play a role in tissue repair. It is also possible 
that nucleotide precursors could be exported for biosynthetic application in peripheral tissue 
such as bone marrow or intestinal epithelium cells that undergo rapid cell division. In fact, 
certain cancers have a higher demand for phosphorus precisely because these cancers have 
more nucleotides (Elser et al., 2006). Collectively, these observations suggest the possibility 
that higher nucleotide synthesis might drive both tolerance (e.g. replenishing tissue damaged 
by DXR) and resistance (explaining the enhanced tumour growth in the HD group). 
Finally, in comparing mouse liver proteome to the proteome of Hep2G human liver carcinoma 
cells, very similar trends were demonstrated in the protein expression in response to DXR 
(Figure 6.23). This includes an upregulation of proteins involved in lipid and cholesterol 
synthesis, mitochondrial alterations (particularly in context of apoptosis) and cytoskeletal or 
contractile proteins. A notable exception includes the higher activation of Ras-signalling 
activity in HepG2 cells, which possibly reflects the cancerous nature of these cells. The 
comparison also indicated that our data exhibited fewer enriched GO terms, as well as that 
metabolic pathways were generally identified by fewer representative proteins: for most 
metabolic pathways, only a handful of proteins were upregulated in our data set compared to 
that of HepG2 cells. In fact, this is illustrated by the well-connected nodes in the graph for 
HepG2 cells (Figure 6.23). Consequently, our data set provided few opportunities to identify 
a definitive metabolic processes activated in a given intervention group. 
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Figure 6.23.TreeMap (top) and graph (bottom) of biological processes upregulated in HepG2 cells in 
reaction to DXR. 
The lower yield of informative GO terms, as well as the low connectivity between GO terms 
(i.e. fewer nodes connected to each other) in our samples compared to HepG2 cells is surprising 
in light of the fact that liver samples are derived from different cells (endothelium, hepatic 
stellate cells, Kupffer cells and hepatocytes), and are thus expected to be more complex (and 
give rise to more potential protein-protein interactions). A number of reasons may be put 
forward in this regard to explain the lower connectivity between GO terms, as well as the lower 
yield of significant GO terms. First, cell culture conditions are expected to be more stable, 
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giving rise to lower variance in data and thus rendering results more significant. Secondly, for 
the proteomic study on HepG2 cells, the authors (Hammer et al., 2010) considered a 1.2-fold 
protein increase/decrease as selection threshold, whereas the current study implemented a more 
conservative 2-fold increase. Consequently, the data set for HepG2 cells was expected to 
contain more proteins since the selection criteria were lower. 
6.10 Comparison between EO771 and B16 mice 
A comparison between GO terms unique to and shared by B16 (M: melanoma cells) and EO771 
(T: EO771 breast cancer cells) revealed a number of GO upregulated terms unique to each 
group, whereas downregulated terms shared more GO terms (Figure 6.24). Comparisons 
between T and M groups were subsequently analysed in a manner similar to the groups 
following DXR treatment. 
 
Figure 6.24. Differential enrichment of GO terms between groups. M: B16 melanoma; T: EO771 
breast cancer cells. Diagram generated in BioVenn. 
Of note is that a number of downregulated proteins are not completely understood. As an 
example, a number of proteins involved in the transfer of methyl groups were observed (Figure 
6.25). These include histamine n-methyltransferase (Hnmt) which plays a role in histamine 
clearance in the brain, kidney and liver of mice (Kitanaka et al., 2002). Indolethylamine n-
methyltransferase has been implicated in the metabolism of xenobiotics (which is unexpected 
since these mice did not receive DXR) as well as neuro-transmitters (Thompson et al., 1999), 
whereas AS3MT has been found to play a role in the metabolism of inorganic arsenic into 
methylated metabolites (Thomas et al., 2007). The downregulation of these proteins in mice 
bearing B16 tumours is not clear. 
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Figure 6.25. 2-D viewer in DAVID of proteins (horizontal) and their functional relationship (vertical) 
involved in methyltransferase processes downregulated. 
However, a number of proteins involved in vitamin A (retinoic acid -RA) metabolism were 
upregulated (Figure 6.26). Hepatic stellate cells (HSC) represent a major storing site for RA, 
but are also involved in various other activates, ranging from the deposition of connective tissue 
to the expression of key immune regulators (Weiskirchen and Tacke, 2014). The altered 
metabolism of RA results from an increased activation of HSC, and the subsequent ‘metabolic 
retooling’ that takes place in these cells, or in response to external stimuli. 
Alteration in retinoic acids (RA) metabolism is likely to have far-reaching effects since retinoid 
metabolites perform pleiotropic functions in cell-signalling roles. Some of the key 
transcriptional targets or RA-metabolites include the retinoic acid receptor (RAR), the retinoic 
x receptor (RXR) and peroxisome proliferator activated receptors (PPAR) (Al Tanoury et al., 
2013). The diverse role of RA-metabolites is exemplified by the observation that retinoids can 
both inhibit and promote cell growth. As an example, the anti-proliferative effect of retinoids 
has been used in treating malignancies (Altucci and Gronemeyer, 2001; Di Masi et al., 2015); 
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yet, in contrast, retinoids have also been shown to promote cell proliferation in certain cancers 
(Perri et al., 2010). 
 
Figure 6.26. Proteins involved in retinoid metabolism.  Upregulated proteins are indicated by red 
stars (★). Diagram from KEGG (diagram abridged). Numbers indicate proteins, according to the 
International Union of Biochemistry and Molecular Biology Enzyme Nomenclature. 
In previous in vitro studies, it was shown that all-trans retinoic acids can suppress melanin 
production and cell proliferation in B16 cells (Niles, 2003; Sato et al., 2008). Thus, an 
upregulation in proteins involved in retinoic metabolism would suggest an inhibitory effect on 
B16 cancer cells. Yet, B16 tumours were the most rapidly growing tumours in the current 
study, casting doubt on any direct effect of elevated RA. Alternatively, RA might promote 
tumour growth indirectly via its role on glucose homeostasis. As an example, 9-cis-retinoic 
acid inhibits the secretion of insulin in response to glucose in mouse islet cells (Kane et al., 
2010). Insulin itself is an anabolic hormone, suggesting that a decrease in this hormone might 
similarly impede cell growth. Also, though 9-cis-retinoic acid was indeed formed in the 
metabolic path of regulated enzymes, most metabolic pathways resulted in the formation of all-
trans retinoic acids. It is thus not clear if altered glucose homeostasis resulted in the increase in 
B16 cell growth. 
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By another indirect mechanism, RA might exert a tumour-promoting effect by altering the 
immune system. As an example, RA induces apoptosis in antigen-presenting cells such as 
dendritic cells (Geissmann et al., 2003), suggesting that this might lower the immunogenic 
profile of cancer cells. Similarly, RA plays a role in regulatory T-cell development (Benson et 
al., 2007). An increase in regulatory T-cells might enhance the immune tolerance to cancerous 
cells, thus promoting tumour growth. However, it should be noted that RA plays a key role in 
the normal immune system (Pino‐Lagos et al., 2008; Semba, 1994; Smith and Hayes, 1987) 
and that many of the immune-regulatory effects might be dose-dependent. 
6.11 Conclusion 
Many proteins were generically regulated between groups. These include ribosomal proteins, 
various peptidase and catabolic enzymes, and various proteins involved in cytoskeletal 
architecture and cell motility. Similarly, mitochondrial proteins were also among the GO terms 
most enriched. Furthermore, proteins that take part in various interactions with vitamins were 
also enriched. GO terms such as ‘cofactor binding’ or ‘cofactor metabolism’ often refer to 
proteins that bind to vitamins. As an example, thiamine (vitamin B1) metabolites are key 
cofactors of mitochondrial enzymes involved in energy homeostasis. However, many of these 
GO terms depicting interaction with vitamins (e.g. ‘vitamin transport activity’ – see e.g. Figure 
6.15) also include reference to vitamin A metabolism. This distinction was not always obvious 
in REVIGO, but became more apparent after performing FCA in DAVID. 
Since the liver performs various metabolic functions, it was challenging to identify a putative 
mechanism by which T/R could be influenced. This is exemplified by the increase in steroid 
metabolism observed in the HD group. Cholesterol moieties can be incorporated into the 
membrane of rapidly dividing cancer cells, decreasing host resistance. Cholesterol also has an 
important function in bile formation, with an increase in bile flow promoting the clearance of 
DXR (decreasing DXR might increase tolerance). Finally, the increase in bile flow might be 
an epiphenomenon of no consequence: an increase in feeding that occurs after prolonged 
suppression of appetite in response to DXR might necessitate an upregulation of proteins 
involved in bile formation. Similarly, an upregulation of nucleotide metabolism is also unclear. 
Nevertheless, the fact that steroid and nucleotide metabolism could affect various T/R circuits 
suggests that these systems might play a key role on the disease trajectory. 
Stellenbosch University  https://scholar.sun.ac.za
   
 
     158 
In summary, it was found that tumour burden repeatedly upregulates proteins involved in 
metabolic activities. It is likely that mice are able to cope well with the additional metabolic 
demands imposed by tumour load, as demonstrated by the higher tolerance in mice bearing 
EO771 tumours. In addition to the direct toxic effects of DXR, the fact that DXR also 
compromises mitochondrial function might render mice more vulnerable to tumour load. In 
particular, the effect of DXR on mitochondrial activity might limit the ‘metabolic flexibility’ 
of mice. 
The higher metabolism of vitamin A is unexpected and difficult to explain. Retinoic acid 
usually exerts a cytostatic effect, and induce cell differentiation. This is in contrast to the hyper-
growth observed in B16 tumours. The various RA-metabolites could have an impact on 
differant tissue types, promoting tumour growth indirectly. However, the broad activity of RA-
metabolites renders it difficult to identify a putative mechanism by which tumour growth would 
be enhanced. It is possible that B16 cells release factors that induce the transcription of enzymes 
involved in RA metabolism, and that the release of RA is in fact a manifestation of pathology 
(e.g. a cytostatic effect on liver cells might render mice less tolerant to tumour burden). 
However, in the absence of any supporting evidence, this remains pure conjecture. 
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7.  Chapter 7 
In this chapter, a brief overview of main findings and future recommendations are 
provided. 
7.1 Introduction 
The observation during the First Wold that mustard gas supresses bone marrow eventually led 
to the first rational cancer therapy for leukemia (Papac, 2001). Subsequent refinement later 
lead to the development of antimetabolites such as antifolates and fluorouracil which is still 
used today (Papac, 2001). Decades of basic research resulted in a deeper understanding of basic 
cancer biology, culminating in the so called era of ‘targeted therapy’ which targets key 
biological functions of cancer cells, such as hormone receptors. This approach is exemplified 
by Trastuzumab (also known as Herceptin), a monoclonal antibody that block human epidermal 
growth factor receptor 2 (HER2), a tyrosine kinase receptor which is often upregulated in 
cancer cells (Nahta et al., 2006). However, both targeted therapy, as well as antimetabolites, 
despite the initial responsiveness, inevitably result in the development of drug resistance in 
cancer (Holohan et al., 2013). 
Interestingly, what have been hailed as “arguably the most exciting advance made in cancer 
treatment in recent years” (Ribas, 2015), represents a completely different therapeutic 
approach. These novel therapeutic interventions do not target cancer cells, but rather host cells 
by targeting and inactivating so called ‘immune checkpoint blockers’ that are usually activated 
by cancer cells in order to avoid immune surveillance (Larkin et al., 2015). Though it is to be 
seen how effective these therapies will prove to be, initial results are promising. If as effective 
as initial findings suggest (Larkin et al., 2015), this therapy will represent a completely novel 
approach to cancer: targeting the host instead of cancer. 
Similar, the tolerance/resistance (T/R) framework represents an approach that emphasise the 
role of the host in the developing disease trajectory. The ultimate clinical utility may initially 
find more application in palliative context or situations where a cure is no longer a realistic 
clinical goal. However, as support for cancer patients increase, it might become more realistic 
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to pursue a clinical outcome where people die with cancer, and not because of neoplastic 
infections. 
7.2 Main findings 
The implementation of the T/R framework within an immunological setting remains an 
emerging field, and there is continual interest in developing novel tools for quantifying the 
disease state (Louie et al., 2016). The approach implemented in this study (Chapter 3) was 
effective in quantifying tolerance and resistance. An interesting observation however was the 
differences in variance between groups when measuring tolerance: groups receiving DXR 
exhibited less variance (i.e. clustered closer to the fitted regression line) than the tumour control 
group. The underlying biological reason for this observation is not clear. This observation also 
suggests that, whereas traditional hypothesis testing (i.e. comparing means) are undoubtedly 
insightful, studying the biological origin of differences in variation might also highlight novel 
aspects that are not usually obtained.  
The observation that DXR increased tumour growth (Chapter 3) was unexpected, but also 
documented by others (Bandyopadhyay et al., 2010).  Attempts to explain the origin of this 
increase (Chapter 4) was however less successful: the only significant result includes the 
elevated phosphorylation of ERK in groups receiving DXR. Although ERK induce cell growth 
and proliferation, it is not clear why ERK was activated in mice receiving DXR. 
Results from both immunoblotting and liver proteomic analyses were occasionally counter 
intuitive and difficult to interpret with no definite mechanism identified as a driver for tolerance 
or resistance. In particular, the absence of autophagic proteins were unexpected. However, the 
study also highlight novel insight. As an example, the observation that proteins involved in 
radical scavenging were both up- and down-regulated in mice liver in response to DXR might 
suggest that DXR toxicity could be mitigated more effectively by using antioxidants that are 
more selective in the species of radicals they target (thereby possibly sparing adaptive radical 
signalling). This would explain why ‘generic’ antioxidant therapies have failed to attenuate 
DXR-associated cardiopathologies (Štěrba et al., 2013). Gene ontology analyses also suggest 
that proteins involved in the host-symbiote (i.e. intestinal biota) could be altered in DXR 
groups. The significance of this finding is not clear. It is possible that DXR adversely affects 
the host immune system, which may impact on intestinal biota, permitting the expansion of 
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bacterial strains which are usually constrained by the host’s immune system. Alternatively, the 
results may be an epi-phenomena: if DXR damage the intestinal lining, more bacteria (and 
bacterial particles such as LPS) might enter circulation. Exposing the liver to bacteria and their 
components might explain the haptic response. What is evident is that a change in host 
intestinal biota could greatly impact on host health. Intestinal biota contain far more non-
overlaying genes (also referred to as the ‘metagenome’) that that of the human genome (Cho 
and Blaser, 2012). Therefore, altering host-microbe interaction is likely to alter microbial 
population, and with it, the biochemical potentiality contained within the host metagenome. 
There is also evidence that cell contractile functioning is altered in liver cells in response to 
DXR. In line with other observations, this might include an increase in intracellular vesicle 
trafficking, cell mobility, as well as contraction. With regards to the contraction function, the 
observation might relate to altered hemodynamics since the liver contains a large fraction of 
the total blood supply. The observation of altered cholesterol synthesis is also surprising, yet, 
it was not possible to identify the reason why an increase in cholesterol synthesis would take 
place in response to DXR. Finally, the observation that B16 tumours increase the expression 
of a number of enzymes associated with retinoic acids (RA) metabolism is also of interest given 
the fact that this could alter both tolerance and resistance. As an example, the anti-mitotic effect 
of certain RA-metabolites (Altucci and Gronemeyer, 2001; Di Masi et al., 2015) could explain 
the lower tolerance in mice bearing B16 tumours. Similar, RA has been demonstrated to 
enhance the growth of some cancer cells (Perri et al., 2010), thus potentially explaining 
increased tumour growth. 
7.3  Limitations and future prospects 
More metrics of health should have been used to quantify tolerance, particularly markers 
unique for a given organ as this might have assisted in the identification of putative tolerance 
mechanisms. As an example, we speculated that the increase in contractile proteins observed 
in the liver proteome might be a result of decreased blood volume: large tumours are richly 
vascularised, though the tumour vascular bed itself is chaotic and poorly developed, resulting 
in hemorrhagic tumours. In this scenario, increased constriction of the liver might redirect 
blood flow in response to hypovolemia resulting from blood that accumulates in the tumour 
region. However, it is also possible that DXR-induced cardiotoxicity resulted in poor cardiac 
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performance, with lower circulatory velocity or some associated decrease in blood flow. 
According to this narrative, hepatic constriction might be a downstream consequence of 
cardiac-associated pathology. 
It is also advisable to make use of adult mice that are not growing as this simplify interpretation 
of a tolerance metric that makes use of body weight. Tolerance could still be measured in 
growing individuals, manifesting as a ‘failure to thrive’. However, since resistance differ 
greatly between EO771 and B16 groups (B16 growing faster than EO771 tumours), the 
increase in body weight (a metric for tolerance) in EO771 might reflect the longer time the 
mice spend growing (and subsequently higher body mass). Also, there is evidence that a host 
often exhibits different tolerance to a pathogen, depending on life history (e.g. age) of the host 
(Sears et al., 2015). As an example, small pox is usually well tolerated if contracted during 
childhood, but often lead to complications in adults. Similarly, the tolerance exhibited by an 
adult versus juvenile mice could markedly differ.  
Also, the use of different inoculation media, e.g. Matrigel® or Hanks' Balanced Salt solution 
would undoubtedly also impact on tumour growth. One advantage of using Matrigel® includes 
the standardisation of tumour inoculation: many tumours do not grow in mice unless inoculated 
with Matrigel®. 
Also, the inability to capture serum markers represent another key limitation of this study. The 
attempt made to capture data regarding a panel of cytokines and growth factors using a 
Luminex Bead-based Multiplex Assay was unsuccessful due to results falling below the 
detectable range. The results could have shed more light on both tolerance and resistance. As 
an example, the observation that DXR increased tumour growth might have resulted from 
DXR-tissue injury, stimulating the release of growth factors in order to expand the cell 
population during tissue regeneration. These cytokines or growth factors released could have 
accelerated tumour growth (explaining lower resistance in mice receiving DXR).  Similarly, 
inflammatory markers as well as protein markers for liver damage (e.g. alanine amino 
transferase or alkaline phosphatase) could have provided additional information on liver-
specific tolerance. 
Arguably the biggest shortfall in the current study relates to the timing of tissue harvesting and 
the subsequent pooling of liver samples. Mice were administered DXR once tumours became 
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palpable, and subsequently sacrificed when tumours reached a size of approximately 400 mm3. 
However, tumour growth rates varied greatly between mice, even within a group. 
Consequently, for mice with rapidly growing tumours, liver tissue was harvested near the time 
the last round of DXR were administered. In contrast, in mice with more slowly growing 
tumours, liver samples were harvested at a time point more distant to when the last round of 
DXR was received. Consequently, it is very likely that some livers were in a state of tissue 
regeneration, whereas livers of mice harvested more recently might have exhibited a stress 
response to the DXR recently administered. This factor most likely ‘diluted’ certain proteins, 
since different liver samples would have been enriched for different proteins. This might, as an 
example, explain why it was not possible to identify the relevance of an increase in cholesterol 
synthesis: mice might have all synthesised cholesterol, but for different purposes (e.g. local 
synthesis of cholic acid for bile formation versus cholesterol synthesised for the incorporation 
into cell membranes or hormone synthesis in distal tissue). 
7.4 To conclude 
Tolerance & resistance framework 
● Immunologist distinguishes between the host’s ability to resist infectious agents, versus 
capacity to accommodate stress imposed by the infection tolerance. 
● Consequently, disease trajectory is dependent not only on pathogen load, but also the 
‘noxious phenotype’ of the infectious agent. 
● This demarcation implicit to the tolerance/resistance (T/R) framework is also applicable 
within an oncological context. 
Quantifying cancer tolerance & resistance 
● Cancer tolerance represents the ‘unit health cost per unit tumour volume’ 
● Cancer tolerance can be expressed as the slope of a regression line, with cancer burden as 
predictor variable and a metric of health as the response variable. 
● Cancer resistance can similarly be expressed as the slope of tumour growth during a log-
linear growth (LLG) phase. 
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Implications of the T/R framework 
● Treatment efficacy is emphasized by this approach: The ratio between the tolerance slope 
and LLG-slope (resistance slope) provides an expression of the harm-to-benefit ratio of a 
treatment intervention (i.e., reduction in tumour growth vs cost in terms of health). 
● This approach allows a finer resolution on the disease state and can distinguish between 
pathology manifesting from tumour growth versus intolerance toward tumour. 
● Although T/R is ‘host centric’, the framework can be extended to include cancer versus host 
factors that interact in dictating disease trajectory (e.g., distinguish between host tolerance vs 
cancer pathogenic phenotype). 
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8.  Appendix I  
Haematoxylin and eosin progressive staining 
8.1 Reagents 
• Ethanol: 100%, 95%, 70%  
• Xylene  
• Acetic alcohol (10 ml 1% HCl in 1ℓ 70 % ethanol)  
• Eosin (Stock: 10 g Eosin dissolved into 1ℓ dH2O) 
Working solution: Prepare fresh: 10 ml Eosin stock in 90 ml dH2O. Filter solution. Add 2~3 
drops glacial acetic acid in to 100 ml work-solution 
• Mayer's Haematoxylin: Add the following reagents to 1ℓ dH2O  
o aluminium potassium 50g  
o dissolve in dH2O  
o 5 g Haematoxylin powder dissolve in dH2O  
o 0.4g sodium iodate  
o 20ml glacial acetic acid  
Heat solution up to boiling point. Remove from heat and rapidly cool down in fridge ¾ Add 4 
ml glacial acetic acid to 100 ml Haematoxylin solution before staining. Filter before use  
• Scott’s tap water  
o Dissolve 3.5 g NaHCO3 in tap water  
o Add 20 mg MgSO4 129  
o Add 10 ml 37% formalin 
8.2 Methods  
Prepare 21 Coplin jars in series flied 2/3 with the above mentioned reagents, according to 
following schedule for each sample incubation step:  
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1) Xylene (10 min)  
2) 100% ethanol (10 dips)  
3) 100% ethanol (10 dips)  
4) 95% ethanol (10 dips)  
5) 95% ethanol (10 dips) 
 6) 70% ethanol (10 dips)  
7) dH2O (10 dips)  
8) Haematoxylin (10 min) 
 9) dH2O (10 dips)  
10) Acetic alcohol (10 dips)  
11) dH2O (10 dips)  
12) Scott’s tap water (10 dips)  
13) dH2O (10 dips)  
14) Eosin (2 min)  
15) dH2O (10 dips)  
16) 70% ethanol (10 dips)  
17) 95% ethanol (10 dips)  
18) 95% ethanol (10 dips)  
19) 100% ethanol (10 dips)  
20) 100% ethanol (10 dips)  
21) Xylene (10 dips)  
Gently tap of execs xylene and mount sample with mounting media and coverslip. 
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8.3 Automatic tissue processing 
• Reagents 
o Paraffin wax (Histosec, Merk) 
o Xylene (Sigma-Aldric) ~2ℓ 
o Ethanol: 100%, 95%, 90% 70% (2.5, 1.5, 0.8 and1.5 ℓ respectively) 
• Method 
Tissue sample previously soaked in formaldehyde was (a) dehydrated, (b) “cleared” and (c) 
impregnation with paraffin. After preparing reagents, pour ~700 ml of each reagent into glass 
flask on tissue processor in the order (as indicated below). Tissue processor should be pre-
programmed according to following time-schedule per sample incubation step: 
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9.  Appendix II 
List of differentially regulated proteins: liver proteomics 
Key to groups: 
H: high dose DXR group 
L: low dose DXR group 
T: tumour control (EO771 cancer cell line) 
M: melanoma (B16 cancer cell line) 
               
  
Group Accession number Description 
Confidence 
score 
Anova (p) 
Fold 
change     
  H >sp|A2AS89|SPEB  Agmatinase, mitochondrial  60,52 8,590E-04 -4,0 
  H >sp|B1AR13|CISD3 
 CDGSH iron-sulfur domain-containing 
protein 3, mitochondrial  8,01 4,696E-04 -4,4 
  H >sp|G3X982|AOXC  Aldehyde oxidase 3  120,25 7,543E-03 -2,1 
  H >sp|O08749|DLDH 
 Dihydrolipoyl dehydrogenase, 
mitochondrial  137,90 2,428E-03 -2,2 
  H >sp|O08807|PRDX4  Peroxiredoxin-4  47,98 3,480E-03 3,3 
  H >sp|O09061|PSB1  Proteasome subunit beta type-1  34,47 7,949E-04 -6,1 
  H >sp|O35286|DHX15 
 Pre-mRNA-splicing factor ATP-dependent 
RNA helicase DHX15  13,23 4,279E-03 -2,3 
  H >sp|O55234|PSB5  Proteasome subunit beta type-5  16,24 5,481E-04 -4,2 
  H >sp|O70435|PSA3  Proteasome subunit alpha type-3  8,53 1,531E-03 -9,2 
  H >sp|O88451|RDH7  Retinol dehydrogenase 7  130,14 2,167E-05 -3,3 
  H >sp|O89017|LGMN  Legumain  36,28 2,645E-02 2,2 
  H >sp|P06330|HVM51  Ig heavy chain V region AC38 205.12  13,64 1,235E-03 5,7 
  H >sp|P10518|HEM2  Delta-aminolevulinic acid dehydratase  142,33 3,203E-03 -2,5 
  H >sp|P11352|GPX1  Glutathione peroxidase 1  154,94 8,793E-04 -3,5 
  H >sp|P14246|GTR2 
 Solute carrier family 2, facilitated glucose 
transporter member 2  6,57 2,175E-02 -2,1 
  H >sp|P16546|SPTN1  Spectrin alpha chain, non-erythrocytic 1  42,85 1,688E-05 5,7 
  H >sp|P17879|HS71B  Heat shock 70 kDa protein 1B  113,76 1,402E-04 3,0 
  H >sp|P18572|BASI  Basigin  30,31 5,610E-05 -2,3 
  H >sp|P20065|TYB4  Thymosin beta-4  39,98 2,860E-02 4,3 
  H >sp|P21300|ALD1  Aldose reductase-related protein 1  8,12 2,271E-03 -5,1 
  H >sp|P21614|VTDB  Vitamin D-binding protein  148,26 4,746E-04 -2,5 
  H >sp|P24456|CP2DA  Cytochrome P450 2D10  194,38 4,877E-04 -2,1 
  H >sp|P26041|MOES  Moesin  71,14 5,566E-04 2,0 
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  H >sp|P27046|MA2A1  Alpha-mannosidase 2  14,55 1,903E-05 -2,4 
  H >sp|P28063|PSB8  Proteasome subunit beta type-8  16,08 1,910E-02 -2,2 
  H >sp|P28651|CAH8  Carbonic anhydrase-related protein  35,72 3,485E-05 4,8 
  H >sp|P28798|GRN  Granulins  16,30 3,485E-05 -29,9 
  H >sp|P34884|MIF  Macrophage migration inhibitory factor  74,65 1,105E-02 -2,2 
  H >sp|P34927|ASGR1  Asialoglycoprotein receptor 1  32,22 9,440E-04 -2,1 
  H >sp|P35492|HUTH  Histidine ammonia-lyase  376,41 1,676E-04 -2,6 
  H >sp|P35505|FAAA  Fumarylacetoacetase  449,36 2,350E-03 -5,2 
  H >sp|P42925|PXMP2  Peroxisomal membrane protein 2  6,68 2,080E-02 -2,3 
  H >sp|P50295|ARY2  Arylamine N-acetyltransferase 2  23,34 1,941E-04 2,1 
  H >sp|P52760|UK114  Ribonuclease UK114  168,04 2,244E-02 -2,2 
  H >sp|P52792|HXK4  Glucokinase  19,75 1,853E-03 2,1 
  H >sp|P52843|ST2A1  Bile salt sulfotransferase 1  22,62 8,574E-04 -7,3 
  H >sp|P53996|CNBP  Cellular nucleic acid-binding protein  12,28 5,797E-03 -2,3 
  H >sp|P55302|AMRP 
 Alpha-2-macroglobulin receptor-
associated protein  14,28 5,040E-03 2,3 
  H >sp|P56391|CX6B1  Cytochrome c oxidase subunit 6B1  14,61 9,768E-03 -2,6 
  H >sp|P59325|IF5  Eukaryotic translation initiation factor 5  17,03 1,622E-03 -2,6 
  H >sp|P60229|EIF3E 
 Eukaryotic translation initiation factor 3 
subunit E  24,24 7,426E-04 12,0 
  H >sp|P61514|RL37A  60S ribosomal protein L37a  13,94 5,379E-04 5,2 
  H >sp|P62204|CALM  Calmodulin  15,87 7,850E-03 2,3 
  H >sp|P62827|RAN  GTP-binding nuclear protein Ran  24,89 7,816E-06 -4,6 
  H >sp|P62862|RS30  40S ribosomal protein S30  8,12 6,148E-04 -3,7 
  H >sp|P63073|IF4E  Eukaryotic translation initiation factor 4E  13,97 4,136E-03 4,2 
  H >sp|P63085|MK01  Mitogen-activated protein kinase 1  13,73 3,247E-03 -2,4 
  H >sp|P70398|USP9X 
 Probable ubiquitin carboxyl-terminal 
hydrolase FAF-X  14,40 3,994E-03 2,6 
  H >sp|P83882|RL36A  60S ribosomal protein L36a  6,64 8,349E-05 -4,2 
  H >sp|P84091|AP2M1  AP-2 complex subunit mu  21,34 9,765E-04 -3,6 
  H >sp|P84244|H33  Histone H3.3  4,86 4,396E-03 -2,4 
  H >sp|P99026|PSB4  Proteasome subunit beta type-4  23,09 2,587E-03 -6,1 
  H >sp|P99028|QCR6 
 Cytochrome b-c1 complex subunit 6, 
mitochondrial  26,22 1,040E-02 -2,1 
  H >sp|Q00519|XDH  Xanthine dehydrogenase/oxidase  120,97 2,592E-03 -3,6 
  H >sp|Q07813|BAX  Apoptosis regulator BAX  7,24 1,035E-02 -2,5 
  H >sp|Q3THK7|GUAA  GMP synthase [glutamine-hydrolyzing]  22,83 8,233E-04 -2,5 
  H >sp|Q3UNZ8|QORL2  Quinone oxidoreductase-like protein 2  33,01 1,030E-05 10,4 
  H >sp|Q5SUR0|PUR4 
 Phosphoribosylformylglycinamidine 
synthase  14,96 1,334E-03 -2,2 
  H >sp|Q60692|PSB6  Proteasome subunit beta type-6  24,38 9,348E-04 -4,4 
  H >sp|Q61699|HS105  Heat shock protein 105 kDa  65,84 4,202E-02 2,9 
  H >sp|Q62264|THRSP 
 Thyroid hormone-inducible hepatic 
protein  63,13 1,352E-03 -3,5 
  H >sp|Q62348|TSN  Translin  3,38 4,956E-03 -3,6 
  H >sp|Q62376|RU17 
 U1 small nuclear ribonucleoprotein 70 
kDa  6,88 6,792E-04 -2,9 
  H >sp|Q62452|UD19  UDP-glucuronosyltransferase 1-9  134,47 2,394E-03 -2,0 
  H >sp|Q64374|RGN  Regucalcin  474,77 1,225E-04 -2,7 
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  H >sp|Q6P8I4|PCNP 
 PEST proteolytic signal-containing nuclear 
protein  8,89 5,262E-05 -3,3 
  H >sp|Q76LS9|FA63A  Protein FAM63A  14,09 1,605E-02 2,1 
  H >sp|Q7TPV4|MBB1A  Myb-binding protein 1A  9,94 2,593E-03 2,1 
  H >sp|Q8BFZ3|ACTBL  Beta-actin-like protein 2  194,76 1,488E-02 -2,3 
  H >sp|Q8BH69|SPS1  Selenide, water dikinase 1  16,62 1,181E-05 -3,5 
  H >sp|Q8BWM0|PGES2  Prostaglandin E synthase 2  3,99 1,695E-02 -2,4 
  H >sp|Q8C1B7|SEP11  Septin-11  26,97 3,914E-04 2,3 
  H >sp|Q8CAQ8|MIC60  MICOS complex subunit Mic60  7,80 5,560E-03 2,5 
  H >sp|Q8CAS9|PARP9  Poly [ADP-ribose] polymerase 9  11,36 7,125E-04 2,1 
  H >sp|Q8K010|OPLA  5-oxoprolinase  206,63 3,220E-07 27,5 
  H >sp|Q8R050|ERF3A 
 Eukaryotic peptide chain release factor 
GTP-binding subunit ERF3A  20,28 6,261E-05 2,9 
  H >sp|Q8R317|UBQL1  Ubiquilin-1  38,38 3,764E-02 2,3 
  H >sp|Q8VCC1|PGDH 
 15-hydroxyprostaglandin dehydrogenase 
[NAD(+)]  41,97 1,041E-02 -2,7 
  H >sp|Q8VCH6|DHC24  Delta(24)-sterol reductase  10,41 6,011E-04 -2,8 
  H >sp|Q91VS7|MGST1  Microsomal glutathione S-transferase 1  110,95 5,391E-03 -3,8 
  H >sp|Q91W97|HKDC1  Putative hexokinase HKDC1  3,11 3,555E-03 2,2 
  H >sp|Q91XE8|TM205  Transmembrane protein 205  16,47 4,048E-06 3,6 
  H >sp|Q920A5|RISC 
 Retinoid-inducible serine 
carboxypeptidase  14,69 1,412E-04 2,3 
  H >sp|Q922Q1|MARC2 
 Mitochondrial amidoxime reducing 
component 2  34,67 1,271E-05 -3,2 
  H >sp|Q99KP6|PRP19  Pre-mRNA-processing factor 19  11,47 1,564E-06 12,5 
  H >sp|Q99KV1|DJB11  DnaJ homolog subfamily B member 11  38,78 1,606E-02 2,0 
  H >sp|Q99LY9|NDUS5 
 NADH dehydrogenase [ubiquinone] iron-
sulfur protein 5  6,11 2,114E-04 -4,7 
  H >sp|Q99P30|NUDT7 
 Peroxisomal coenzyme A diphosphatase 
NUDT7  132,96 4,441E-04 -2,4 
  H >sp|Q9CPU0|LGUL  Lactoylglutathione lyase  157,33 7,819E-05 -2,5 
  H >sp|Q9CPX6|ATG3  Ubiquitin-like-conjugating enzyme ATG3  6,07 2,944E-03 -2,3 
  H >sp|Q9CQC6|BZW1 
 Basic leucine zipper and W2 domain-
containing protein 1  15,15 1,898E-03 -3,2 
  H >sp|Q9CXS4|CENPV  Centromere protein V  14,44 3,399E-02 2,1 
  H >sp|Q9CYZ2|TPD54  Tumor protein D54  24,45 2,177E-04 2,9 
  H >sp|Q9D1G1|RAB1B  Ras-related protein Rab-1B  43,53 8,573E-03 2,1 
  H >sp|Q9D1R9|RL34  60S ribosomal protein L34  12,19 9,227E-03 -2,1 
  H >sp|Q9D2R0|AACS  Acetoacetyl-CoA synthetase  22,28 5,676E-04 3,9 
  H >sp|Q9D2V7|CORO7  Coronin-7  24,62 1,647E-02 -2,6 
  H >sp|Q9D7G0|PRPS1  Ribose-phosphate pyrophosphokinase 1  48,75 1,538E-07 -67,2 
  H >sp|Q9D820|PRXD1 
 Prolyl-tRNA synthetase associated 
domain-containing protein 1  4,86 8,386E-05 -5,5 
  H >sp|Q9DBE0|CSAD  Cysteine sulfinic acid decarboxylase  131,84 1,735E-02 -2,5 
  H >sp|Q9DCH4|EIF3F 
 Eukaryotic translation initiation factor 3 
subunit F  20,34 2,785E-02 -2,0 
  H >sp|Q9EPQ7|STAR5  StAR-related lipid transfer protein 5  8,78 1,901E-03 -2,2 
  H >sp|Q9EQ06|DHB11  Estradiol 17-beta-dehydrogenase 11  21,95 4,838E-03 -2,7 
  H >sp|Q9ERG0|LIMA1  LIM domain and actin-binding protein 1  28,82 9,280E-05 2,1 
  H >sp|Q9JHE3|ASAH2  Neutral ceramidase  8,73 4,741E-03 2,1 
  H >sp|Q9JHS4|CLPX 
 ATP-dependent Clp protease ATP-binding 
subunit clpX-like 25,06 1,323E-05 13,5 
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  H >sp|Q9JIL4|NHRF3 
 Na(+)/H(+) exchange regulatory cofactor 
NHE-RF3  28,83 3,295E-03 2,8 
  H >sp|Q9JLY0|SOCS6  Suppressor of cytokine signaling 6  2,73 2,485E-04 2,5 
  H >sp|Q9JMA1|UBP14  Ubiquitin carboxyl-terminal hydrolase 14  43,37 4,681E-03 4,9 
  H >sp|Q9QZD8|DIC  Mitochondrial dicarboxylate carrier  25,27 4,606E-02 -2,2 
  H >sp|Q9R0A0|PEX14  Peroxisomal membrane protein PEX14  13,61 1,458E-03 2,3 
  H >sp|Q9R0M5|TPK1  Thiamin pyrophosphokinase 1  8,59 9,983E-03 -4,8 
  H >sp|Q9R0Q9|MPU1 
 Mannose-P-dolichol utilization defect 1 
protein  7,59 6,942E-04 -2,4 
  H >sp|Q9R1J0|NSDHL 
 Sterol-4-alpha-carboxylate 3-
dehydrogenase, decarboxylating  18,92 4,937E-05 -2,3 
  H >sp|Q9R1P1|PSB3  Proteasome subunit beta type-3  32,66 3,703E-04 -6,0 
  H >sp|Q9R1P3|PSB2  Proteasome subunit beta type-2  27,17 4,797E-04 -6,3 
  H >sp|Q9WU19|HAOX1  Hydroxyacid oxidase 1  67,82 1,064E-02 2,2 
  H >sp|Q9Z2U0|PSA7  Proteasome subunit alpha type-7  61,80 4,219E-04 -5,1 
  H >sp|Q9Z2U1|PSA5  Proteasome subunit alpha type-5  59,85 1,696E-03 -4,7 
  H >sp|Q9Z2W0|DNPEP  Aspartyl aminopeptidase  43,74 8,086E-03 -2,5 
  H >sp|Q9Z2Z6|MCAT 
 Mitochondrial carnitine/acylcarnitine 
carrier protein  20,71 4,390E-02 -2,3 
  H >tr|A0A0A0MQC3  5-hydroxyisourate hydrolase  50,54 9,407E-05 -3,3 
  H >tr|A2AGR0|A2AGR0 
 MAP kinase-activating death domain 
protein  4,87 3,710E-05 5,4 
  H >tr|A2AQZ2|A2AQZ2 
 Phytanoyl-CoA dioxygenase domain-
containing protein 1 (Fragment)  54,28 4,692E-05 4,4 
  H >tr|D3Z0R5|D3Z0R5 
 Glucosamine-6-phosphate isomerase 1 
(Fragment)  6,97 9,352E-04 -2,4 
  H >tr|D3Z5G7|D3Z5G7  Carboxylic ester hydrolase  37,61 5,939E-03 2,4 
  H >tr|E9PV38|E9PV38  Carboxylic ester hydrolase  53,04 1,976E-03 2,3 
  H >tr|E9PW69|E9PW69 
 Proteasome subunit alpha type 
(Fragment)  31,99 2,768E-04 -6,3 
  H >tr|E9PZ00|E9PZ00  Prosaposin  54,04 2,561E-02 -2,5 
  H >tr|E9Q455|E9Q455  Tropomyosin alpha-1 chain  42,17 9,618E-05 4,6 
  H >tr|E9Q9F5|E9Q9F5  Septin-7  57,02 3,489E-06 28,0 
  H >tr|E9QNW6|E9QNW6 
 Platelet-activating factor acetylhydrolase 
2, cytoplasmic  8,02 5,794E-04 4,1 
  H >tr|F7CBP1|F7CBP1 
 Eukaryotic translation initiation factor 4 
gamma 2  8,19 8,781E-05 -4,1 
  H >tr|G3UWG1|G3UWG1  MCG115977  142,03 4,987E-04 -2,3 
  H >tr|G5E902|G5E902  MCG10343, isoform CRA_b  35,02 2,884E-05 3,1 
  H >tr|H3BJ51|H3BJ51  All-trans-retinol 13,14-reductase  31,98 4,332E-02 -2,2 
  H >tr|H7BX99|H7BX99  Prothrombin  19,69 9,163E-06 14,0 
  H >tr|Q3TUE1|Q3TUE1  Far upstream element-binding protein 1  18,66 3,536E-04 -2,6 
  H >tr|Q6GT24|Q6GT24  Peroxiredoxin 6  341,89 1,388E-02 3,0 
  H >tr|Q6ZWZ6|Q6ZWZ6  40S ribosomal protein S12  15,79 2,930E-04 -2,2 
  H >tr|Q8BJL9|Q8BJL9  MCG131372  23,16 1,465E-03 -6,6 
  H >tr|Q8BVD2|Q8BVD2 
 Cytochrome P450, family 2, subfamily d, 
polypeptide 12  46,90 1,882E-03 -2,4 
  H >tr|Q91Z40|Q91Z40  Gbp6 protein  5,97 1,379E-03 -2,5 
  H >tr|Q9CQM8|Q9CQM8  60S ribosomal protein L21  48,39 6,073E-04 4,7 
  H >tr|Q9WUD0|Q9WUD0  Cytochrome P450 2B10  16,12 1,197E-03 -2,4 
  L >sp|A2AS89|SPEB  Agmatinase, mitochondrial  60,52 5,357E-06 -4,0 
  L >sp|B1AR13|CISD3 
 CDGSH iron-sulfur domain-containing 
protein 3, mitochondrial  8,01 1,656E-04 -5,4 
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  L >sp|E9Q4Z2|ACACB  Acetyl-CoA carboxylase 2  72,01 1,047E-04 2,4 
  L >sp|O08807|PRDX4  Peroxiredoxin-4  47,98 1,291E-03 3,1 
  L >sp|O09061|PSB1  Proteasome subunit beta type-1  34,47 2,916E-03 -4,3 
  L >sp|O35286|DHX15 
 Pre-mRNA-splicing factor ATP-dependent 
RNA helicase DHX15  13,23 1,830E-02 -2,1 
  L >sp|O55135|IF6  Eukaryotic translation initiation factor 6  47,88 8,102E-04 2,1 
  L >sp|O55137|ACOT1  Acyl-coenzyme A thioesterase 1  121,46 5,512E-05 -2,5 
  L >sp|O55142|RL35A  60S ribosomal protein L35a  14,18 7,236E-04 -2,1 
  L >sp|O55234|PSB5  Proteasome subunit beta type-5  16,24 2,810E-03 -3,6 
  L >sp|O70435|PSA3  Proteasome subunit alpha type-3  8,53 7,447E-04 -6,8 
  L >sp|O88451|RDH7  Retinol dehydrogenase 7  130,14 5,437E-06 -4,2 
  L >sp|O88456|CPNS1  Calpain small subunit 1  15,07 7,863E-05 2,3 
  L >sp|P02089|HBB2  Hemoglobin subunit beta-2  269,71 4,767E-05 -3,3 
  L >sp|P06330|HVM51  Ig heavy chain V region AC38 205.12  13,64 1,794E-05 5,9 
  L >sp|P06801|MAOX  NADP-dependent malic enzyme  364,83 5,985E-04 -2,0 
  L >sp|P07724|ALBU  Serum albumin  884,36 1,169E-05 -2,1 
  L >sp|P07759|SPA3K  Serine protease inhibitor A3K  132,97 9,592E-04 -2,0 
  L >sp|P08752|GNAI2 
 Guanine nucleotide-binding protein G(i) 
subunit alpha-2  16,63 6,090E-03 3,5 
  L >sp|P11352|GPX1  Glutathione peroxidase 1  154,94 2,192E-03 -3,0 
  L >sp|P12790|CP2B9  Cytochrome P450 2B9  26,56 1,136E-02 -2,2 
  L >sp|P14246|GTR2 
 Solute carrier family 2, facilitated glucose 
transporter member 2  6,57 8,786E-04 -3,1 
  L >sp|P14602|HSPB1  Heat shock protein beta-1  4,97 1,143E-03 2,9 
  L >sp|P16546|SPTN1  Spectrin alpha chain, non-erythrocytic 1  42,85 1,367E-05 7,9 
  L >sp|P16627|HS71L  Heat shock 70 kDa protein 1-like  78,03 3,586E-03 -2,3 
  L >sp|P17563|SBP1  Selenium-binding protein 1  448,05 7,429E-04 -2,1 
  L >sp|P17879|HS71B  Heat shock 70 kDa protein 1B  113,76 2,298E-04 3,0 
  L >sp|P18572|BASI  Basigin  30,31 5,715E-05 -2,2 
  L >sp|P21614|VTDB  Vitamin D-binding protein  148,26 6,398E-05 -2,5 
  L >sp|P24456|CP2DA  Cytochrome P450 2D10  194,38 8,622E-04 -2,3 
  L >sp|P27046|MA2A1  Alpha-mannosidase 2  14,55 4,805E-04 -2,2 
  L >sp|P28651|CAH8  Carbonic anhydrase-related protein  35,72 1,027E-04 4,0 
  L >sp|P28798|GRN  Granulins  16,30 7,310E-05 -35,0 
  L >sp|P34927|ASGR1  Asialoglycoprotein receptor 1  32,22 1,830E-03 -2,0 
  L >sp|P35492|HUTH  Histidine ammonia-lyase  376,41 4,409E-04 -2,0 
  L >sp|P35505|FAAA  Fumarylacetoacetase  449,36 1,702E-04 -4,8 
  L >sp|P42925|PXMP2  Peroxisomal membrane protein 2  6,68 1,753E-03 -3,3 
  L >sp|P50295|ARY2  Arylamine N-acetyltransferase 2  23,34 1,452E-04 3,5 
  L >sp|P52792|HXK4  Glucokinase  19,75 2,568E-03 2,7 
  L >sp|P56391|CX6B1  Cytochrome c oxidase subunit 6B1  14,61 4,747E-02 -2,0 
  L >sp|P59325|IF5  Eukaryotic translation initiation factor 5  17,03 1,208E-04 -2,7 
  L >sp|P59999|ARPC4 
 Actin-related protein 2/3 complex subunit 
4  23,53 1,045E-03 2,0 
  L >sp|P60229|EIF3E 
 Eukaryotic translation initiation factor 3 
subunit E  24,24 5,137E-05 6,2 
  L >sp|P61514|RL37A  60S ribosomal protein L37a  13,94 2,530E-05 5,6 
  L >sp|P62204|CALM  Calmodulin  15,87 3,004E-02 2,0 
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  L >sp|P62827|RAN  GTP-binding nuclear protein Ran  24,89 2,542E-04 -6,2 
  L >sp|P62862|RS30  40S ribosomal protein S30  8,12 5,254E-04 -8,0 
  L >sp|P63085|MK01  Mitogen-activated protein kinase 1  13,73 1,170E-03 -2,3 
  L >sp|P70398|USP9X 
 Probable ubiquitin carboxyl-terminal 
hydrolase FAF-X  14,40 9,517E-03 2,4 
  L >sp|P83882|RL36A  60S ribosomal protein L36a  6,64 4,079E-05 -5,8 
  L >sp|P84091|AP2M1  AP-2 complex subunit mu  21,34 3,118E-04 -4,5 
  L >sp|P84244|H33  Histone H3.3  4,86 5,960E-04 -4,8 
  L >sp|P97351|RS3A  40S ribosomal protein S3a  97,26 3,078E-04 -2,5 
  L >sp|P99026|PSB4  Proteasome subunit beta type-4  23,09 8,997E-03 -4,1 
  L >sp|Q00519|XDH  Xanthine dehydrogenase/oxidase  120,97 1,112E-03 -2,8 
  L >sp|Q01339|APOH  Beta-2-glycoprotein 1  13,44 1,240E-02 -2,3 
  L >sp|Q01730|RSU1  Ras suppressor protein 1  29,83 1,186E-03 2,8 
  L >sp|Q05915|GCH1  GTP cyclohydrolase 1  5,10 5,749E-05 3,2 
  L >sp|Q07813|BAX  Apoptosis regulator BAX  7,24 3,614E-03 -2,1 
  L >sp|Q3THK7|GUAA  GMP synthase [glutamine-hydrolyzing]  22,83 8,106E-04 -2,3 
  L >sp|Q3UNZ8|QORL2  Quinone oxidoreductase-like protein 2  33,01 2,044E-05 8,6 
  L >sp|Q4VAA2|CDV3  Protein CDV3  49,10 1,194E-02 2,3 
  L >sp|Q60692|PSB6  Proteasome subunit beta type-6  24,38 1,646E-03 -3,7 
  L >sp|Q61704|ITIH3 
 Inter-alpha-trypsin inhibitor heavy chain 
H3  7,97 8,595E-05 2,5 
  L >sp|Q62186|SSRD 
 Translocon-associated protein subunit 
delta  11,23 9,160E-03 2,7 
  L >sp|Q62264|THRSP 
 Thyroid hormone-inducible hepatic 
protein  63,13 1,618E-03 -3,5 
  L >sp|Q62348|TSN  Translin  3,38 8,647E-03 -3,0 
  L >sp|Q62376|RU17 
 U1 small nuclear ribonucleoprotein 70 
kDa  6,88 3,308E-04 -3,2 
  L >sp|Q62452|UD19  UDP-glucuronosyltransferase 1-9  134,47 1,798E-04 -2,6 
  L >sp|Q64374|RGN  Regucalcin  474,77 1,666E-04 -2,1 
  L >sp|Q6P542|ABCF1 
 ATP-binding cassette sub-family F 
member 1  25,71 3,750E-03 2,8 
  L >sp|Q6P8I4|PCNP 
 PEST proteolytic signal-containing nuclear 
protein  8,89 2,347E-05 -3,6 
  L >sp|Q76LS9|FA63A  Protein FAM63A  14,09 9,562E-03 2,4 
  L >sp|Q76MZ3|2AAA 
 Serine/threonine-protein phosphatase 2A 
65 kDa regulatory subunit 70,84 2,240E-03 2,2 
  L >sp|Q7TPV4|MBB1A  Myb-binding protein 1A  9,94 1,599E-03 2,5 
  L >sp|Q80VP1|EPN1  Epsin-1  18,13 5,771E-04 2,5 
  L >sp|Q8BFP9|PDK1 
 [Pyruvate dehydrogenase (acetyl-
transferring)] kinase isozyme 1 6,93 6,219E-03 2,9 
  L >sp|Q8BFZ3|ACTBL  Beta-actin-like protein 2  194,76 3,010E-04 -2,9 
  L >sp|Q8BH69|SPS1  Selenide, water dikinase 1  16,62 8,027E-06 -4,9 
  L >sp|Q8BKZ9|ODPX 
 Pyruvate dehydrogenase protein X 
component, mitochondrial  10,55 1,090E-04 2,0 
  L >sp|Q8BL66|EEA1  Early endosome antigen 1  3,80 1,222E-03 2,0 
  L >sp|Q8BP56|ATHL1  Acid trehalase-like protein 1  5,60 2,255E-02 3,4 
  L >sp|Q8BWM0|PGES2  Prostaglandin E synthase 2  3,99 5,082E-03 -2,0 
  L >sp|Q8C1B7|SEP11  Septin-11  26,97 3,592E-05 2,7 
  L >sp|Q8CAQ8|MIC60  MICOS complex subunit Mic60  7,80 1,338E-04 2,6 
  L >sp|Q8CAS9|PARP9  Poly [ADP-ribose] polymerase 9  11,36 1,390E-03 2,1 
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  L >sp|Q8K010|OPLA  5-oxoprolinase  206,63 1,399E-07 20,1 
  L >sp|Q8K0C4|CP51A  Lanosterol 14-alpha demethylase  31,93 3,170E-05 2,4 
  L >sp|Q8K297|GT251  Procollagen galactosyltransferase 1  7,80 1,756E-03 2,5 
  L >sp|Q8K3K7|PLCB 
 1-acyl-sn-glycerol-3-phosphate 
acyltransferase beta  16,90 1,444E-02 2,2 
  L >sp|Q8K411|PREP  Presequence protease, mitochondrial  38,78 6,749E-03 2,6 
  L >sp|Q8K441|ABCA6 
 ATP-binding cassette sub-family A 
member 6  26,53 6,478E-03 2,6 
  L >sp|Q8R016|BLMH  Bleomycin hydrolase  21,17 4,793E-03 -2,1 
  L >sp|Q8R050|ERF3A 
 Eukaryotic peptide chain release factor 
GTP-binding subunit ERF3A  20,28 1,690E-06 5,2 
  L >sp|Q8R317|UBQL1  Ubiquilin-1  38,38 1,739E-02 2,2 
  L >sp|Q8VCC1|PGDH 
 15-hydroxyprostaglandin dehydrogenase 
[NAD(+)]  41,97 1,346E-04 -2,5 
  L >sp|Q8VCH6|DHC24  Delta(24)-sterol reductase  10,41 3,133E-05 -3,1 
  L >sp|Q8VCH8|UBXN4  UBX domain-containing protein 4  14,67 6,364E-03 -2,2 
  L >sp|Q8VCT3|AMPB  Aminopeptidase B  63,09 1,369E-03 2,6 
  L >sp|Q8VCU1|EST3B  Carboxylesterase 3B  125,07 6,130E-03 -2,6 
  L >sp|Q91VS7|MGST1  Microsomal glutathione S-transferase 1  110,95 1,517E-04 -6,4 
  L >sp|Q91VT4|CBR4  Carbonyl reductase family member 4  63,93 8,152E-04 2,0 
  L >sp|Q91W97|HKDC1  Putative hexokinase HKDC1  3,11 1,580E-03 2,4 
  L >sp|Q91XE8|TM205  Transmembrane protein 205  16,47 8,595E-06 3,8 
  L >sp|Q921M3|SF3B3  Splicing factor 3B subunit 3  14,37 8,615E-03 2,2 
  L >sp|Q99KP3|CRYL1  Lambda-crystallin homolog  37,47 3,997E-03 3,0 
  L >sp|Q99KP6|PRP19  Pre-mRNA-processing factor 19  11,47 7,550E-06 13,2 
  L >sp|Q99LY9|NDUS5 
 NADH dehydrogenase [ubiquinone] iron-
sulfur protein 5  6,11 2,175E-02 -2,8 
  L >sp|Q99P30|NUDT7 
 Peroxisomal coenzyme A diphosphatase 
NUDT7  132,96 3,369E-04 -2,2 
  L >sp|Q9CPX6|ATG3  Ubiquitin-like-conjugating enzyme ATG3  6,07 9,676E-04 -3,2 
  L >sp|Q9CQC6|BZW1 
 Basic leucine zipper and W2 domain-
containing protein 1  15,15 7,564E-03 -2,5 
  L >sp|Q9CYZ2|TPD54  Tumor protein D54  24,45 6,048E-06 3,5 
  L >sp|Q9D154|ILEUA  Leukocyte elastase inhibitor A  3,96 2,427E-02 -2,0 
  L >sp|Q9D1M0|SEC13  Protein SEC13 homolog  41,90 8,547E-04 2,2 
  L >sp|Q9D1R9|RL34  60S ribosomal protein L34  12,19 1,829E-04 -3,0 
  L >sp|Q9D273|MMAB 
 Cob(I)yrinic acid a,c-diamide 
adenosyltransferase, mitochondrial  20,12 1,827E-03 2,2 
  L >sp|Q9D2R0|AACS  Acetoacetyl-CoA synthetase  22,28 3,568E-04 3,8 
  L >sp|Q9D7G0|PRPS1  Ribose-phosphate pyrophosphokinase 1  48,75 1,259E-05 -112,1 
  L >sp|Q9D820|PRXD1 
 Prolyl-tRNA synthetase associated 
domain-containing protein 1  4,86 1,327E-04 -10,6 
  L >sp|Q9DBC7|KAP0 
 cAMP-dependent protein kinase type I-
alpha regulatory subunit  3,95 2,634E-03 2,7 
  L >sp|Q9DBE0|CSAD  Cysteine sulfinic acid decarboxylase  131,84 4,147E-04 -6,5 
  L >sp|Q9DBH5|LMAN2 
 Vesicular integral-membrane protein 
VIP36  24,00 5,650E-03 2,2 
  L >sp|Q9DBS5|KLC4  Kinesin light chain 4  8,68 2,550E-03 3,8 
  L >sp|Q9DCH4|EIF3F 
 Eukaryotic translation initiation factor 3 
subunit F  20,34 1,803E-02 -3,7 
  L >sp|Q9DCT2|NDUS3 
 NADH dehydrogenase [ubiquinone] iron-
sulfur protein 3 13,34 9,044E-03 2,0 
  L >sp|Q9DD20|MET7B  Methyltransferase-like protein 7B  53,21 6,404E-04 -2,0 
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  L >sp|Q9EPQ7|STAR5  StAR-related lipid transfer protein 5  8,78 2,425E-04 -4,9 
  L >sp|Q9EQ06|DHB11  Estradiol 17-beta-dehydrogenase 11  21,95 1,067E-04 -3,7 
  L >sp|Q9ET22|DPP2  Dipeptidyl peptidase 2  5,13 7,200E-03 -2,0 
  L >sp|Q9JHE3|ASAH2  Neutral ceramidase  8,73 2,495E-04 3,9 
  L >sp|Q9JHS4|CLPX 
 ATP-dependent Clp protease ATP-binding 
subunit clpX-like 25,06 4,975E-05 10,8 
  L >sp|Q9JIL4|NHRF3 
 Na(+)/H(+) exchange regulatory cofactor 
NHE-RF3  28,83 1,751E-04 4,6 
  L >sp|Q9JLY0|SOCS6  Suppressor of cytokine signaling 6  2,73 8,931E-04 2,4 
  L >sp|Q9JMA1|UBP14  Ubiquitin carboxyl-terminal hydrolase 14  43,37 9,072E-03 3,9 
  L >sp|Q9JMA7|CP341  Cytochrome P450 3A41  142,20 3,709E-02 2,1 
  L >sp|Q9R092|H17B6 
 17-beta-hydroxysteroid dehydrogenase 
type 6  98,04 5,570E-04 -2,5 
  L >sp|Q9R0M5|TPK1  Thiamin pyrophosphokinase 1  8,59 1,128E-02 -2,8 
  L >sp|Q9R0Q9|MPU1 
 Mannose-P-dolichol utilization defect 1 
protein  7,59 1,780E-04 -2,5 
  L >sp|Q9R1J0|NSDHL 
 Sterol-4-alpha-carboxylate 3-
dehydrogenase, decarboxylating  18,92 7,055E-04 -2,3 
  L >sp|Q9R1P1|PSB3  Proteasome subunit beta type-3  32,66 3,443E-04 -5,4 
  L >sp|Q9R1P3|PSB2  Proteasome subunit beta type-2  27,17 4,611E-04 -4,7 
  L >sp|Q9WV02|RBMX 
 RNA-binding motif protein, X 
chromosome  6,24 8,392E-03 3,2 
  L >sp|Q9Z1J3|NFS1  Cysteine desulfurase, mitochondrial  15,05 2,370E-04 2,7 
  L >sp|Q9Z2U0|PSA7  Proteasome subunit alpha type-7  61,80 3,203E-04 -4,3 
  L >sp|Q9Z2U1|PSA5  Proteasome subunit alpha type-5  59,85 1,348E-03 -5,0 
  L >sp|Q9Z2W0|DNPEP  Aspartyl aminopeptidase  43,74 3,760E-03 -2,5 
  L >sp|Q9Z2Z6|MCAT 
 Mitochondrial carnitine/acylcarnitine 
carrier protein  20,71 6,473E-03 -2,5 
  L >tr|A0A0A0MQC3  5-hydroxyisourate hydrolase  50,54 5,446E-04 -3,6 
  L >tr|A2AGR0|A2AGR0 
 MAP kinase-activating death domain 
protein  4,87 8,213E-05 4,9 
  L >tr|A2AQZ2|A2AQZ2 
 Phytanoyl-CoA dioxygenase domain-
containing protein 1 (Fragment)  54,28 3,414E-07 4,8 
  L >tr|D3YUK4|D3YUK4 
 NADH dehydrogenase [ubiquinone] 1 
beta subcomplex subunit 10 (Fragment)  7,57 1,386E-02 2,1 
  L >tr|D3YUP6|D3YUP6  Protein Ugt2b36 (Fragment)  48,07 3,814E-05 -2,1 
  L >tr|D3Z0R5|D3Z0R5 
 Glucosamine-6-phosphate isomerase 1 
(Fragment)  6,97 1,559E-03 -2,1 
  L >tr|D3Z5G7|D3Z5G7  Carboxylic ester hydrolase  37,61 2,179E-03 2,3 
  L >tr|E9PV38|E9PV38  Carboxylic ester hydrolase  53,04 3,002E-04 2,2 
  L >tr|E9PVM7|E9PVM7 
 Glutathione S-transferase Mu 5 
(Fragment)  16,27 3,864E-02 2,0 
  L >tr|E9PW69|E9PW69 
 Proteasome subunit alpha type 
(Fragment)  31,99 5,818E-04 -4,8 
  L >tr|E9PXC3|E9PXC3  Protein Cyp2c69  134,37 1,542E-03 -2,8 
  L >tr|E9PZ00|E9PZ00  Prosaposin  54,04 1,230E-02 -2,4 
  L >tr|E9Q455|E9Q455  Tropomyosin alpha-1 chain  42,17 7,525E-07 7,7 
  L >tr|E9Q9F5|E9Q9F5  Septin-7  57,02 4,623E-07 23,7 
  L >tr|E9QNW6|E9QNW6 
 Platelet-activating factor acetylhydrolase 
2, cytoplasmic  8,02 6,299E-03 5,8 
  L >tr|F7CBP1|F7CBP1 
 Eukaryotic translation initiation factor 4 
gamma 2  8,19 9,533E-05 -3,6 
  L >tr|G5E902|G5E902  MCG10343, isoform CRA_b  35,02 3,334E-05 3,0 
  L >tr|H3BJ51|H3BJ51  All-trans-retinol 13,14-reductase  31,98 5,624E-03 -4,0 
  L >tr|H7BX99|H7BX99  Prothrombin  19,69 2,154E-05 11,5 
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  L >tr|Q3TKD0|Q3TKD0  Transportin-1 (Fragment)  7,72 9,237E-03 2,4 
  L >tr|Q5EBP8|Q5EBP8 
 Heterogeneous nuclear 
ribonucleoprotein A1  42,56 1,360E-03 2,2 
  L >tr|Q6ZWZ6|Q6ZWZ6  40S ribosomal protein S12  15,79 6,019E-04 -2,2 
  L >tr|Q8BH80|Q8BH80 
 Vesicle-associated membrane protein, 
associated protein B and C  5,82 1,157E-02 -2,4 
  L >tr|Q8CBB6|Q8CBB6  Histone H2B  17,91 2,921E-03 -3,6 
  L >tr|Q8K169|Q8K169  MCG1789  99,83 1,187E-03 -2,2 
  L >tr|Q91X75|Q91X75  Cyp2a4 protein  92,05 3,009E-03 -2,0 
  L >tr|Q91Z40|Q91Z40  Gbp6 protein  5,97 1,288E-04 -3,1 
  L >tr|Q9CQM8|Q9CQM8  60S ribosomal protein L21  48,39 2,179E-04 3,0 
  L >tr|Q9WUD0|Q9WUD0  Cytochrome P450 2B10  16,12 3,394E-04 -2,1 
  M >sp|A2AS89|SPEB  Agmatinase, mitochondrial  60,52 4,295E-05 -8,1 
  M >sp|B1AR13|CISD3 
 CDGSH iron-sulfur domain-containing 
protein 3, mitochondrial  8,01 1,327E-02 -3,4 
  M >sp|E9Q4Z2|ACACB  Acetyl-CoA carboxylase 2  72,01 4,871E-05 2,1 
  M >sp|O08583|THOC4  THO complex subunit 4  14,57 6,252E-05 3,9 
  M >sp|O08709|PRDX6  Peroxiredoxin-6  360,97 3,286E-03 12,3 
  M >sp|O08749|DLDH 
 Dihydrolipoyl dehydrogenase, 
mitochondrial  137,90 1,330E-03 -2,0 
  M >sp|O09061|PSB1  Proteasome subunit beta type-1  34,47 5,185E-03 -7,1 
  M >sp|O35215|DOPD  D-dopachrome decarboxylase  23,57 1,835E-02 -9,2 
  M >sp|O35841|API5  Apoptosis inhibitor 5  15,45 5,115E-03 -3,5 
  M >sp|O35945|AL1A7  Aldehyde dehydrogenase, cytosolic 1  341,03 1,749E-03 -2,9 
  M >sp|O55234|PSB5  Proteasome subunit beta type-5  16,24 1,051E-02 -3,0 
  M >sp|O70435|PSA3  Proteasome subunit alpha type-3  8,53 3,589E-03 -6,3 
  M >sp|O88451|RDH7  Retinol dehydrogenase 7  130,14 5,368E-04 -2,5 
  M >sp|P00329|ADH1  Alcohol dehydrogenase 1  490,89 1,900E-05 -2,6 
  M >sp|P00920|CAH2  Carbonic anhydrase 2  139,00 2,904E-03 -2,1 
  M >sp|P01864|GCAB  Ig gamma-2A chain C region secreted form  9,98 5,539E-03 -2,5 
  M >sp|P02089|HBB2  Hemoglobin subunit beta-2  269,71 1,260E-05 7,2 
  M >sp|P06330|HVM51  Ig heavy chain V region AC38 205.12  13,64 7,381E-06 11,7 
  M >sp|P07724|ALBU  Serum albumin  884,36 1,476E-04 -2,1 
  M >sp|P08752|GNAI2 
 Guanine nucleotide-binding protein G(i) 
subunit alpha-2  16,63 1,169E-02 4,2 
  M >sp|P12790|CP2B9  Cytochrome P450 2B9  26,56 3,613E-02 -2,0 
  M >sp|P13634|CAH1  Carbonic anhydrase 1  24,59 3,060E-04 2,9 
  M >sp|P14602|HSPB1  Heat shock protein beta-1  4,97 3,320E-02 2,1 
  M >sp|P15105|GLNA  Glutamine synthetase  404,84 9,960E-06 -2,1 
  M >sp|P16045|LEG1  Galectin-1  21,49 5,079E-03 -3,2 
  M >sp|P16546|SPTN1  Spectrin alpha chain, non-erythrocytic 1  42,85 1,154E-04 6,8 
  M >sp|P17879|HS71B  Heat shock 70 kDa protein 1B  113,76 2,296E-03 3,1 
  M >sp|P20152|VIME  Vimentin  70,04 1,641E-02 -2,9 
  M >sp|P21614|VTDB  Vitamin D-binding protein  148,26 9,237E-06 -2,8 
  M >sp|P23953|EST1C  Carboxylesterase 1C  68,02 2,005E-03 3,3 
  M >sp|P28651|CAH8  Carbonic anhydrase-related protein  35,72 6,405E-04 4,8 
  M >sp|P28798|GRN  Granulins  16,30 5,444E-04 -29,8 
  M >sp|P29758|OAT 
 Ornithine aminotransferase, 
mitochondrial  309,01 1,074E-02 -2,5 
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  M >sp|P34884|MIF  Macrophage migration inhibitory factor  74,65 2,422E-03 -2,4 
  M >sp|P35492|HUTH  Histidine ammonia-lyase  376,41 1,558E-04 -3,3 
  M >sp|P35505|FAAA  Fumarylacetoacetase  449,36 2,068E-05 -15,0 
  M >sp|P40936|INMT  Indolethylamine N-methyltransferase  232,81 5,185E-04 -2,3 
  M >sp|P47738|ALDH2  Aldehyde dehydrogenase, mitochondrial  479,74 2,325E-04 -2,0 
  M >sp|P50295|ARY2  Arylamine N-acetyltransferase 2  23,34 4,434E-04 -3,9 
  M >sp|P52760|UK114  Ribonuclease UK114  168,04 5,839E-03 -2,3 
  M >sp|P52792|HXK4  Glucokinase  19,75 4,395E-03 2,5 
  M >sp|P55050|FABPI  Fatty acid-binding protein, intestinal  22,35 3,018E-02 2,4 
  M >sp|P55258|RAB8A  Ras-related protein Rab-8A  15,71 6,228E-03 -2,3 
  M >sp|P56389|CDD  Cytidine deaminase  20,42 1,627E-03 -2,2 
  M >sp|P56654|CP237  Cytochrome P450 2C37  235,53 8,530E-06 -4,9 
  M >sp|P56656|CP239  Cytochrome P450 2C39  77,68 3,695E-04 19,7 
  M >sp|P59325|IF5  Eukaryotic translation initiation factor 5  17,03 1,313E-03 -2,5 
  M >sp|P60229|EIF3E 
 Eukaryotic translation initiation factor 3 
subunit E  24,24 8,432E-04 18,7 
  M >sp|P61514|RL37A  60S ribosomal protein L37a  13,94 8,781E-03 4,8 
  M >sp|P62827|RAN  GTP-binding nuclear protein Ran  24,89 4,075E-04 -3,8 
  M >sp|P62862|RS30  40S ribosomal protein S30  8,12 1,366E-03 -4,0 
  M >sp|P63073|IF4E  Eukaryotic translation initiation factor 4E  13,97 2,772E-02 3,4 
  M >sp|P63085|MK01  Mitogen-activated protein kinase 1  13,73 9,588E-03 -2,5 
  M >sp|P70699|LYAG  Lysosomal alpha-glucosidase  34,98 1,355E-02 2,7 
  M >sp|P83882|RL36A  60S ribosomal protein L36a  6,64 1,310E-03 -3,2 
  M >sp|P84091|AP2M1  AP-2 complex subunit mu  21,34 6,561E-03 -2,9 
  M >sp|P84244|H33  Histone H3.3  4,86 8,209E-03 -2,7 
  M >sp|P99026|PSB4  Proteasome subunit beta type-4  23,09 5,296E-03 -7,6 
  M >sp|Q00519|XDH  Xanthine dehydrogenase/oxidase  120,97 1,007E-03 -3,9 
  M >sp|Q00897|A1AT4  Alpha-1-antitrypsin 1-4  107,74 1,200E-02 -3,0 
  M >sp|Q01339|APOH  Beta-2-glycoprotein 1  13,44 2,845E-02 -3,3 
  M >sp|Q03249|GALT 
 Galactose-1-phosphate 
uridylyltransferase  44,59 2,856E-02 -2,9 
  M >sp|Q05816|FABP5  Fatty acid-binding protein, epidermal  129,51 3,401E-02 2,1 
  M >sp|Q05915|GCH1  GTP cyclohydrolase 1  5,10 2,583E-03 2,1 
  M >sp|Q07813|BAX  Apoptosis regulator BAX  7,24 2,189E-02 -2,1 
  M >sp|Q3THK7|GUAA  GMP synthase [glutamine-hydrolyzing]  22,83 7,200E-04 -2,0 
  M >sp|Q3TW96|UAP1L 
 UDP-N-acetylhexosamine 
pyrophosphorylase-like protein 1  10,69 3,620E-02 2,4 
  M >sp|Q3UNZ8|QORL2  Quinone oxidoreductase-like protein 2  33,01 1,049E-05 10,3 
  M >sp|Q4VAA2|CDV3  Protein CDV3  49,10 3,403E-02 2,1 
  M >sp|Q5RKZ7|MOCS1 
 Molybdenum cofactor biosynthesis 
protein 1  29,26 3,212E-02 2,3 
  M >sp|Q5SUR0|PUR4 
 Phosphoribosylformylglycinamidine 
synthase  14,96 4,154E-03 -2,4 
  M >sp|Q5U4C1|GASP1 
 G-protein coupled receptor-associated 
sorting protein 1  3,61 7,753E-03 2,4 
  M >sp|Q60692|PSB6  Proteasome subunit beta type-6  24,38 2,465E-03 -3,7 
  M >sp|Q60866|PTER  Phosphotriesterase-related protein  81,65 8,475E-04 -2,4 
  M >sp|Q61704|ITIH3 
 Inter-alpha-trypsin inhibitor heavy chain 
H3  7,97 1,345E-04 3,4 
Stellenbosch University  https://scholar.sun.ac.za
   
 
     188 
  M >sp|Q62348|TSN  Translin  3,38 4,009E-02 -2,9 
  M >sp|Q62376|RU17 
 U1 small nuclear ribonucleoprotein 70 
kDa  6,88 2,460E-02 -2,6 
  M >sp|Q63836|SBP2  Selenium-binding protein 2  488,39 1,804E-02 2,5 
  M >sp|Q63886|UD11  UDP-glucuronosyltransferase 1-1  187,68 1,540E-03 -2,4 
  M >sp|Q64374|RGN  Regucalcin  474,77 1,370E-03 -2,2 
  M >sp|Q6P1B1|XPP1  Xaa-Pro aminopeptidase 1  13,35 1,094E-02 3,3 
  M >sp|Q6P542|ABCF1 
 ATP-binding cassette sub-family F 
member 1  25,71 3,504E-02 2,0 
  M >sp|Q6P8I4|PCNP 
 PEST proteolytic signal-containing nuclear 
protein  8,89 6,437E-04 -3,4 
  M >sp|Q76LS9|FA63A  Protein FAM63A  14,09 4,205E-02 2,2 
  M >sp|Q7TMK9|HNRPQ 
 Heterogeneous nuclear 
ribonucleoprotein Q  42,82 1,907E-03 2,2 
  M >sp|Q80VP1|EPN1  Epsin-1  18,13 3,321E-02 3,1 
  M >sp|Q80W22|THNS2  Threonine synthase-like 2  51,71 1,098E-03 -3,9 
  M >sp|Q8BFP9|PDK1 
 [Pyruvate dehydrogenase (acetyl-
transferring)] kinase isozyme 1 6,93 2,337E-03 6,5 
  M >sp|Q8BFZ3|ACTBL  Beta-actin-like protein 2  194,76 2,087E-02 -2,6 
  M >sp|Q8BH69|SPS1  Selenide, water dikinase 1  16,62 4,584E-03 -3,8 
  M >sp|Q8BKZ9|ODPX 
 Pyruvate dehydrogenase protein X 
component, mitochondrial  10,55 3,590E-04 -4,8 
  M >sp|Q8BLF1|NCEH1  Neutral cholesterol ester hydrolase 1  3,69 3,316E-02 2,1 
  M >sp|Q8BMA6|SRP68  Signal recognition particle subunit SRP68  27,06 8,770E-04 2,5 
  M >sp|Q8BRK8|AAPK2 
 5'-AMP-activated protein kinase catalytic 
subunit alpha-2  16,94 3,148E-03 2,5 
  M >sp|Q8BTY1|KAT1  Kynurenine--oxoglutarate transaminase 1  73,86 1,724E-02 -2,4 
  M >sp|Q8C5W3|TBCEL 
 Tubulin-specific chaperone cofactor E-like 
protein  21,28 4,150E-03 -2,3 
  M >sp|Q8CAS9|PARP9  Poly [ADP-ribose] polymerase 9  11,36 2,121E-04 2,1 
  M >sp|Q8K010|OPLA  5-oxoprolinase  206,63 5,570E-06 22,2 
  M >sp|Q8K3J1|NDUS8 
 NADH dehydrogenase [ubiquinone] iron-
sulfur protein 8 16,46 7,938E-04 -3,5 
  M >sp|Q8K3W0|BRE  BRCA1-A complex subunit BRE  4,24 2,680E-02 -2,6 
  M >sp|Q8K411|PREP  Presequence protease, mitochondrial  38,78 1,387E-02 2,2 
  M >sp|Q8R050|ERF3A 
 Eukaryotic peptide chain release factor 
GTP-binding subunit ERF3A  20,28 2,326E-04 4,0 
  M >sp|Q8R123|FAD1  FAD synthase  18,17 8,777E-03 -2,0 
  M >sp|Q8VCB3|GYS2  Glycogen [starch] synthase, liver  36,35 3,517E-04 8,2 
  M >sp|Q8VCH6|DHC24  Delta(24)-sterol reductase  10,41 6,807E-03 -2,7 
  M >sp|Q8VCH8|UBXN4  UBX domain-containing protein 4  14,67 3,233E-02 -2,2 
  M >sp|Q8VCR2|DHB13 
 17-beta-hydroxysteroid dehydrogenase 
13  51,73 1,498E-02 -4,2 
  M >sp|Q91VF2|HNMT  Histamine N-methyltransferase  10,60 1,160E-02 -4,0 
  M >sp|Q91VS7|MGST1  Microsomal glutathione S-transferase 1  110,95 3,732E-03 -3,2 
  M >sp|Q91VT4|CBR4  Carbonyl reductase family member 4  63,93 4,840E-03 2,2 
  M >sp|Q91W97|HKDC1  Putative hexokinase HKDC1  3,11 2,551E-03 -4,0 
  M >sp|Q91WS4|BHMT2 
 S-methylmethionine--homocysteine S-
methyltransferase BHMT2  100,28 6,396E-05 13,5 
  M >sp|Q91WU5|AS3MT  Arsenite methyltransferase  32,67 4,108E-03 -2,5 
  M >sp|Q91XE8|TM205  Transmembrane protein 205  16,47 2,132E-05 3,0 
  M >sp|Q91YP0|L2HDH 
 L-2-hydroxyglutarate dehydrogenase, 
mitochondrial  32,92 2,574E-03 -2,2 
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  M >sp|Q91Z98|CHIL4  Chitinase-like protein 4  9,09 9,410E-03 -2,6 
  M >sp|Q921H8|THIKA  3-ketoacyl-CoA thiolase A, peroxisomal  497,03 1,385E-05 2,1 
  M >sp|Q921M3|SF3B3  Splicing factor 3B subunit 3  14,37 1,513E-02 2,5 
  M >sp|Q922Q1|MARC2 
 Mitochondrial amidoxime reducing 
component 2  34,67 2,267E-02 -2,3 
  M >sp|Q99KP3|CRYL1  Lambda-crystallin homolog  37,47 1,221E-03 2,7 
  M >sp|Q99KP6|PRP19  Pre-mRNA-processing factor 19  11,47 1,401E-05 11,6 
  M >sp|Q99MN1|SYK  Lysine--tRNA ligase  53,77 1,133E-02 -2,1 
  M >sp|Q99PG0|AAAD  Arylacetamide deacetylase  121,17 2,289E-04 -2,1 
  M >sp|Q9CPU0|LGUL  Lactoylglutathione lyase  157,33 3,293E-05 -2,4 
  M >sp|Q9CPX6|ATG3  Ubiquitin-like-conjugating enzyme ATG3  6,07 4,432E-02 -2,3 
  M >sp|Q9CQC6|BZW1 
 Basic leucine zipper and W2 domain-
containing protein 1  15,15 7,398E-03 -2,7 
  M >sp|Q9D0M1|KPRA 
 Phosphoribosyl pyrophosphate synthase-
associated protein 1  35,38 8,411E-07 18,2 
  M >sp|Q9D1R9|RL34  60S ribosomal protein L34  12,19 2,888E-03 -2,1 
  M >sp|Q9D2R0|AACS  Acetoacetyl-CoA synthetase  22,28 7,333E-04 3,4 
  M >sp|Q9D2V7|CORO7  Coronin-7  24,62 2,131E-03 -3,2 
  M >sp|Q9D7G0|PRPS1  Ribose-phosphate pyrophosphokinase 1  48,75 1,845E-04 -29,9 
  M >sp|Q9D820|PRXD1 
 Prolyl-tRNA synthetase associated 
domain-containing protein 1  4,86 1,819E-04 -6,0 
  M >sp|Q9D8T2|GSDMD  Gasdermin-D  7,69 6,625E-03 2,6 
  M >sp|Q9DAR7|DCPS  m7GpppX diphosphatase  33,32 2,266E-03 -2,5 
  M >sp|Q9DB29|IAH1 
 Isoamyl acetate-hydrolyzing esterase 1 
homolog  50,22 6,319E-04 -3,8 
  M >sp|Q9DBE0|CSAD  Cysteine sulfinic acid decarboxylase  131,84 8,841E-03 -3,5 
  M >sp|Q9DBS5|KLC4  Kinesin light chain 4  8,68 3,762E-02 2,0 
  M >sp|Q9DCD0|6PGD 
 6-phosphogluconate dehydrogenase, 
decarboxylating  80,30 3,403E-03 -2,1 
  M >sp|Q9EPQ7|STAR5  StAR-related lipid transfer protein 5  8,78 4,186E-02 -2,0 
  M >sp|Q9EQ06|DHB11  Estradiol 17-beta-dehydrogenase 11  21,95 2,815E-03 -2,2 
  M >sp|Q9JHE3|ASAH2  Neutral ceramidase  8,73 8,710E-04 3,1 
  M >sp|Q9JHS4|CLPX 
 ATP-dependent Clp protease ATP-binding 
subunit clpX-like 25,06 5,596E-04 11,0 
  M >sp|Q9JIL4|NHRF3 
 Na(+)/H(+) exchange regulatory cofactor 
NHE-RF3  28,83 1,048E-02 3,8 
  M >sp|Q9JLF6|TGM1 
 Protein-glutamine gamma-
glutamyltransferase K  8,63 4,134E-02 -2,4 
  M >sp|Q9JLY0|SOCS6  Suppressor of cytokine signaling 6  2,73 7,824E-04 2,7 
  M >sp|Q9JMA1|UBP14  Ubiquitin carboxyl-terminal hydrolase 14  43,37 1,689E-02 3,0 
  M >sp|Q9JMA7|CP341  Cytochrome P450 3A41  142,20 2,876E-03 9,8 
  M >sp|Q9NYQ2|HAOX2  Hydroxyacid oxidase 2  46,32 2,122E-04 8,2 
  M >sp|Q9QWR8|NAGAB  Alpha-N-acetylgalactosaminidase  6,07 1,521E-02 -2,2 
  M >sp|Q9QXD6|F16P1  Fructose-1,6-bisphosphatase 1  562,37 9,500E-04 -2,3 
  M >sp|Q9QYB1|CLIC4  Chloride intracellular channel protein 4  85,49 8,122E-04 3,1 
  M >sp|Q9QYY9|ADH4  Alcohol dehydrogenase 4  39,13 1,165E-03 4,7 
  M >sp|Q9R0M5|TPK1  Thiamin pyrophosphokinase 1  8,59 5,719E-04 -3,6 
  M >sp|Q9R1P1|PSB3  Proteasome subunit beta type-3  32,66 9,657E-04 -6,0 
  M >sp|Q9R1P3|PSB2  Proteasome subunit beta type-2  27,17 1,070E-03 -6,4 
  M >sp|Q9WUR9|KAD4  Adenylate kinase 4, mitochondrial  46,10 1,938E-02 2,1 
  M >sp|Q9WV54|ASAH1  Acid ceramidase  22,25 6,901E-03 -3,2 
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  M >sp|Q9WVE8|PACN2 
 Protein kinase C and casein kinase 
substrate in neurons protein 2  8,88 1,136E-03 -2,1 
  M >sp|Q9Z1J3|NFS1  Cysteine desulfurase, mitochondrial  15,05 2,627E-03 2,1 
  M >sp|Q9Z2U0|PSA7  Proteasome subunit alpha type-7  61,80 1,671E-03 -4,6 
  M >sp|Q9Z2U1|PSA5  Proteasome subunit alpha type-5  59,85 9,868E-03 -4,2 
  M >tr|A0A0A0MQC3  5-hydroxyisourate hydrolase  50,54 2,784E-04 -2,2 
  M >tr|A2AGR0|A2AGR0 
 MAP kinase-activating death domain 
protein  4,87 1,235E-03 4,2 
  M >tr|A2AQZ2|A2AQZ2 
 Phytanoyl-CoA dioxygenase domain-
containing protein 1 (Fragment)  54,28 5,865E-05 4,1 
  M >tr|A8DUK4|A8DUK4  Beta-globin  426,02 1,084E-05 -91,4 
  M >tr|A8Y5N4|A8Y5N4 
 17-beta-hydroxysteroid dehydrogenase 
13  54,29 6,720E-03 -17,7 
  M >tr|D3YUP6|D3YUP6  Protein Ugt2b36 (Fragment)  48,07 2,380E-03 -2,1 
  M >tr|D3Z5G7|D3Z5G7  Carboxylic ester hydrolase  37,61 1,281E-03 5,0 
  M >tr|E9PW69|E9PW69 
 Proteasome subunit alpha type 
(Fragment)  31,99 2,830E-03 -4,9 
  M >tr|E9PXC3|E9PXC3  Protein Cyp2c69  134,37 6,226E-03 -2,1 
  M >tr|E9Q455|E9Q455  Tropomyosin alpha-1 chain  42,17 2,770E-04 6,1 
  M >tr|E9Q9F5|E9Q9F5  Septin-7  57,02 5,362E-05 22,2 
  M >tr|E9QNW6|E9QNW6 
 Platelet-activating factor acetylhydrolase 
2, cytoplasmic  8,02 3,568E-02 3,0 
  M >tr|E9QPE7|E9QPE7  Myosin-11  74,90 4,057E-03 -2,0 
  M >tr|G5E902|G5E902  MCG10343, isoform CRA_b  35,02 9,685E-04 3,3 
  M >tr|H3BJ51|H3BJ51  All-trans-retinol 13,14-reductase  31,98 2,324E-03 -19,1 
  M >tr|H7BX99|H7BX99  Prothrombin  19,69 1,877E-03 14,4 
  M >tr|I7HPX6|I7HPX6  Cytochrome b-c1 complex subunit 8  10,16 3,114E-04 13,0 
  M >tr|L7N466|L7N466  5-formyltetrahydrofolate cyclo-ligase  22,29 6,265E-05 2,2 
  M >tr|Q059N0|Q059N0  Sulfotransferase  81,14 6,033E-04 6,7 
  M >tr|Q3TUE1|Q3TUE1  Far upstream element-binding protein 1  18,66 4,925E-03 -2,3 
  M >tr|Q3U3J1|Q3U3J1 
 2-oxoisovalerate dehydrogenase subunit 
alpha, mitochondrial  239,03 1,966E-04 3,1 
  M >tr|Q3UW66|Q3UW66  Sulfurtransferase  118,51 1,251E-05 2,4 
  M >tr|Q91VB8|Q91VB8  Alpha globin 1  413,96 3,541E-04 -2,9 
  M >tr|Q91Z40|Q91Z40  Gbp6 protein  5,97 2,637E-02 -2,4 
  M >tr|Q9CQM8|Q9CQM8  60S ribosomal protein L21  48,39 3,912E-04 5,1 
  T >sp|A2AS89|SPEB  Agmatinase, mitochondrial  60,52 2,171E-03 -3,5 
  T >sp|B1AR13|CISD3 
 CDGSH iron-sulfur domain-containing 
protein 3, mitochondrial  8,01 3,703E-02 -3,2 
  T >sp|G3X982|AOXC  Aldehyde oxidase 3  120,25 2,567E-02 -2,0 
  T >sp|O08807|PRDX4  Peroxiredoxin-4  47,98 3,758E-04 3,4 
  T >sp|O09061|PSB1  Proteasome subunit beta type-1  34,47 1,076E-02 -3,5 
  T >sp|O35215|DOPD  D-dopachrome decarboxylase  23,57 3,090E-02 -4,9 
  T >sp|O35286|DHX15 
 Pre-mRNA-splicing factor ATP-dependent 
RNA helicase DHX15  13,23 1,015E-02 -2,3 
  T >sp|O35841|API5  Apoptosis inhibitor 5  15,45 9,009E-03 -2,1 
  T >sp|O55234|PSB5  Proteasome subunit beta type-5  16,24 5,636E-04 -3,9 
  T >sp|O70435|PSA3  Proteasome subunit alpha type-3  8,53 1,621E-03 -6,0 
  T >sp|O88451|RDH7  Retinol dehydrogenase 7  130,14 1,416E-04 -3,7 
  T >sp|O88456|CPNS1  Calpain small subunit 1  15,07 1,108E-04 2,1 
  T >sp|O89017|LGMN  Legumain  36,28 2,168E-02 2,4 
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  T >sp|P02089|HBB2  Hemoglobin subunit beta-2  269,71 4,909E-04 -2,7 
  T >sp|P06330|HVM51  Ig heavy chain V region AC38 205.12  13,64 2,489E-05 5,4 
  T >sp|P07724|ALBU  Serum albumin  884,36 2,028E-04 -2,3 
  T >sp|P10518|HEM2  Delta-aminolevulinic acid dehydratase  142,33 4,713E-03 -2,5 
  T >sp|P11352|GPX1  Glutathione peroxidase 1  154,94 1,267E-02 -2,8 
  T >sp|P16546|SPTN1  Spectrin alpha chain, non-erythrocytic 1  42,85 3,474E-05 5,5 
  T >sp|P17563|SBP1  Selenium-binding protein 1  448,05 7,712E-03 -2,0 
  T >sp|P17879|HS71B  Heat shock 70 kDa protein 1B  113,76 2,589E-02 2,2 
  T >sp|P20065|TYB4  Thymosin beta-4  39,98 4,230E-02 3,5 
  T >sp|P21300|ALD1  Aldose reductase-related protein 1  8,12 1,419E-04 -4,5 
  T >sp|P21614|VTDB  Vitamin D-binding protein  148,26 5,050E-06 -2,8 
  T >sp|P24456|CP2DA  Cytochrome P450 2D10  194,38 1,891E-03 -2,2 
  T >sp|P27046|MA2A1  Alpha-mannosidase 2  14,55 1,302E-03 -2,1 
  T >sp|P27612|PLAP  Phospholipase A-2-activating protein  24,01 2,839E-03 -2,1 
  T >sp|P28063|PSB8  Proteasome subunit beta type-8  16,08 4,500E-02 -2,2 
  T >sp|P28651|CAH8  Carbonic anhydrase-related protein  35,72 1,295E-06 5,5 
  T >sp|P28798|GRN  Granulins  16,30 7,131E-08 -36,2 
  T >sp|P34884|MIF  Macrophage migration inhibitory factor  74,65 1,182E-03 -2,5 
  T >sp|P34927|ASGR1  Asialoglycoprotein receptor 1  32,22 9,805E-04 -2,1 
  T >sp|P35492|HUTH  Histidine ammonia-lyase  376,41 1,953E-04 -2,5 
  T >sp|P35505|FAAA  Fumarylacetoacetase  449,36 1,390E-03 -5,6 
  T >sp|P50295|ARY2  Arylamine N-acetyltransferase 2  23,34 1,178E-03 2,1 
  T >sp|P51880|FABP7  Fatty acid-binding protein, brain  15,14 3,933E-02 3,3 
  T >sp|P52760|UK114  Ribonuclease UK114  168,04 2,018E-02 -2,3 
  T >sp|P52792|HXK4  Glucokinase  19,75 8,124E-03 2,1 
  T >sp|P52843|ST2A1  Bile salt sulfotransferase 1  22,62 6,065E-05 -3,1 
  T >sp|P55302|AMRP 
 Alpha-2-macroglobulin receptor-
associated protein  14,28 2,931E-03 2,2 
  T >sp|P56389|CDD  Cytidine deaminase  20,42 3,585E-03 -2,3 
  T >sp|P56391|CX6B1  Cytochrome c oxidase subunit 6B1  14,61 3,029E-02 -3,0 
  T >sp|P58389|PTPA 
 Serine/threonine-protein phosphatase 2A 
activator  16,25 4,027E-03 -2,1 
  T >sp|P59325|IF5  Eukaryotic translation initiation factor 5  17,03 5,914E-03 -2,5 
  T >sp|P60229|EIF3E 
 Eukaryotic translation initiation factor 3 
subunit E  24,24 4,645E-05 6,7 
  T >sp|P61514|RL37A  60S ribosomal protein L37a  13,94 5,730E-05 3,8 
  T >sp|P62827|RAN  GTP-binding nuclear protein Ran  24,89 1,481E-04 -4,4 
  T >sp|P62862|RS30  40S ribosomal protein S30  8,12 4,048E-03 -3,5 
  T >sp|P63073|IF4E  Eukaryotic translation initiation factor 4E  13,97 6,956E-03 3,7 
  T >sp|P63085|MK01  Mitogen-activated protein kinase 1  13,73 3,804E-03 -2,3 
  T >sp|P68373|TBA1C  Tubulin alpha-1C chain  288,68 3,683E-02 -2,0 
  T >sp|P83882|RL36A  60S ribosomal protein L36a  6,64 7,129E-05 -4,6 
  T >sp|P84091|AP2M1  AP-2 complex subunit mu  21,34 1,384E-03 -3,9 
  T >sp|P84244|H33  Histone H3.3  4,86 3,822E-03 -3,1 
  T >sp|P97328|KHK  Ketohexokinase  169,67 3,835E-03 -12,4 
  T >sp|P99026|PSB4  Proteasome subunit beta type-4  23,09 6,686E-03 -6,3 
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  T >sp|Q00519|XDH  Xanthine dehydrogenase/oxidase  120,97 1,097E-03 -3,2 
  T >sp|Q07813|BAX  Apoptosis regulator BAX  7,24 5,203E-03 -2,8 
  T >sp|Q3THK7|GUAA  GMP synthase [glutamine-hydrolyzing]  22,83 1,579E-04 -2,7 
  T >sp|Q3UNZ8|QORL2  Quinone oxidoreductase-like protein 2  33,01 1,785E-06 12,0 
  T >sp|Q4VAA2|CDV3  Protein CDV3  49,10 2,387E-02 2,0 
  T >sp|Q60692|PSB6  Proteasome subunit beta type-6  24,38 1,384E-03 -3,6 
  T >sp|Q62264|THRSP 
 Thyroid hormone-inducible hepatic 
protein  63,13 1,342E-03 -5,7 
  T >sp|Q62376|RU17 
 U1 small nuclear ribonucleoprotein 70 
kDa  6,88 6,483E-04 -2,5 
  T >sp|Q62452|UD19  UDP-glucuronosyltransferase 1-9  134,47 1,305E-03 -2,1 
  T >sp|Q64374|RGN  Regucalcin  474,77 4,121E-04 -2,3 
  T >sp|Q6P8I4|PCNP 
 PEST proteolytic signal-containing nuclear 
protein  8,89 8,632E-04 -3,2 
  T >sp|Q76LS9|FA63A  Protein FAM63A  14,09 2,016E-02 2,1 
  T >sp|Q7TPV4|MBB1A  Myb-binding protein 1A  9,94 8,120E-04 2,4 
  T >sp|Q80VP1|EPN1  Epsin-1  18,13 1,210E-04 2,1 
  T >sp|Q8BFP9|PDK1 
 [Pyruvate dehydrogenase (acetyl-
transferring)] kinase isozyme 1 6,93 1,022E-02 2,4 
  T >sp|Q8BFZ3|ACTBL  Beta-actin-like protein 2  194,76 1,242E-02 -2,1 
  T >sp|Q8BH69|SPS1  Selenide, water dikinase 1  16,62 3,679E-03 -3,4 
  T >sp|Q8C0Y0|PP4R4 
 Serine/threonine-protein phosphatase 4 
regulatory subunit 4  4,86 1,966E-03 2,0 
  T >sp|Q8C1B7|SEP11  Septin-11  26,97 1,601E-04 2,2 
  T >sp|Q8C5W3|TBCEL 
 Tubulin-specific chaperone cofactor E-like 
protein  21,28 3,389E-02 -2,2 
  T >sp|Q8CAQ8|MIC60  MICOS complex subunit Mic60  7,80 2,123E-02 2,2 
  T >sp|Q8K010|OPLA  5-oxoprolinase  206,63 1,907E-06 22,6 
  T >sp|Q8R050|ERF3A 
 Eukaryotic peptide chain release factor 
GTP-binding subunit ERF3A  20,28 1,127E-06 3,2 
  T >sp|Q8VCC1|PGDH 
 15-hydroxyprostaglandin dehydrogenase 
[NAD(+)]  41,97 4,754E-04 -2,4 
  T >sp|Q8VCH6|DHC24  Delta(24)-sterol reductase  10,41 4,007E-03 -2,6 
  T >sp|Q8VCH8|UBXN4  UBX domain-containing protein 4  14,67 5,336E-03 -2,1 
  T >sp|Q91VS7|MGST1  Microsomal glutathione S-transferase 1  110,95 4,745E-03 -3,7 
  T >sp|Q91W97|HKDC1  Putative hexokinase HKDC1  3,11 5,125E-03 2,4 
  T >sp|Q91XE8|TM205  Transmembrane protein 205  16,47 7,710E-06 3,5 
  T >sp|Q921M3|SF3B3  Splicing factor 3B subunit 3  14,37 1,303E-02 2,1 
  T >sp|Q922Q1|MARC2 
 Mitochondrial amidoxime reducing 
component 2  34,67 3,745E-03 -3,6 
  T >sp|Q99KP6|PRP19  Pre-mRNA-processing factor 19  11,47 1,733E-06 10,5 
  T >sp|Q99LC3|NDUAA 
 NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 10 39,77 6,221E-05 -2,1 
  T >sp|Q99LY9|NDUS5 
 NADH dehydrogenase [ubiquinone] iron-
sulfur protein 5  6,11 3,469E-03 -7,4 
  T >sp|Q99P30|NUDT7 
 Peroxisomal coenzyme A diphosphatase 
NUDT7  132,96 3,381E-04 -2,4 
  T >sp|Q9CPU0|LGUL  Lactoylglutathione lyase  157,33 5,006E-05 -2,5 
  T >sp|Q9CQC6|BZW1 
 Basic leucine zipper and W2 domain-
containing protein 1  15,15 1,282E-04 -3,3 
  T >sp|Q9CYZ2|TPD54  Tumor protein D54  24,45 6,887E-03 2,6 
  T >sp|Q9D1G1|RAB1B  Ras-related protein Rab-1B  43,53 1,165E-02 2,1 
  T >sp|Q9D1R9|RL34  60S ribosomal protein L34  12,19 4,462E-03 -2,4 
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  T >sp|Q9D2V7|CORO7  Coronin-7  24,62 2,381E-03 -2,8 
  T >sp|Q9D7G0|PRPS1  Ribose-phosphate pyrophosphokinase 1  48,75 8,027E-05 -106,1 
  T >sp|Q9D820|PRXD1 
 Prolyl-tRNA synthetase associated 
domain-containing protein 1  4,86 4,981E-04 -5,1 
  T >sp|Q9DBE0|CSAD  Cysteine sulfinic acid decarboxylase  131,84 3,709E-03 -3,3 
  T >sp|Q9DD20|MET7B  Methyltransferase-like protein 7B  53,21 2,502E-02 -2,0 
  T >sp|Q9EPQ7|STAR5  StAR-related lipid transfer protein 5  8,78 3,777E-04 -2,4 
  T >sp|Q9EQ06|DHB11  Estradiol 17-beta-dehydrogenase 11  21,95 4,243E-03 -2,7 
  T >sp|Q9JHE3|ASAH2  Neutral ceramidase  8,73 1,402E-03 2,3 
  T >sp|Q9JHS4|CLPX 
 ATP-dependent Clp protease ATP-binding 
subunit clpX-like 25,06 3,321E-05 11,0 
  T >sp|Q9JIL4|NHRF3 
 Na(+)/H(+) exchange regulatory cofactor 
NHE-RF3  28,83 2,805E-02 2,6 
  T >sp|Q9JKV1|ADRM1  Proteasomal ubiquitin receptor ADRM1  27,79 8,805E-04 -2,0 
  T >sp|Q9JMA1|UBP14  Ubiquitin carboxyl-terminal hydrolase 14  43,37 4,662E-03 4,6 
  T >sp|Q9QYJ0|DNJA2  DnaJ homolog subfamily A member 2  34,68 1,824E-02 -2,1 
  T >sp|Q9R0M5|TPK1  Thiamin pyrophosphokinase 1  8,59 1,072E-03 -7,4 
  T >sp|Q9R0Q7|TEBP  Prostaglandin E synthase 3  26,48 7,458E-03 -2,1 
  T >sp|Q9R0Q9|MPU1 
 Mannose-P-dolichol utilization defect 1 
protein  7,59 8,970E-03 -2,3 
  T >sp|Q9R1J0|NSDHL 
 Sterol-4-alpha-carboxylate 3-
dehydrogenase, decarboxylating  18,92 1,303E-02 -2,2 
  T >sp|Q9R1P1|PSB3  Proteasome subunit beta type-3  32,66 2,233E-04 -5,3 
  T >sp|Q9R1P3|PSB2  Proteasome subunit beta type-2  27,17 9,446E-04 -4,9 
  T >sp|Q9WVE8|PACN2 
 Protein kinase C and casein kinase 
substrate in neurons protein 2  8,88 1,946E-03 -2,0 
  T >sp|Q9Z2U0|PSA7  Proteasome subunit alpha type-7  61,80 9,058E-04 -4,0 
  T >sp|Q9Z2U1|PSA5  Proteasome subunit alpha type-5  59,85 1,426E-03 -5,0 
  T >sp|Q9Z2Z6|MCAT 
 Mitochondrial carnitine/acylcarnitine 
carrier protein  20,71 3,653E-02 -2,4 
  T >tr|A0A0A0MQC3  5-hydroxyisourate hydrolase  50,54 4,155E-03 -3,6 
  T >tr|A2AGR0|A2AGR0 
 MAP kinase-activating death domain 
protein  4,87 5,471E-04 5,1 
  T >tr|A2AQZ2|A2AQZ2 
 Phytanoyl-CoA dioxygenase domain-
containing protein 1 (Fragment)  54,28 4,431E-06 4,5 
  T >tr|D3YUP6|D3YUP6  Protein Ugt2b36 (Fragment)  48,07 6,004E-03 -2,1 
  T >tr|D3Z0R5|D3Z0R5 
 Glucosamine-6-phosphate isomerase 1 
(Fragment)  6,97 1,096E-03 -2,4 
  T >tr|D3Z5G7|D3Z5G7  Carboxylic ester hydrolase  37,61 1,088E-03 2,6 
  T >tr|E9PV38|E9PV38  Carboxylic ester hydrolase  53,04 9,379E-04 2,2 
  T >tr|E9PW69|E9PW69 
 Proteasome subunit alpha type 
(Fragment)  31,99 4,343E-04 -5,4 
  T >tr|E9PXC3|E9PXC3  Protein Cyp2c69  134,37 1,596E-02 -2,4 
  T >tr|E9PZ00|E9PZ00  Prosaposin  54,04 6,531E-03 -3,1 
  T >tr|E9Q1Q9|E9Q1Q9  Ketohexokinase  166,27 7,333E-04 -5,1 
  T >tr|E9Q455|E9Q455  Tropomyosin alpha-1 chain  42,17 8,595E-05 4,3 
  T >tr|E9Q9F5|E9Q9F5  Septin-7  57,02 5,275E-07 19,6 
  T >tr|E9QNW6|E9QNW6 
 Platelet-activating factor acetylhydrolase 
2, cytoplasmic  8,02 4,329E-03 2,4 
  T >tr|F7CBP1|F7CBP1 
 Eukaryotic translation initiation factor 4 
gamma 2  8,19 4,915E-03 -3,1 
  T >tr|G5E902|G5E902  MCG10343, isoform CRA_b  35,02 1,235E-05 3,5 
  T >tr|H7BX99|H7BX99  Prothrombin  19,69 7,435E-05 15,6 
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  T >tr|Q5JC28|Q5JC28 
 Epidermal growth factor receptor 
pathway substrate 15 isoform B  17,82 2,164E-02 2,1 
  T >tr|Q5SW88|Q5SW88  Ras-related protein Rab-1A  46,59 1,209E-03 2,1 
  T >tr|Q6ZWZ4|Q6ZWZ4  60S ribosomal protein L36  14,98 3,452E-02 2,3 
  T >tr|Q6ZWZ6|Q6ZWZ6  40S ribosomal protein S12  15,79 1,497E-02 -2,1 
  T >tr|Q91Z40|Q91Z40  Gbp6 protein  5,97 1,239E-02 -2,2 
  T >tr|Q9CQM8|Q9CQM8  60S ribosomal protein L21  48,39 1,610E-03 3,2 
  T >tr|Q9WUD0  Cytochrome P450 2B10  16,12 6,634E-03 -2,1 
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